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Abstract
Purpose: The purpose of this dissertation is to explore factors affecting accrual and
completion of pediatric oncology clinical trials. This dissertation includes a scoping
review of barriers and facilitators to enrollment in pediatric oncology clinical trials, a
systematic review of trial-level factors affecting accrual and completion of oncology
clinical trials, and an exploratory analysis of trial-level factors affecting accrual and
completion of pediatric oncology clinical trials from ClinicalTrials.gov data.
Problem/Aims: Cancer is the second leading cause of death in children. Clinical trials
explore potential new therapies for children with cancer by determining safety and
effectiveness of interventions. The literature demonstrates widespread inadequate accrual
of trial participants and associated early termination of oncology clinical trials. This
dissertation aimed to provide evidence of trial-level factors affecting accrual and
completion of pediatric oncology clinical trials by reviewing the literature, identifying
possible trial-level factors, and performing an exploratory analysis of the
ClinicalTrials.gov dataset.
Design including theoretical basis: A modified version of the Social Ecological Model
and Arskey and O’Malley’s framework guided the scoping review. Bennette et al.’s
framework, along with that of Knafl and Whittmore, directed the systematic review.
Bennette et al.’s framework also guided the exploratory analysis using the
ClinicalTrials.gov dataset.
Findings: Barriers to enrollment in pediatric oncology clinical trials exist at the trial,
individual, interpersonal and organizational levels. Several trial-level barriers to
vi

enrollment in adult oncology clinical trials previously were identified, such as
enrollment, intervention type, phase, allocation, arm type, sponsor, number of
participating facilities, and primary disease. The exploratory analysis indicated none of
the aforementioned variables and others such as primary purpose, number of primary
outcomes, interventional study model, and number of arms were predictive of early
termination of pediatric oncology trials due to low accrual. However, odds for studies to
terminate early were 4.7 times higher for those that used a data and safety monitoring
committee compared to those that did not (p = 0.05).
Conclusion: Findings from the scoping and systematic reviews suggest there are triallevel factors that affect early termination of pediatric oncology trials due to low accrual.
Findings from the exploratory study indicated that use of a data and safety monitoring
committee plays an important role in early trial termination due to low accrual. The
design of future pediatric oncology clinical trials should incorporate approaches to
minimize trial-level factors that are associated with or predictive of early trial
termination. Additional studies examining trial-level factors should utilize multiple trial
databases and investigate pediatric oncology trials that have been conducted worldwide.

Key words – Clinical trials, oncology, cancer, pediatric, children, enrollment, accrual,
recruitment
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Introduction
Cancer is the second leading cause of death in children, exceeded only by injuries.
In 2020, 11,050 children ages 0-14 years are predicted to be newly diagnosed with
cancer. Moreover, 1,190 children in this same age group years are predicted to die from
cancer.[1] Cancer affects children of all ethnicities, socioeconomic backgrounds, and
genders.[2] Available cancer therapies often result in toxicities, secondary cancers, and
long-term financial challenges for affected children and their families.[3,4] Thus, new
cancer therapies for children are urgently needed.
Clinical trials explore potential new therapies for children with cancer by
determining the safety and effectiveness of investigational drugs, devices, surgeries, and
other interventions.[5] As a result of increased public pressure for more efficacious and
less toxic cancer therapies, the number and costs of oncology clinical trials have
increased. Thirty-two oncology clinical trials for children were opened in 2010,
increasing to 137 in 2019.[6] Clinical trials for FDA-approved oncology drugs in 20152017 had a median cost of $37.1 million per trial (interquartile range = $17.0 - $60.4
million).[7] Consequently, the increase in number of oncology clinical trials and their
associated high cost present challenges to their successful completion.
The increase in number and high cost of oncology clinical trials present
challenges to their successful completion due to required financial and human resources.
Sponsors of clinical trials and cancer centers that participate in oncology clinical trials
have limited resources to support the clinical and administrative operations necessary for
trials.[8,9] Federal funding and monetary support from pharmaceutical companies for the
1

conduct of clinical trials have decreased over time, while trial activation and maintenance
are often complex and require many resources. For example, the activation of a phase III
trial may consist of greater than 370 processes.[10].
The Institute of Medicine (IOM) cited inefficiencies in the development and
conduct of clinical trials in the United States. One of these inefficiencies is the inability to
prioritize trials likely to be most successful. The IOM’s report called for improvement in
the speed and efficiency of the design and conduct of clinical trials, including the
prioritization, selection, and completion of oncology clinical trials.[11] The lack of
prioritization results in scarce resources being wasted or misappropriated to clinical trials
that fail to successfully complete, thus impeding the availability of new, effective
therapies for patients who desperately need them.
The literature has demonstrated widespread inadequate accrual of trial
participants and associated early termination of oncology clinical trials. One study
revealed 40% of National Cancer Institute (NCI) Cancer Therapy Evaluation Program
(CTEP) trials did not meet accrual goals.[12] In another study, more than 70% of phase
III oncology trials reported inadequate accrual and only 37.9% of closed phase III trials
reached their targeted accrual.[13] Moreover, one in five surgical randomized clinical
trials is terminated prematurely because of inadequate accrual[14]. In addition,
researchers have reported approximately one randomized clinical trial involving radiation
failed to complete for every two of these types of trials that completed. Inadequate
accrual was the main reason for the failed trials.[15] Accrual is important
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because an adequate sample size is required for valid trial results.[16] Consequently,
accrual is an indicator of a clinical trial’s success.
In addition to lack of validity of study outcomes due to small sample sizes,
inadequate accrual can have several other negative effects on a clinical trial’s financial
resources and participants. First, the enrollment period for a trial may need to be extended
to obtain the targeted sample size, thus delaying results and increasing the trial’s
costs.[17] Each additional month for the conduct of a phase 3 clinical trial regardless of
therapeutic indication costs a median of $671,000.[18] Second, the early termination of a
clinical trial due to inadequate accrual results in significant loss of financial and human
resources that were utilized in the trials’ design, activation, recruitment, data collection
and analysis, and management of the trial[19-21]. Consequently, those resources are not
available to use for trials for the same target population that may have had a successful
completion.[20] Third, the efforts of patients who participated in a clinical trial that
terminates early due to low accrual have been in vain because the trial did not contribute
knowledge in science.[17,19,20] Therefore, there are also ethical implications of
inadequate accrual and early termination of clinical trials.
Factors that affect the successful accrual and completion of oncology clinical
trials operate at the trial, individual, interpersonal, organizational, community, and policy
levels. Many researchers have investigated these factors for adult oncology clinical trials
[22-36]; however, limited research exists about trial level factors that may affect
successful accrual for pediatric oncology clinical trials. Trial level factors (e.g., eligibility
criteria, planned sample size, phase of study, study design, use of randomization, funder,
3

and location) have been found to be associated with, or predictive of, completion of
cardiovascular clinical trials, adult oncology clinical trials, and quality of pediatric
clinical trials.[37-39] However, these trial level factors have not been investigated for
pediatric oncology clinical trials, lest using a robust national dataset such as
ClinicalTrials.gov. Precise estimates of which types of trials will be able to successfully
meet their accrual targets based upon trial characteristics will support rapid translation of
bench discoveries to therapies for children with cancer.[39] Identification of trial-level
factors that affect the successful accrual and completion of oncology clinical trials is
necessary for precise estimates.
Over recent years, the government and public have insisted on transparency in
clinical trials to facilitate drug development and safety. Subsequently, federal regulations
were established to require sponsors of clinical trials to provide pre-defined data about
their clinical trials in the ClinicalTrials.gov database.[6] Thus, ClinicalTrials.gov has
become the largest and most inclusive database of clinical trials in the world due to it
having the most predefined data[40] Changes in regulations instituted over the last two
decades resulted in discrepancies in the type and amount of data that investigators
submitted into the database during that timeframe.[6] As a result, the number of available
variables differs among different time periods, study types (phase I, II, III, or IV),
allocation (randomized or nonrandomized), and intervention model (parallel, crossover,
factorial, or single-arm). Assessment of the completeness of variables in
ClinicalTrials.gov may identify variables to be included in the design of future studies
about clinical trials as an enterprise (studies about clinical trials as a whole based on large
4

databases of clinical trials rather than data from a few clinical trials at a single or few
institutions).
Theoretical Models
This dissertation includes a scoping review of barriers and facilitators to
enrollment in pediatric oncology clinical trials, a systematic review of trial-level factors
affecting accrual and completion of oncology clinical trials, and an exploratory analysis
of trial-level factors affecting accrual and completion of pediatric oncology clinical trials
from ClinicalTrial.gov data. Each of these investigations utilized a theoretical model to
guide the data analysis and organization of the results. The scoping review of barriers and
facilitators to enrollment in pediatric oncology clinical trials utilized a modified version
of the Social Ecological Model (SEM) by McLeroy et al. [41] The SEM model was used
because clinical trial enrollment is affected by a myriad of factors at multiple levels,
including the trial, individual/intrapersonal, interpersonal, organizational, community,
and policy levels. Trial-level factors affecting enrollment include the availability of a
clinical trial, the status of the trial (e.g. open or closed), and eligibility criteria. Individual
factors relate to study participants and include age, sex, race, ethnicity, insurance status,
cancer characteristics, and motivation. Interpersonal factors include parents’ desire for
continuity of care by healthcare providers, physicians’ discussions with parents and
children about clinical trials, and physicians’ attitudes about clinical trials. Organizational
factors include local availability of a clinical trial and continuity of care. Community
factors include a culture of fear and distrust among minority groups because of
exploitative practices in past trials, such as the Tuskegee syphilis study. Finally, policy
5

includes laws that mandate insurance coverage for routine patient care costs associated
with participation in clinical trials, hence lessening the financial burden of trial
participation.
Both the systematic review of trial-level factors affecting accrual and completion
of oncology clinical trials and the exploratory analysis of trial-level factors affecting
accrual and completion of pediatric oncology clinical trials utilized Bennette et al’s [42]
conceptual model of trial-level factors associated with low trial accrual. The model offers
four critical domains for assessing trial-level factors associated with low trial accrual:
background, disease-related, treatment-related, and trial design. Background factors
include greater competition from other trials and less state-level coverage of clinical trial
costs. Disease-related factors include less advanced disease, solid tumor setting, less
compelling scientific rationale, and lower annual incidence of the eligible population.
Treatment-related factors include greater deviation from standard of care, research
question not relevant to clinical practice, patient or provider preference for a particular
treatment, radiotherapy or surgical treatment, not an investigational new agent, more
expensive treatment, higher risk for toxicity, multimodality, and less compelling
scientific rationale. Trial design factors include stricter or more eligibility criteria,
randomized design, placebo-controlled arm, greater trial complexity, longer follow-up,
and higher patient burden.
Contributions of manuscripts
Each manuscript in this dissertation compendium contributes to the identification
of barriers to enrollment and, consequently, successful completion of pediatric oncology
6

clinical trials. The first manuscript, Barriers and Facilitators to Enrollment in Pediatric
Oncology Clinical Trials, is a scoping review with the purpose of determining the state of
knowledge of barriers and facilitators to enrollment in pediatric oncology clinical trials.
Results and discussion were organized by trial, individual/intrapersonal, interpersonal,
organizational, community, and policy levels. One finding of the review was the gap in
knowledge about trial-level barriers and facilitators to enrollment in pediatric oncology
clinical trials. Therefore, currently known trial-level barriers and facilitators to enrollment
in adult oncology clinical trials were investigated in the second manuscript.
The purpose of the second manuscript in this dissertation compendium, Triallevel Factors Affecting Accrual and Completion of Oncology Clinical Trials: A
Systematic Review, was to explore the literature to identify trial-level factors that affect
accrual and/or completion of adult and pediatric oncology clinical trials, gaps in the
literature, and prospective future research. A finding of this review was that none of the
reviewed studies focused solely on pediatric oncology clinical trials and only three
studies included a small number of pediatric trials. The identified trial-level factors
identified in the first and second manuscripts, along with the available variables in the
ClinicalTrials.gov dataset, informed the third manuscript. The identified trial-level factors
and variables in the ClinicalTrials.gov dataset included enrollment, primary purpose, trial
phase, interventional study model, number of arms, arm type, masking, allocation,
intervention type, end points, number of primary outcomes, sponsors, number of
participating facilities, primary disease, and data monitoring committee.
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The purpose of the third manuscript, Predictors of Early Termination of Pediatric
Oncology Clinical Trials Due to Poor Accrual: An Exploratory Analysis, was to describe
the presence of variables and completeness of data entry for variables in the
ClinicalTrials.gov database over time. The frequency and proportion of pediatric
oncology clinical trials with data for a given variable and data differed across four
periods which were based on the effective dates of regulations affecting data
requirements for ClinicalTrials.gov. The manuscript also reports on the investigation of
trial-related factors that may predict early termination of pediatric oncology clinical trials
due to low accrual. Results showed that use of a data and safety monitoring committee
plays an important role in early trial termination due to low accrual.
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Scoping Review: Barriers and Facilitators to Enrollment in Pediatric Oncology
Clinical Trials
Abstract
Cancer is the second-leading cause of death among children in the United States.
Oncology clinical trials are designed to investigate new potential therapies.
Approximately 60% of children with cancer are treated on clinical trials. The purpose of
this scoping review of the literature is to explore what is known about barriers and
facilitators to enrollment in pediatric oncology clinical trials. Arskey and O’Malley’s
methodological framework guided the scoping review. The electronic databases of
PubMed and SCOPUS were searched for relevant publications. Thirty publications met
eligibility criteria, which included empirical publications related to barriers and
facilitators to enrollment in pediatric oncology clinical trials. The results and discussion
of barriers and facilitators were organized by utilizing a modified version of the Social
Ecological Model (SEM). Trial-level barriers included lack of an available trial, trials
closed to accrual, and eligibility criteria. Individual factors included age, sex,
race/ethnicity, insurance status, cancer characteristics, and motivation. Interpersonal
factors included parents’ desire for continuity of care by healthcare providers, physicians’
discussions with parents and children about clinical trials, and physicians’ attitudes about
clinical trials. Organizational factors that influenced enrollment included local
availability of a clinical trial and continuity of care. No studies of community or policylevel barriers and facilitators were found. Theoretically based studies need to be
conducted to identify factors at SEM levels not previously studied and investigate
interventions to address factors that adversely affect enrollment. Furthermore,
14

interdisciplinary collaboration among nurses and other professionals working at each
SEM level is vital to surmount enrollment obstacles.
Keywords: Clinical trials, oncology, cancer, pediatric, enrollment
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Scoping Review: Barriers and Facilitators to Enrollment in Pediatric Oncology
Clinical Trials
Surpassed only by injury, cancer is the second-leading cause of death among
children in the United States (American Cancer Society [ACS], 2020). In 2020, 11,050
children under 15 years old are predicted to be newly diagnosed with cancer, and of
these, 1,190 are expected to die (ACS, 2020). As evidenced by these statistics, new
effective oncological therapies are needed for children. Oncology clinical trials are
designed to discover safe and efficacious means to prevent, diagnose, treat cancer and
manage its symptoms (National Cancer Institute [NCI], 2020). Clinical trials are
responsible for the childhood cancer cure rate increasing from less than 10% to over 80%
during the past 40 years (Children’s Oncology Group [COG], n.d.). There are over 1,900
active oncology clinical trials for 1 – 17-year-old patients in the ClinicalTrials.gov
database (U.S. National Library of Medicine, 2020).
Enrollment is significant because it is a key metric in determining the success of a
clinical trial, as optimal sample size is required for valid results (Melnyk & MorrisonBeedy, 2012). Also, if a clinical trial is extended due to poor enrollment, its costs
continue to rise resulting in budget deficits and wasted resources (Steinman et al., 2017).
However, enrollment of participants in oncology clinical trials is a challenge.
Approximately 60% of children with cancer are treated on clinical trials (COG, n.d.).
Existing literature about barriers and facilitators to enrollment in pediatric oncology
clinical trials is limited. Identifying factors inhibiting enrollment is imperative so that
interventions addressing enrollment challenges be developed, implemented, and
evaluated to foster the successful completion of oncology clinical trials. Thus, the
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purpose of this scoping review of the literature is to explore what is known about barriers
and facilitators to enrollment in oncology clinical trials for children. The research
question driving this review is “What are the barriers and facilitators to enrollment in
oncology clinical trials for children?”
Methods
Arksey and O’Malley’s (2005) methodological framework guided the scoping
review. The authors chose this framework because it facilitates rigor and transparency in
each stage, thus increasing the reliability of findings. The five stages of the framework
that were utilized were (1) identification of the research question, (2) search for
applicable studies, (3) selection of the most appropriate studies utilizing inclusion and
exclusion criteria, (4) collation, and (5) summary of results.
The authors conferred with a reference librarian to determine the best approach to
search the literature for relevant studies (most recent search on November 23, 2019). A
PRISMA flow chart graphically detailed the identified records, included and excluded
records, and reasons for excluded records (Moher et al., 2009) (Figure 1). The titles and
abstracts of the publications were evaluated for relevance based on inclusion and
exclusion criteria. Inclusion criteria were empirical publications related to barriers and
facilitators to enrollment in pediatric oncology clinical trials. Exclusion criteria included
the following: non-English speaking; children over 21 years old; diagnoses other than
cancer; publications solely related to the prevention, screening, and survivorship of
cancer; interventions; commentaries, statements, and recommendations. There were no
publication date delimiters since 1) there were limited publications about barriers and
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facilitators to enrollment in oncology clinical trials for children and 2) this scoping
review was intended to summarize and analyze all applicable study results to date.
Adhering to stage 2 of Arskey and O’Malley’s (2005) framework, the electronic
databases of PubMed and SCOPUS were searched for relevant publications. Due to
variations in terms used to describe enrollment of oncology clinical trials, the following
key words with appropriate Boolean operators were utilized: (pediatric[Title/Abstract]
OR children[Title/Abstract] OR adolescents[Title/Abstract] OR
teenagers[Title/Abstract]) AND (cancer[Title/Abstract] OR oncology[Title/Abstract])
AND ("clinical trials"[Title/Abstract] OR "clinical research trials"[Title/Abstract] OR
"therapeutic trials"[Title/Abstract]) AND (enrollment[Title/Abstract] OR
accrual[Title/Abstract] OR recruitment[Title/Abstract] OR participation[Title/Abstract]
OR selection[Title/Abstract]). Publications were limited to English language and peerreviewed journal articles. The reference lists of retrieved publications were also hand
searched for primary sources and additional applicable publications.
To accomplish stage 3 of Arskey and O’Malley’s (2005) framework, a scoping
review matrix was used to organize the selected publications. Publications were
organized by the following: author/date, purpose, country, ages of children, cancer type,
sample size and description, number and type of sites/number of clinical trials/phase of
clinical trials, study design/data collection methods, barriers/facilitators, SEM levels, and
results.
The results and discussion of barriers and facilitators to enrollment in pediatric
oncology clinical trials were organized by utilizing a modified version of the Social
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Ecological Model (SEM) by McLeroy et al. (1988). This model was selected because
clinical trial enrollment is influenced by factors at multiple levels. The modified SEM
addresses trial, individual/intrapersonal, interpersonal, organizational, community, and
policy levels (see Table 1 for definitions).
Results
The initial search produced 2,335 citations. With 715 duplicates removed, 1,564
citations were removed due to ineligibility based on the review of titles and abstracts. Of
the 59 remaining full-text publications, 30 met inclusion criteria (Table 2). These studies
represented diverse settings, designs, and implementation strategies. The studies about
pediatric clinical trials were conducted in multiple countries, with only 13 conducted in
the United States. The majority of studies (n=23) specified a facility setting specializing
in pediatric cancer or a database containing data about pediatric patients and/or pediatric
oncology clinical trials. Almost half (n=13) did not specify types of cancers. Of those that
did specify cancer type, leukemia was most frequently studied (n=15). Phase of clinical
trial was specified for 17 studies (phase I or I/II=9; phase III/late phase=8). Most studies
about clinical trials (n=18) did not specify number of clinical trials examined. Four
studies involved only one clinical trial, while the remaining 26 studies involved anywhere
from 2-26 clinical trials. Eighteen studies used quantitative methods, and 12 used
qualitative methods. None of the studies used mixed methods. For the quantitative
studies, the most frequent source of data were electronic databases containing data about
pediatric oncology clinical trials and/or their participants (n=10) whereas for qualitative
studies it was interviews (n=12).
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Social Ecological Model (SEM)
Only four studies were explicitly based on a theoretical framework, and none of
the studies relied on the SEM for the design or analyses. Of the 30 studies included in the
final analysis, 18 addressed one level of the SEM, and seven addressed two levels. Only
five studies addressed three or four levels of the SEM, and none addressed five or six
levels. Most of the studies (n=26) addressed the individual/intrapersonal level of the SEM
(Table 3).
SEM Levels
Trial
Five studies examined trial-level barriers and facilitators to enrollment in pediatric
oncology clinical trials. Trial-level barriers included lack of an available trial, trials
closed to accrual, and eligibility criteria that children did not meet (Dechartres et al.,
2011; Dodgshun et al., 2014; Pole et al., 2017; Surun et al., 2018). Type of dosing in
clinical trials also influenced enrollment. Adolescents were more likely to decline dose
intensification trials than dose reduction trials compared to younger children (Tulstrup et
al., 2016).
Individual/Intrapersonal
Twenty-seven studies examined several types of individual/intrapersonal barriers
and facilitators to enrollment in pediatric oncology clinical trials. Demographic factors
such as age, sex, race/ethnicity, parental language, insurance status, distance from cancer
center, geographical and urban/rural residence have been examined (Aristizabal et al.,
2015; Donnelly et al., 2017; Lund et al., 2009; Nooka et al., 2016; Pole et al., 2017; Shah
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et al., 2014; Shochat et al., 2001; Thomas et al., 2018; Winestone et al., 2019). In general,
adolescents compared to younger children and Hispanics compared to non-Hispanics are
underrepresented in oncology clinical trials (Aristizabal et al., 2015; Lund et al., 2009;
Nooka et al., 2016; Shochat et al., 2001). Being of Asian and Arab/west Asian ancestry
and greater distance from cancer center were associated with non-enrollment (Pole et al.,
2017). Males were also less likely to participate in clinical trials than females (Donnelly
et al., 2017). Children who lacked insurance had lower rates of clinical trial participation
(Shochat et al., 2001). Individual factors such as cancer characteristics have also been
investigated in relation to enrollment of children in clinical trials (Aristizabal et al., 2015;
Dodgshun et al., 2014; Donnelly et al., 2017; Eiser et al., 2005). Children with
hematological cancers have higher clinical trial participation rates than those with other
types of cancers (Dodgshun et al., 2014; Donnelly et al., 2017; Thomas et al., 2018).
Other individual factors such as understanding of clinical trials and motivation for
enrollment into pediatric oncology clinical trials have been investigated (Eiser et al.,
2005; Ingersgaard et al., 2018; Miller et al., 2013; Robertson et al., 2019). In one study,
most mothers described the aim of a clinical trial as comparing old and new therapies, but
they lacked understanding of randomization (Eiser et al., 2005). Parents’ and children’s
motivations for trial participation include the following: hope for a cure, desire to try
anything, continuity of care, maintenance of quality of life, increased life expectancy, less
toxicity, and altruism (Barrera et al., 2005; Crane et al., 2019; Hinds et al., 2005;
Ingersgaard et al., 2018; Miller et al., 2013; Oppenheim et al., 2005; Robertson et al.,
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2019; Simon et al., 2006; Unguru, et al., 2010; van der Geest et al., 2016; Woodgate &
Yanofsky, 2010).
Interpersonal
Interpersonal factors have been explored in relation to enrollment of children in
clinical trials. Parents’ desire for continuity of care by healthcare providers can influence
the decision to participate in a clinical trial (Barrera et al., 2005). Also, the content and
quality of physicians’ discussions about clinical trials can affect parents’ perceptions and
understanding of clinical trials, thus affecting the decision about trial participation
(Byrne-Davis et al., 2010; Deatrick et al., 2002; Miller et al., 2014; Robertson et al.,
2019; Simon et al., 2006). A physician’s attitude about clinical trials or belief about what
is in a child’s best interest can affect enrollment (Dechartres et al., 2011; De Vries et al.,
2010; Dodgshun et al., 2014; Pole et al., 2017; Robertson et al., 2019). In addition, when
there is a conflict between parents and an adolescent about enrollment, parents’ wishes
usually take precedence (Ingersgaard et al., 2018). Finally, a trusting relationship
between healthcare providers and children/parents can facilitate trial participation
(Woodgate & Yanofsky, 2010).
Organizational, Community and Policy
Five studies examined organizational barriers and facilitators to enrollment in
pediatric oncology clinical trials. Lack of a locally available clinical trial adversely
affects enrollment (Dechartres et al., 2011; Dodgshun et al., 2014; Surun et al., 2018). In
contrast, one of the main reasons for participation in phase I clinical trials is that the trials
provide continuity of care compared to the other option of no further treatment (Barrera
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et al., 2005). No studies of community or policy-level barriers and facilitators to
enrollment in pediatric oncology clinical trials were found.
Discussion
Social Ecological Model (SEM)
A key finding of this scoping review is that barriers and facilitators at several
SEM levels influence enrollment of children in oncology clinical trials. According to
SEM, interventions at several, if not all, of these levels will be required to substantially
increase enrollment of children in oncology clinical trials.
Trial
Surprisingly, few studies examined trial-level barriers and facilitators to
enrollment in pediatric oncology clinical trials. The main trial-level barriers examined
were related to the availability of a clinical trial open for enrollment for children with
cancer. Trial availability was influenced by the type of cancer targeted by pediatric
oncology clinical trials. Determining the most prevalent childhood cancers that do not
have available clinical trials is of the utmost importance. Clinical trials for these cancers
can then be developed and implemented to establish the safety and efficacy of new
treatments to benefit pediatric cancer patients. Also important is the coordination of
opening clinical trials. Often there are multiple open trials that are competing against
each other for enrollment of the same population. At other times, there are no open trials
for that same population. Coordination of the opening of trials may help prevent these
situations from occurring and facilitate trials with reaching their enrollment goals.
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The number and types of research studies about trial-level barriers and facilitators
that influence enrollment in pediatric oncology clinical trials is lacking compared to those
about adult oncology clinical trials. Few characteristics of pediatric oncology clinical
trials were investigated in relation to enrollment except for eligibility criteria and dosing
schema. Unlike with pediatric oncology trials, much research has been conducted about
trial-level barriers and facilitators that influence enrollment in adult oncology clinical
trials. These barriers and facilitators include, but are not limited to, eligibility criteria,
disease type, treatment type, research question, design complexity, phase of trial, planned
sample size, sponsor, number of sites, and location(s) of sites (Adams-Campbell et al.,
2004; Al-Refaie et al., 2011; Baum, 2002; Bennette et al., 2016; Benson et al., 1991;
Cheng et al., 2010; Diehl et al., 2011; Freedman et al., 2018; Go et al., 2006; Khunger et
al., 2018; Kim et al., 2015; Kornblith et al., 2002; Logan et al., 2017; Massett et al., 2016;
McKane et al., 2013; Meric-Bernstam et al., 2015; Moore et al., 2004; Penberthy et al.,
2012; Schroen et al., 2010; Schroen et al., 2011; Simon et al., 2004; Spiegel et al., 2017;
Statler et al., 2018; Stensland et al., 2014; Swain-Cabriales et al., 2013; Tang et al., 2017;
Tibes et al., 2011).
The trial-level barriers for pediatric oncology clinical trials may be different than
those for adults. Children are often diagnosed with different types of cancers than adults,
thus the clinical trials target these different cancer types and have different eligibility
criteria and treatments. Also, since childhood cancer is less prevalent than adult cancer,
there are fewer sites participating in clinical trials. In addition, pediatric oncology clinical
trials have different sponsors and participating sites than those of adult oncology trials.
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Most pediatric oncology clinical trials are sponsored by COG, which is supported by the
NCI. Over 90% of children with cancer in the United States are treated at COG member
institutions, which consist mainly of children’s hospitals and academic cancer centers
(COG, n.d). Unlike pediatric clinical trials, most adult oncology clinical trials are
sponsored by pharmaceutical companies (Lechleiter, 2015). Also, adult cancer clinical
trials are conducted at many facilities besides hospitals and academic cancer centers, such
as community hospitals and private physician offices. Additional research is needed to
determine if the differences in sites and sponsors between adult and pediatric oncology
trials affect enrollment. For example, those trials sponsored by pharmaceutical companies
may have better enrollment than those sponsored by COG since pharmaceutical
companies tend to have larger financial resources for advertising and participant
incentives such as travel vouchers.
Researchers have also examined many barriers and facilitators to enrollment in
adult oncology clinical trials in detail. For example, the following eligibility criteria
pertaining to characteristics of potential participants were related to poor accrual: the
presence of comorbidities, poor performance status, advanced age, histopathology, past
history of cancer, a current second cancer, inadequate laboratory results, fewer prior
systemic chemotherapy regimens, and disease-specific inclusion criteria such as
testosterone levels, PSA results, Gleason scores, and number of positive lymph nodes
(Adams-Campbell et al., 2004; Al-Refaie et al., 2011; Bennette et al., 2016; Diehl et al.,
2011; Freedman et al., 2018; Go et al., 2006; Kornblith et al., 2002; Massett et al., 2016;
McKane et al., 2013; Meric-Bernstam et al., 2015; Moore et al., 2004; Penberthy et al.,
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2012; Schroen et al., 2011; Simon et al., 2004; Statler et al., 2018). Even in studies where
eligibility criteria were found to influence enrollment in pediatric oncology clinical trials,
specific eligibility criteria were not investigated to determine which of the criteria served
as barriers to enrollment. Restrictive eligibility criteria may be able to be amended to
facilitate enrollment while still maintaining internal validity of pediatric oncology clinical
trials.
Individual/Intrapersonal
Almost all the studies examined barriers and facilitators to enrollment in pediatric
oncology clinical trials at the individual level. Overall, the studies demonstrated
disparities with enrollment in pediatric oncology clinical trials in relation to age, sex,
race/ethnicity, language, and insurance status, same as demonstrated in the previously
discussed studies about influential factors of enrollment in adult oncology clinical trials.
These disparities may indicate Healthy People 2020’s objectives is to reduce health care
disparities for cancer has not been met (U.S. Office of Disease Prevention and Health
Promotion, 2019). Pediatric oncology clinical trials need to be developed and
implemented to facilitate enrollment as they are the key to discovering and testing new,
effective treatments.
Desperation for a cancer cure and/or extension of a child’s life was consistently
demonstrated as a motivation for clinical trial enrollment. When children and their
parents receive a cancer diagnosis and/or a poor prognosis, they are overwhelmed and
may not be able to think rationally about potential treatments and possible associated
adverse events. Parents will often do anything to save their children. In this mindset, they
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may be unable to rationally consider the possible lack of efficacy and presence of
toxicities associated with treatments on clinical trials. Healthcare providers must ensure
true assent and informed consent have been given before children are enrolled on clinical
trials.
Interpersonal
The most commonly examined interpersonal barriers and facilitators to
enrollment in pediatric oncology clinical trials were those related to parental consent. The
content of physicians’ discussions with parents about clinical trials affected the parents’
perceptions and understanding of clinical trials, possibly affecting the parents’ decisions
about their children enrolling in the clinical trial (Byrne-Davis et al., 2010; Deatrick et
al., 2002; Miller et al., 2014; Robertson et al., 2019; Simon et al., 2006). Therefore,
healthcare providers need to provide clear and comprehensive clinical trial information to
parents to facilitate enrollment.
When there was a conflict between parents and an adolescent about trial
participation, parents’ wishes usually took precedence (Ingersgaard et al., 2018).
Therefore, healthcare providers need to provide a supportive environment that facilitates
communication and understanding between parents and children to avoid continuing
conflict. Healthcare providers also need to ensure proper assent and informed consent
procedures are followed, especially when a child’s wishes conflict with his parent(s).
Organizational
Only five studies examined organizational barriers and facilitators to enrollment
in pediatric oncology clinical trials. Most of these studies found lack of an available trial
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adversely affected enrollment. Besides being a trial-level barrier, lack of an available trial
can also be considered an organizational barrier influencing enrollment in pediatric
oncology clinical trials. Even though an appropriate oncology clinical trial may exist for a
child, the trial may not be open at the institution where the child is receiving care. Also,
the child’s family may not have the resources to travel long distances to receive care at an
institution that is participating in the trial. Grant-funded agencies and pharmaceutical
companies should be incentivized to open pediatric oncology clinical trials at institutions
that are strategically located to meet the needs of the most children as possible. In
addition, since clinical trials are costly to operate, organizations should be encouraged to
manage their limited financial and human resources, so they are able to financially open
additional much-needed pediatric oncology clinical trials. When its not possible open
new trials, centers can educate parents/adolescents about important trials that may be
available at other institutions.
Community and Policy
None of the studies examined barriers and facilitators to enrollment in pediatric
oncology clinical trials at the community and policy levels. The conduct of research
about barriers and facilitators that influence enrollment in pediatric oncology clinical
trials at the community and policy levels may require more time and financial resources
than the conduct of research at the individual and interpersonal levels. Hence, current
limited and competitive research funding may contribute to the unequal proportion of
research about barriers and facilitators at the community and policy SEM levels that
influence enrollment in pediatric oncology clinical trials.
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Barriers and Facilitators in General
A finding of this scoping review is the majority of studies were conducted in
Europe addressing barriers and facilitators that influence enrollment of children in
oncology clinical trials. Barriers and facilitators investigated in this scoping review may
not have the same influence as they have in other countries due to different cultures,
healthcare delivery systems, and regulations. Thus, researchers and health care providers
need to be cautious in applying specific study findings from one community or country to
others.
Findings from some studies exploring differences in enrollment for cancer type
and insurance status differed from those of others exploring the same factors. Aristizabal
et al. (2015) found no significant differences in enrollment for cancer type and insurance
status. However, Shochat et al. (2001) found children who lacked insurance had lower
rates of clinical trial participation. These conflicting findings may be due to different
types of insurance available in the different states in which the children lived. Findings
from several, but not all, studies suggest hematological cancers are associated with higher
clinical trial participation rates than other types of cancers (Dodgshun et al., 2014;
Donnelly et al., 2017; Thomas et al., 2018). These conflicting findings could be due to
different types of cancers that were examined in the studies. Hematological cancers have
a higher frequency than other cancers in children. If there are more patients with a certain
cancer, it may be easier to enroll a larger number of participants into a clinical trial,
compared to patients with rare cancers.
Gaps in the Literature
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Barriers and facilitators to enrollment in pediatric oncology clinical trials have
been described in the literature. However, very few, if any, were examined at the trial,
organizational, community, and policy levels. In addition, the sample of studies in this
scoping review did not specify which factors were most influential on enrollment. The
studies did not specify if some factors such as trial phase, age, and race/ethnicity were
more influential than others based on the type of cancer targeted in clinical trials, patient
demographics, and settings.
The sample of reviewed studies generally lacked a theoretical framework and
large sample sizes of clinical trials. Only four of the reviewed studies were theoretically
based. In future studies, the utilization of theory to explore factors at all SEM levels will
strengthen internal validity and increase interpretability of results (Melnyk & MorrisonBeedy, 2012). Many of the reviewed studies also lacked a large sample size of clinical
trials. In addition, many of them did not use a comprehensive database of clinical trials
that includes trials conducted throughout a country or the world. Small sample sizes of
clinical trials conducted in a single or few locations limit the generalizability of study
results.
Limitations
This scoping review framed by the SEM presented a general synopsis of the
current literature related to factors associated with enrollment of children in oncology
clinical trials and identified opportunities for future research on this topic. However, the
literature search may not have included all available studies in the published literature
because additional terms describing enrollment may have been inadvertently omitted.
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Moreover, since only one reviewer was available, selected studies included in the final
review could not be assessed for inter-rater reliability based on the inclusion and
exclusion criteria.
Implications for Future Research
Future research on enrollment in pediatric oncology trials should consider
investigating barriers and facilitators at the trial, organizational, community, and policy
levels and developing novel interventions to address factors at all SEM levels. Also,
future studies on enrollment of children in oncology clinical trials can include large
samples of clinical trials and utilize large databases of clinical trials conducted in
multiple countries. Finally, more research is needed to understand the reasons for the
contradictory findings in the sampled studies.
With an increased incidence of childhood cancers and low pediatric participation
rates in oncology clinical trials that may hold promise for future treatments, it is
imperative that factors addressing enrollment challenges be examined and addressed.
Many factors at each SEM level affect enrollment. Following a theory-based evaluation
and synthesis of research about factors that influence enrollment in pediatric oncology
clinical trials, this scoping review demonstrated a lack of adequate research. To address
this gap, theoretically based studies with rigorous designs and adequate sample sizes need
to be conducted to address factors at SEM levels not previously studied. Finally,
interventions should address factors that influence enrollment while using innovative
approaches, such as trial designs that eliminate unnecessary eligibility criteria; electronic
educational materials that can be adapted based on a parent’s/child’s knowledge of
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oncology clinical trials; and organizational, community, and federal policies incentivizing
the opening of pediatric oncology clinical trials in locations where they are needed.

Acknowledgements
None

32

References
Adams-Campbell, L. L., Ahaghotu, C., Gaskins, M., Dawkins, F. W., Smoot, D., Polk, O.
D., Gooding, R., & DeWitty, R. L. (2004). Enrollment of African Americans onto
clinical treatment trials: study design barriers. Journal of Clinical Oncology,
22(4), 730-734. https://doi.org/10.1200/JCO.2004.03.160
Al-Refaie, W. B., Vickers, S. M., Zhong, W., Parsons, H., Rothenberger, D., &
Habermann, E. B. (2011). Cancer trials versus the real world in the United States.
Annals of Surgery, 254(3), 438-442; discussion 442-433.
https://doi.org/10.1097/SLA.0b013e31822a7047
American Cancer Society. (2020, January 8). Key statistics for childhood
cancers. https://www.cancer.org/cancer/cancer-in-children/key-statistics.html
Aristizabal, P., Singer, J., Cooper, R., Wells, K. J., Nodora, J., Milburn, M., Gahagan, S.,
Schiff, D. E., & Martinez, M. E. (2015). Participation in pediatric oncology
research protocols: Racial/ethnic, language and age-based disparities. Pediatric
Blood & Cancer, 62(8), 1337-1344. https://doi.org/10.1002/pbc.25472
Arksey, H., & O'Malley, L. (2005). Scoping studies: towards a methodological
framework. International Journal of Social Research Methodology, 8(1), 19-32.
https://doi.org/10.1080/1364557032000119616
Barrera, M., D'Agostino, N., Gammon, J., Spencer, L., & Baruchel, S. (2005).
Health-related quality of life and enrollment in phase 1 trials in children with
incurable cancer. Palliative & Supportive Care, 3(3), 191-196.
https://doi.org/10.1017/S1478951505050315
33

Baum, M. (2002). The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant
breast cancer trial in postmenopausal patients: factors influencing the success of
patient recruitment. European Journal of Cancer, 38(15), 1984-1986.
https://doi.org/10.1016/s0959-8049(02)00154-5
Bennette, C. S., Ramsey, S. D., McDermott, C. L., Carlson, J. J., Basu, A., & Veenstra,
D. L. (2016). Predicting Low Accrual in the National Cancer Institute's
Cooperative Group Clinical Trials. Journal of the National Cancer Institute,
108(2). https://doi.org/10.1093/jnci/djv324
Benson, A. B., Pregler, J. P., Bean, J. A., Rademaker, A. W., Eshler, B., & Anderson, K.
(1991). Oncologists' reluctance to accrue patients onto clinical trials: an Illinois
Cancer Center study. Journal of Clinical Oncology, 9(11), 2067-2075.
https://doi.org/10.1200/JCO.1991.9.11.2067
Byrne-Davis, L. M., Salmon, P., Gravenhorst, K., Eden, T. O., & Young, B. (2010).
Balancing high accrual and ethical recruitment in paediatric oncology: a
qualitative study of the 'look and feel' of clinical trial discussions. BMC Medical
Research Methodology, 10, 101. https://doi.org/10.1186/1471-2288-10-101
Cheng, S. K., Dietrich, M. S., & Dilts, D. M. (2010). A sense of urgency: Evaluating the
link between clinical trial development time and the accrual performance of
cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clinical
Cancer Research, 16(22), 5557-5563. https://doi.org/10.1158/1078-0432.CCR10-0133
Children’s Oncology Group. (n.d.). What is a clinical trial.
34

https://childrensoncologygroup.org/index.php/what-is-a-clinical-trial
Crane, S., Haase, J. E., & Hickman, S. E. (2019). Parental Experiences of Child
Participation in a Phase I Pediatric Oncology Clinical Trial: "We Don't Have
Time to Waste". Qualitative Health Research, 29(5), 632-644.
https://doi.org/10.1177/1049732318766513
De Vries, M. C., Wit, J. M., Engberts, D. P., Kaspers, G. J. L., & Van Leeuwen, E.
(2010). Pediatric oncologists' attitudes towards involving adolescents in decisionmaking concerning research participation. Pediatric Blood & Cancer, 55(1), 123128. https://doi.org/10.1002/pbc.22510
Deatrick, J. A., Angst, D. B., & Moore, C. (2002). Parents' views of their children's
participation in phase I oncology clinical trials. Journal of Pediatric Oncology
Nursing, 19(4), 114-121. https://doi.org/10.1177/104345420201900402
Dechartres, A., Chevret, S., Lambert, J., Calvo, F., & Lévy, V. (2011). Inclusion of
patients with acute leukemia in clinical trials: A prospective multicenter survey of
1066 cases. Annals of Oncology, 22(1), 224-233.
https://doi.org/10.1093/annonc/mdq336
Diehl, K. M., Green, E. M., Weinberg, A., Frederick, W. A., Holmes, D. R., Green, B.,
Morris, A., Kuerer, H. M., Beltran, R. A., Mendez, J., Gines, V., Ota, D. M.,
Nelson, H., & Newman, L. A. (2011). Features associated with successful
recruitment of diverse patients onto cancer clinical trials: report from the
American College of Surgeons Oncology Group. Annals of Surgical Oncology,
18(13), 3544-3550. https://doi.org/10.1245/s10434-011-1818-9
35

Dodgshun, A. J., De Silva, M. P., Bradbeer, P., & Cross, S. (2014). Enrollment in clinical
cancer trials: how are we doing and what are the obstacles to improving
enrollment rates? A 2-year retrospective review of pediatric cancer trial
enrollment in New Zealand. Journal of Pediatric Hematology/Oncology, 36(8),
630-634. https://doi.org/10.1097/mph.0000000000000123
Donnelly, C. B., Wotherspoon, A. C., Morris, M., Wilson, R. H., Chen, J. J., Cairnduff,
V., Morgan, E., Devlin, A., & Gavin, A. T. (2017). A population-level
investigation of cancer clinical trials participation in a UK region. European
Journal of Cancer Prevention, S229-S235.
https://doi.org/10.1097/CEJ.0000000000000373
Eiser, C., Davies, H., Jenney, M., & Glaser, A. (2005). Mothers' attitudes to the
randomized controlled trial (RCT): the case of acute lymphoblastic leukaemia
(ALL) in children. Child: Care, Health and Development, 31(5), 517-523.
https://doi.org/10.1111/j.1365-2214.2005.00538.x
Freedman, R. A., Dockter, T. J., Lafky, J. M., Hurria, A., Muss, H. J., Cohen, H. J., Jatoi,
A., Kemeny, M. M., &. Ruddy, K. J. (2018). Promoting Accrual of Older Patients
with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology
Member Survey (A171602). Oncologist, 23(9), 1016-1023.
https://doi.org/10.1634/theoncologist.2018-0033
Go, R. S., Frisby, K. A., Lee, J. A., Mathiason, M. A., Meyer, C. M., Ostern, J. L.,
Walther, S. M., Schroeder, J. E., Meyer, L. A. & Umberger, K. E. (2006). Clinical
trial accrual among new cancer patients at a community-based cancer center: A
36

prospective study. Cancer, 106(2), 426-433. https://doi.org/10.1002/cncr.21597
Hinds, P. S., Drew, D., Oakes, L. L., Fouladi, M., Spunt, S. L., Church, C., & Furman,
W. L. (2005). End-of-life care preferences of pediatric patients with cancer.
Journal of Clinical Oncology, 23(36), 9146-9154.
https://doi.org/10.1200/JCO.2005.10.538
Ingersgaard, M. V., Tulstrup, M., Schmiegelow, K., & Larsen, H. B. (2018). A
qualitative study of decision-making on Phase III randomized clinical trial
participation in paediatric oncology: Adolescents' and parents' perspectives and
preferences. Journal of Advanced Nursing, 74(1), 110-118.
https://doi.org/10.1111/jan.13407
Khunger, M., Rakshit, S., Hernandez, A. V., Pasupuleti, V., Glass, K., Galsky, M. D., &
Grivas, P. (2018). Premature Clinical Trial Discontinuation in the Era of Immune
Checkpoint Inhibitors. Oncologist, 23(12), 1494-1499.
https://doi.org/10.1634/theoncologist.2018-0003
Kim, E. S., Bernstein, D., Hilsenbeck, S. G., Chung, C. H., Dicker, A. P., Ersek, J. L.,
Stein, S., Khuri, F. R., Burgess, E., Hunt, K., Ivy, P., Bruinooge, S. S., Meropol,
N., & Schilsky, R. L. (2015). Modernizing Eligibility Criteria for Molecularly
Driven Trials. Journal of Clinical Oncology, 33(25), 2815-2820.
https://doi.org/10.1200/JCO.2015.62.1854
Kornblith, A. B., Kemeny, M., Peterson, B. L., Wheeler, J., Crawford, J., Bartlett, N.,
Fleming, G., Graziano, S., Muss, H., Cohen, H. J., & Cancer and Leukemia Group
B. (2002). Survey of oncologists' perceptions of barriers to accrual of older
37

patients with breast carcinoma to clinical trials. Cancer, 95(5), 989-996.
https://doi.org/10.1002/cncr.10792
Logan, J. K., Tang, C., Liao, Z., Lee, J. J., Heymach, J. V., Swisher, S. G., Welsh, J.,
Zhang, J., Lin, S. H., & Gomez, D. (2017). Analysis of Factors Affecting
Successful Clinical Trial Enrollment in the Context of Three Prospective,
Randomized, Controlled Trials. International Journal of Radiation Oncology
Biology Physics, 97(4), 770-777. https://doi.org/10.1016/j.ijrobp.2016.11.035
Lund, M. J., Eliason, M. T., Haight, A. E., Ward, K. C., Young, J. L., & Pentz, R. D.
(2009). Racial/ethnic diversity in children's oncology clinical trials: Ten years
later. Cancer, 115(16), 3808-3816. https://doi.org/10.1002/cncr.24437
Massett, H. A., Mishkin, G., Rubinstein, L., Ivy, S. P., Denicoff, A., Godwin, E.,
DiPiazza, K., Bolognese, J., Zwiebel, J. A. & Abrams, J. S. (2016). Challenges
Facing Early Phase Trials Sponsored by the National Cancer Institute: An
Analysis of Corrective Action Plans to Improve Accrual. Clinical Cancer
Research, 22(22), 5408-5416. https://doi.org/10.1158/1078-0432.CCR-16-0338
Mckane, A., Sima, C., Ramanathan, R. K., Jameson, G., Mast, C., White, E., Fleck,
S., Downhour, M., Von Hoff, D. D., & Weiss, G. J. (2013). Determinants of
patient screen failures in Phase 1 clinical trials. Investigational New Drugs, 31(3),
774-779. https://doi.org/10.1007/s10637-012-9894-7
McLeroy, K. R., Bibeau, D., Steckler, A., & Glanz, K. (1988). An ecological perspective
on health promotion programs. Health Education & Behavior, 15(4), 351-377.
https://doi.org/10.1177/109019818801500401
38

Melnyk, B. M., & Morrison-Beedy, D. (2012). Intervention research : designing,
conducting, analyzing, and funding. New York: Springer Pub.
Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A.,
Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., Hong, D., De Groot, J., Ravi,
V., Li, Y., Luthra, R., Patel, K., Broaddus, R., Mendelsohn, J., & Mills, G. B.
(2015). Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto
Genomically Matched Clinical Trials. Journal of Clinical Oncology, 33(25),
2753-2762. https://doi.org/10.1200/JCO.2014.60.4165
Miller, V. A., Baker, J. N., Leek, A. C., Drotar, D., & Kodish, E. (2014). Patient
involvement in informed consent for pediatric phase I cancer research. Journal of
Pediatric Hematology/Oncology, 36(8), 635-640.
https://doi.org/10.1097/MPH.0000000000000112
Miller, V. A., Baker, J. N., Leek, A. C., Hizlan, S., Rheingold, S. R., Yamokoski, A. D.,
Drotar, D., & Kodish, E. (2013). Adolescent perspectives on phase I cancer
research. Pediatric Blood & Cancer, 60(5), 873-878.
https://doi.org/10.1002/pbc.24326
Mitchell, J.A. (2010). Social ecological factors influencing cancer-related preventive
health behaviors in African American men. Ohio State University.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, P. (2009). Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA statement.
British Medical Journal, 339, b2535. https://doi.org/10.1136/bmj.b2535
Moore, D. H., Kauderer, J. T., Bell, J., Curtin, J. P., & Van Le, L. (2004). An assessment
39

of age and other factors influencing protocol versus alternative treatments for
patients with epithelial ovarian cancer referred to member institutions: A
Gynecologic Oncology Group study. Gynecologic Oncology, 94(2), 368-374.
https://doi.org/10.1016/j.ygyno.2004.05.033
National Cancer Institute. (2020, February 4). What are clinical trials.
https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials
Nooka, A. K., Behera, M., Lonial, S., Dixon, M. D., Ramalingam, S. S., & Pentz, R. D.
(2016). Access to Children's Oncology Group and Pediatric Brain Tumor
Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation.
Cancer, 122(20), 3207-3214. https://doi.org/10.1002/cncr.30090
Oppenheim, D., Geoerger, B., & Hartmann, O. (2005). Ethical issues in pediatric
oncology phase I-II trials based on a mother's point of view. Bulletin du Cancer,
92(11), E57-60.
Penberthy, L., Brown, R., Wilson-Genderson, M., Dahman, B., Ginder, G., & Siminoff,
L. A. (2012). Barriers to therapeutic clinical trials enrollment: differences
between African-American and white cancer patients identified at the time of
eligibility assessment. Clinical Trials, 9(6), 788-797.
https://doi.org/10.1177/1740774512458992
Pole, J. D., Barber, R., Bergeron, R., Carret, A. S., Dix, D., Kulkarni, K., Martineau, E.,
Randall, A., Stammers, D., Strahlendorf, C., Strother, D. R., Truong, T. H., &
Sung, L. (2017). Most children with cancer are not enrolled on a clinical trial in
Canada: a population-based study. BMC Cancer, 17(1), 402.
40

https://doi.org/10.1186/s12885-017-3390-6
Robertson, E. G., Mitchell, R., Wakefield, C. E., Lewis, P., Cousens, N., Marshall, G.
M., Russell, S. J., Ziegler, D. S., Anazodo, A. A., Trahair, T. N., Barbaric, D.,
Cohn, R. J., Alvaro, F., & O'Brien, T. A. (2019). Enrolment in paediatric
oncology early-phase clinical trials: The health-care professionals' perspective.
Journal of Paediatrics and Child Health, 55(5), 561-566.
https://doi.org/10.1111/jpc.14248
Robinson, T. (2008). Applying the socio-ecological model to improving fruit and
vegetable intake among low-income African Americans. Journal of Community
Health, 33(6), 395-406. https://doi.org/10.1007/s10900-008-9109-5
Schroen, A. T., Petroni, G. R., Wang, H., Gray, R., Wang, X. F., Cronin, W., Sargent, D.
J., Benedetti, J., Wickerham, D. L., Djulbegovic, B., & Slingluff, C. L. (2010).
Preliminary evaluation of factors associated with premature trial closure and
feasibility of accrual benchmarks in phase III oncology trials. Clinical Trials,
7(4), 312-321. https://doi.org/10.1177/1740774510374973
Schroen, A. T., Petroni, G. R., Wang, H., Thielen, M. J., Sargent, D., Benedetti, J. K.,
Cronin, W. M., Wickerham, D. L., Wang, X. F., Gray, R., Cohn, W. F., Slingluff,
C. L., & Djulbegovic, B. (2011). Challenges to accrual predictions to phase III
cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCIsponsored trials. Clinical Trials, 8(5), 591-600.
https://doi.org/10.1177/1740774511419683
Shah, A., Diggens, N., Stiller, C., Richards, S., Stevens, M. C., & Murphy, M. F.
41

(2014). Recruitment of childhood leukaemia patients to clinical trials in Great
Britain during 1980-2007: variation by birth weight, congenital malformation,
socioeconomic status and ethnicity. Archives of Disease in Childhood, 99(5), 407412. https://doi.org/10.1136/archdischild-2012-303268
Shochat, S. J., Fremgen, A. M., Murphy, S. B., Hutchison, C., Donaldson, S. S., Haase,
G. M., Provisor, A. J., Clive-Bumpus, R. E., & Winchester, D. P. (2001).
Childhood cancer: patterns of protocol participation in a national survey. CA: A
Cancer Journal for Clinicians, 51(2), 119-130.
https://doi.org/10.3322/canjclin.51.2.119
Simon, C., Eder, M., Kodish, E., & Siminoff, L. (2006). Altruistic discourse in the
informed consent process for childhood cancer clinical trials. The American
Journal of Bioethics, 6(5), 40-47. https://doi.org/10.1080/15265160600862395
Simon, M. S., Du, W., Flaherty, L., Philip, P. A., Lorusso, P., Miree, C., Smith, D., &
Brown, D. R. (2004). Factors associated with breast cancer clinical trials
participation and enrollment at a large academic medical center. Journal of
Clinical Oncology, 22(11), 2046-2052. https://doi.org/10.1200/JCO.2004.03.005
Spiegel, M. L., Goldman, J. W., Wolf, B. R., Nameth, D. J., Grogan, T. R., Lisberg, A.
E., Wong, D. J. L., Ledezma, B. A., Mendenhall, M. A., Genshaft, S. J.,
Gutierrez, A. J., Abtin, F., Wallace, W. D., Adame, C. R., McKenzie, J. R.,
Abarca, P. A., Li, A. J., Strunck, J. L., Famenini, S., & Garon, E. B. (2017). Nonsmall cell lung cancer clinical trials requiring biopsies with biomarker-specific
results for enrollment provide unique challenges. Cancer, 123(24), 4800-4807.
42

https://doi.org/10.1002/cncr.31056
Statler, A., Othus, M., Erba, H. P., Chauncey, T. R., Radich, J. P., Coutre, S., Advani, A.,
Nand, S., Ravandi, F., Mukherjee, S., & Sekeres, M. A. (2018). Comparable
outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood,
131(25), 2782-2788. https://doi.org/10.1182/blood-2018-01-826693
Steinman, G. L., Smith, W. B., Westrick, M. L., & Greenberg, H. E. (2017). Hot Button
Protocol and Operational Issues Between Sponsors and Sites in Clinical
Pharmacology Studies: A Moderated Forum Session. Therapeutic Innovation &
Regulatory Science, 51(3), 298-302. https://doi.org/10.1177/2168479017705688
Stensland, K. D., McBride, R. B., Latif, A., Wisnivesky, J., Hendricks, R., Roper, N.,
Boffetta, P., Hall, S. J., Oh, W. K., & Galsky, M. D. (2014). Adult cancer clinical
trials that fail to complete: an epidemic? Journal of the National Cancer Institute,
106(9). https://doi.org/10.1093/jnci/dju229
Surun, A., Dujaric, M., Aerts, I., Orbach, D., Jiménez, I., Pacquement, H.,
Schleiermacher, G., Bourdeaut, F., Michon, J., Dupont, J. K., & Doz, F. (2018).
Enrollment in early-phase clinical trials in pediatric oncology: The experience at
Institut Curie. Pediatric Blood & Cancer, 65(5), e26916.
https://doi.org/10.1002/pbc.26916
Swain-Cabriales, S., Bourdeanu, L., Niland, J., Stiller, T., & Somlo, G. (2013).
Enrollment onto breast cancer therapeutic clinical trials: a tertiary cancer center
experience. Applied Nursing Research, 26(3), 133-135.
https://doi.org/10.1016/j.apnr.2013.01.003
43

Tang, C., Sherman, S. I., Price, M., Weng, J., Davis, S. E., Hong, D. S., Yao, J. C.,
Buzdar, A., Wilding, G., & Lee, J. J. (2017). Clinical Trial Characteristics and
Barriers to Participant Accrual: The MD Anderson Cancer Center Experience
over 30 years, a Historical Foundation for Trial Improvement. Clinical Cancer
Research, 23(6), 1414-1421. https://doi.org/10.1158/1078-0432.CCR-16-2439
Thomas, S. M., Malvar, J., Tran, H., Shows, J., & Freyer, D. R. (2018). A
prospective, observational cohort study comparing cancer clinical trial availability
and enrollment between early adolescents/young adults and children. Cancer,
124(5), 983-990. https://doi.org/10.1002/cncr.31127
Tibes, R., Piper, B. F., Smith, J. A., James, R. L., Benjamin, M. A., Yim, J. H.,
Ramanathan, R. K., Von Hoff, D. D., Bay, R. C., & Borad, M. J. (2011). Patient
willingness to undergo pharmacodynamic and pharmacokinetic tests in early
phase oncology trials. Cancer, 117(14), 3276-3283.
https://doi.org/10.1002/cncr.25885
Tulstrup, M., Larsen, H. B., Castor, A., Rossel, P., Grell, K., Heyman, M., Abrahamsson,
J., Soderhall, S., Asberg, A., Jonsson, O. G., Vettenranta, K., Frandsen, T. L.,
Albertsen, . K., & Schmiegelow, K. (2016). Parents' and Adolescents' Preferences
for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia
Trials. Pediatric Blood & Cancer, 63(5), 865-871.
https://doi.org/10.1002/pbc.25887
Unguru, Y., Sill, A. M., & Kamani, N. (2010). The experiences of children enrolled in
pediatric oncology research: implications for assent. Pediatrics, 125(4), e876-883.
44

https://doi.org/10.1542/peds.2008-3429
U.S. National Library of Medicine. (2020). ClinicalTrials.gov. https://clinicaltrials.gov/
U.S. Office of Disease Prevention and Health Promotion. (2020, February 20).
Healthy People. https://www.healthypeople.gov/2020/topicsobjectives/topic/cancer
van der Geest, I. M., van den Heuvel-Eibrink, M. M., Zwaan, C. M., Pieters, R.,
Passchier, J., & Darlington, A. S. (2016). Participation in a clinical trial for a child
with cancer is burdensome for a minority of children. ACTA Paediatrica, 105(9),
1100-1104. https://doi.org/10.1111/apa.13405
Winestone, L. E., Getz, K. D., Rao, P., Li, Y., Hall, M., Huang, Y. V., Seif, A. E., Fisher,
B. T., & Aplenc, R. (2019). Disparities in pediatric acute myeloid leukemia
(AML) clinical trial enrollment. Leukemia & Lymphoma, 60(9), 2190-2198.
https://doi.org/10.1080/10428194.2019.1574002
Woodgate, R. L., & Yanofsky, R. A. (2010). Parents' experiences in decision making
with childhood cancer clinical trials. Cancer Nursing, 33(1), 11-18.
https://doi.org/10.1097/NCC.0b013e3181b43389

45

Figure 1. PRISMA flow chart
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Table 1. Social Ecological Model: Levels of influence
Levels of Influence
Definition
Triala
Characteristics of clinical trials that affect enrollment
such as phase, disease indication, and eligibility criteria
Individual/Intrapersonal
Personal characteristics that affect behaviors such as age,
sex, and race/ethnicity
Interpersonal
Relationships that provide social support and contribute
to one’s identity
Organizational
Formal institutions and informal social groups, including
their policies and processes that influence members’
behaviors
Community
Formal or informal networks with their own social norms
among people, groups, and organizations
Policy
Local, state, and national laws and policies that promote
or regulate behavior
a
Note: Trial level added to adapted Social Ecological Model: Levels of Influence
(Mitchell, 2010; Robinson, 2008)
Mitchell, J.A. (2010). Social ecological factors influencing cancer-related preventive
health behaviors in African American men. Ohio State University.
Robinson, T. (2008). Applying the socio-ecological model to improving fruit and
vegetable intake among low-income African Americans. J Community Health,
33(6), 395-406. https://doi:10.1007/s10900-008-9109-5
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Table 2. Literature matrix for barriers and facilitators to enrollment in pediatric oncology clinical trials

Author,
Date

Study Purpose

Countr
y

Ages of
Childr
en

Cancer
Type

Sample
Size and
Descriptio
n

Aristiza
balet
etal.,
2015

Evaluate
differences in
participation of
children in cancer
CTs by age, sex,
race/ethnicity,
parental language,
cancer type and
insurance status

United
States

1-21
years

Unspec
ified

353
patients

Barrera
et al.,
2005

Examine 1)
children’s healthrelated quality of
life (HRQOL)

Canada

7-15
years

Brain
tumor,
neurobl
astoma,

7 mothers,
2 fathers,
and 3 male
children

# and
type of
Sites /
# of CTs/
Phase of
CTs
1
Children’
s
Hospital/
Unspecifi
ed
number
of CTs/
Phase
unspecifi
ed

Study
Design/ Data
Collection
Methods

Examined
Barriers/F
acilitators

SEM Levels
Addressed

Results

Quantitativeretrospective
cohort/
Rady
Children’s
Hospital San
Diego
(RCHSD)
Tumor
Registry and
the RCHSD
Hematology/
Oncology
Research
Center
database

Age, sex,
race/ethnici
ty, parental
language,
cancer type
and
insurance
status

Individual

1 large
children’
s
hospital/

Qualitative/In
terviews

HRQOL
component
s and
reasons for
phase I trial

Individual,
interpersona
l,
organization
al

There was
significant
underrepresentatio
n for Hispanics
compared to NonHispanic whites,
children of
Spanish-speaking
vs. Englishspeaking parents,
and patients 15–21
years old versus
those 0-4 years
old. There were no
significant
differences in
enrollment for
other racial
groups, sex, cancer
type or insurance
status.
The main reasons
for participation in
phase I trials were
hope for a cure,
continuity of care,
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ByrneDavis et
al., 2010

when they are
eligible for
phase 1 trials and
2) their families’
reasons for
considering trial
participation
Determine how
doctors’
communication
could affect
Recruitment

acute
lympho
blastic
leukem
ia

United
Kingdo
m

2 - 11
years

Acute
lympho
blastic
leukem
ia

Unspecifi
ed
number
of CTs/
Phase I

20 doctorpatient
duos and
30 parents
[17 mothers
and 13
fathers])

6
principal
treatment
sites/
1 CT/
Late
phase

49

participatio
n

Qualitative/O
bservations
and
interviews

Doctors‘
discussions
about CT,
parents’
perceptions
and
comprehen
sion of CT

maintenance of
quality of life, and
increased life
expectancy.

Interpersona
l

Doctors discussed
the CT during
most
consultations.
They discussed 1)
their roles as both
an investigator and
clinician by
utilizing
vernacular
aligning them to
the trial and
parent, and 2) the
trial as a scientific
study that allowed
personalized
treatment. Parents
comprehended
voluntariness,
differences from
standard care, and
right to withdraw
at any time. Some
were confused
about the minimal
residual disease
test and
personalized
treatment.

Crane,
Haase &
Hickma
n, 2019

Describe the
meaning of phase I
pediatric oncology
trial participation
experience from
the parental
perspective

United
States

3 – 17
years

Unspec
ified

11 parents

Two
pediatric
academic
medical
centers
and
national
childhoo
d cancer
support
and
advocacy
groups/
15 CTs/
Phase I

Qualitative –
phenomenolo
gy/
Demographic
form,
interview and
child’s CT
record

Parent’s
lived
experiences
of child’s
participatio
n in
oncology
phase I CT

Individual

Parents’
motivation for
their child to
participate in a
phase I oncology
trial was wanting
to try something
new and
everything
possible to help
their child and to
be a part of the
research that leads
to a cancer cure.

Deatrick
, Angst
&
Moore,
2002

Describe parental
perspectives about
their children’s
participation in
phase I oncology
CTs

United
States

2 -18
years

Solid
tumors,
leukem
ias, and
other
cancers

21 parents
(19
mothers, 2
fathers)

One
children’
s cancer
research
center/
Unspecifi
ed
number
of CTs/
Phase I

Quantitativedescriptive,
crosssectional
using
secondary
analysis for
qualitative
data/
Interviews

Parental
perspective
s about
their
children’s
participatio
n in phase I
oncology
CTs

Individual,
Interpersona
l

All parents felt
they had limited or
no choice for a
cure regarding
their children’s
participation in a
phase I CT.
Parents had
several
expectations for
the CT such as
treatment, buying
time for another
treatment, a
miracle,
altruism, and delay
in death.
Healthcare
providers’
openness and
presentation of
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Dechartr
es et al.,
2011

Approximate
prevalence of
adults and children
with acute
leukemia who
participated in CTs
and determine
factors associated
with nonparticipation

Paris

3-11
years
(includ
ed
adults
but
separat
e
analyse
s)

ALL
and
AML

164
children

DeVries
et al.,
2010

Ascertain
clinicians’ views,
attitudes, and
experiences
towards
adolescents’
enrollment in
research

Netherl
ands

10-18
Years

Unspec
ified

15 pediatric
hematooncologists

3
hematolo
gical
departme
nts
specializi
ng in
pediatric
s/
5
pediatric
trials/
Phase
unspecifi
ed
2
pediatric
oncology
centers in
2
academic
hospitals
/
unspecifi
ed
number
of CTs/
51

Quantitativeprospective
observational
/Survey

Trial
availability,
eligibility,
parental or
investigator
decision

Trial,
interpersona
l,
organization
al

QualitativeInterview

Clinicians’
views,
attitudes
and
experiences
towards
adolescents
’
enrollment
in research

Interpersona
l

options helped
parents make the
best decision about
participation.
Parents also made
the decision based
practical issues,
children’s
capacity, and
spirituality.
72% of children
with AML and
68% with ALL
had an available
trial. Only four
cases (5%) of
AML and ALL
were not eligible.
Patient, parental or
investigator
decision
to not participate
was very low
(1%).
Four central
themes: Pediatric
oncologists believe
the following: (1)
most adolescents
do not have the
capacities to
contribute to
research
discussions; (2)
they fail to provide
adolescents with

Phase
unspecifi
ed

Dodgshu
n
et al.,
2014

Determine
enrollment rate in
pediatric cancer
CTs in New
Zealand using a
dataset and
identify
reasons for nonenrollment

New
Zealan
d

<17
years

Unspec
ified

289
children

2 sites
but
encompa
sses most
pediatric
oncology
cases in
New
Zealand/
Unspecifi
ed
number
of CTs/
Focus on
phase III

Quantitativeretrospective
cohort/ New
Zealand
Child Cancer
Registry and
medical
records

No trial
open
locally,
closed to
accrual,
rare tumor,
physician
decision,
technical,
parental
decision,
emergency
treatment,
breach of
protocol,
administrati
ve decision

Trial,
individual,
interpersona
l,
organization
al

Donnell
y et al.,
2017

Determine cancer
CT
participation since
the Northern
Ireland

Norther
n
Ireland

< 15
years
(includ
ed
adults

Unspec
ified

317
children

All
unspecifi
ed

Quantitativeretrospective
cohort;
Northern

Participatio
n in
interventio
nal cancer
CT, sex,

Individual

52

all research
information; (3)
parental consent is
sufficient; and (4)
research protocols
are safe and in
adolescents’ best
interests.
28% of children
with cancer in
New Zealand were
enrolled on CTs.
Enrollment rates
differed by
diagnosis, with
low enrollment
rates for
lymphomas and
neuro-oncology
cancers and high
rates for other
solid tumors and
acute
lymphoblastic
leukemia. The two
most common
reasons for nonenrollment were
no locally open CT
(27%) and CTs
closed to accrual
(20%).
21% of children
with cancer
participated in a
CT. 34% with
hematological

Cancer Trials
Network was
founded;
determine
population and
disease factors
associated with CT
participation

Eiser et
al., 2005

Describe
understanding of
consent by
mothers of
children newly
diagnosed
with ALL in
relation to
recruitment to
randomized
controlled trials

but
separat
e
analyse
s)

United
Kingdo
m

4-16
years

Acute
lympho
blastic
leukem
ia

50 mothers

4 United
Kingdom
Children’
s Cancer
Study
Group
centers/
1 CT/
Phase III

53

Ireland
Cancer
Registry
(NICR) was
linked to the
Northern
Ireland
Cancer Trials
Centre
(NICTC)
database

deprivation,
distance
from cancer
center,
urban/rural
residence,
cancer site

Qualitative/interviews

Mothers’
understandi
ng of CTs

Individual

cancers
participated in a
CT, which was
over 70% of all
trial participants.
Females were
more likely to
participate in
trials than males.
Disease site,
especially
hematological
cancers, were
associated
with CT
participation.
47 of 50 mothers
consented for their
child’s
participation in the
RCT. Reasons for
participation and
views about the
consent process
varied. Mothers’
understanding of
the purpose,
advantages, and
disadvantages of
the CT greatly
varied. Most
mothers described
the aim as
comparing old and
new therapies.
They lacked

Hinds et
al, 2005

Ingersga
ard et
al., 2018

Explore
preferences,
decisions, and
influential factors
of decisions of
children and
adolescents with
advanced cancer
about end-of-life
care
Investigate
adolescents’ and
parents’
motivations and
preferences for
participation in the
ALL2008 trials
and adolescents’
partaking in that
decision

United
States
and
Austral
ia

10-20
years

Solid,
brain,
leukem
ia

20
children/ad
olescents

Denma
rk

1-17
years

Acute
lympho
blastic
leukem
ia

16 (five
patients
12–17
years, six
parents of
adolescents
, and five
parents of
patients 1–
12 years)

2
children’
s
hospitals/
Unspecifi
ed
number
of CTs
and phase
of CTs
Unspecifi
ed
number
of sites/
2 CTs/
Phase III

54

Qualitative/In
terviews

Factors
influencing
CT
participatio
n

Individual

Qualitativeexplorative/
Interviews

Reasons for
decision
about
participatio
n, decisionmaking
process/rol
es

Individual,
Interpersona
l

understanding of
randomization.
Factors related to
participating in
CTs by children
and adolescents
included a chance
for cure and
relationships with
others.

Adolescents and
parents valued
adolescents’
Involvement with
decision-making
about enrollment,
with over half of
the adolescents
being involved
with the decisionmaking. Parents’
wishes took
precedence over
adolescents’
wishes in cases of
conflict.
Motivations and
preferences of
parents of children
did not differ from
those of
adolescents, which
consistently
included altruism.
Decisions were

Johnston
et al.,
2010

Examine factors
affecting CT
participation by
children less than
36 months old
with
central nervous
system tumors

Canada

<36
months

Brain
tumor

579
children

Lund et
al., 2009

Identify
racial/ethnic/age/s
ex representation
in pediatric cancer
treatment trials

United
States

0-19
years

Solid
or
lympho
hemato
poietic

14,188
cases

16 of 17
centers
that treat
all
children
with
cancer in
Canada/
Unspecifi
ed
number
of CTs/
Phase
unspecifi
ed
Unspecifi
ed
number
of sites,
CTs, and
phases

55

Quantitativeretrospective
cohort/ Data
bank
containing
survey data
from
pediatric
oncology
centers

Year of
diagnosis,
age at
diagnosis,
sex, tumor
location,
histology,
grade of
malignancy

Individual

QuantitativeChildren’s
Oncology
Group
(COG),
Surveillance,
Epidemiolog
y, and End

Race,
ethnicity,
age, sex

Individual

based on cure,
toxicity and
preference for
standard or
experimental
treatment.
Thoughts of an
adverse outcome
caused fear about
regretting a
decision, yet
physician’s
expertise was
trusted.
22% were enrolled
in a CT. No factor
was significantly
associated with CT
participation. The
two main reasons
for non-enrollment
were no available
study or none open
at the site.

Each racial and
ethnic group was
proportionally
representative. The
following were
significantly
under-represented

Results
(SEER), and
the US
Census
databases

Miller et
al.,
2013

Investigate
adolescents’
perspectives of
understanding and
decisions about
participation in a
pediatric phase I
cancer study

United
States

14-21
years

Unspec
ified

20
adolescents

6
children’
s
hospitals/
Unspecifi
ed
number
of CTs /
Phase I
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QualitativeInterviews

Understand
ing,
decision
making
process,
expectation
s, reasons
for
consent/no
n-consent

Individual

for solid tumor
subgroups:
whites (especially
males),
adolescents, and
Hispanics aged
<10 years. The
following were
significantly
underrepresented
for
lymphohematopoi
etic
cancers: blacks,
Hispanics, and
adolescents. The
most significantly
under-represented
groups were
adolescents for
both solid and
lymphohematopoi
etic cancers and
Hispanic
females with
lymphohematopoi
etic cancers.
All adolescents
enrolled in the
phase I study, and
85% made the
final decision
about
participation. Most
(90%) understood
voluntariness,
risks, and right to

Miller et
al., 2014

Nooka
et al.,
2016

Describe
children’s and
adolescents’
Involvement in
informed consent
discussions for
phase I cancer
trials and test
associations
between
involvement in the
discussions and
age, patients’
perceptions of
difficulty
understanding, and
pressure to
participate
Evaluate patients
by race, ethnicity,
sex, and age in
pediatric oncology
phase 1 CTs

United
States

14-21
years

Unspec
ified

61 patients
but only 8
interviewed
patients

6
children’
s
hospitals/
Unspecifi
ed
number
of CTs/
Phase I

QualitativeInterviews

Physician
to patient
communica
tion,
perceived
pressure

Interpersona
l

United
States

0-19
years

Lymph
ohemat
opoieti
c

1348
children

Unspecifi
ed
number
of sites
and CTs/

Quantitativeretrospective
cohort/
Children’s
Oncology

Race,
ethnicity,
sex, and
age

Individual

57

withdraw. Most
believed that the
trial would
increase their life
expectancy. The
most frequent
reasons for
participation were
clinical benefit, an
option, improved
quality of life, and
fewer side effects
than their previous
treatments.
Patients reported
low difficulty
understanding and
perceived
pressure.
Proportion of
physician to
patient
communication
was not associated
with perceived
pressured.

The following
were
underrepresented
in phase I CTs: LH
tumors (9.3%

(LH)
and
solid
malign
ancies
(128
malign
ancies)

Phase I

Oppenhe
im et al.,
2005

Explore a mother’s
view of issues
related to pediatric
oncology phase III trials

France

7 years

Germin
al
tumor

1 mother

1
institute/
1 CT/
Phase I-II

Pole et
al., 2017

Determine
proportion of
children newly
diagnosed with
cancer enrolled
on a therapeutic
CT and identify
factors associated
with enrollment
and nonenrollment

Canada

0-14
years

Unspec
ified

9204
children

17 sites;
unspecifi
ed
number
of trials
and phase
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Group
(COG);
Pediatric
Brain Tumor
Consortium
(PBTC);
Surveillance,
Epidemiolog
y,
and End
Results
(SEER); US
Census
databases
Qualitativeinterview

Quantitativeretrospective
cohort;
Cancer in
Young
People in
Canada
(CYP-C)
national
pediatric
cancer
population-

observed vs 37%
expected),
Hispanics (12.6%
observed vs 27%
expected),
particularly
Hispanic females
(6% observed vs
18% expected), the
0- to 4-year age
group (11.7%
observed vs 36.5%
expected).
Reasons for
CT
participatio
n

Individual

Trial
availability,
physician
decision,
age at
diagnosis,
sex, race,
cancer
type,
distance
from care
facility

Trial,
individual,
interpersona
l

CT participation
was accepted by
the mother to
avoid surgery and
gain more time
with her child.
The chance for
cure and altruism
did not affect her
decision.
Lack of available
trial (52.2%) and
physician decision
(11.2%) were the
most frequently
cited factors for
non-enrollment.
The following
were associated
with nonenrollment: Asian
and Arab/west
Asian race,

based
database

Robertso
n et al.,
2019

Explore healthcare professionals’
(HCPs)
perspectives about
obtaining informed
consent for earlyphase pediatric
oncology trials

Austral
ia and
New
Zealan
d

Patient
s under
age 18
years

Unspec
ified

87 HCPs

Number
of sites
and CTs
unspecifi
ed/
Early
phase

59

QuantitativeCrosssectional/
Survey

HCPs’
perceived
obstacles
with
obtaining
consent,
experiences
of parents’
decisionmaking
about
enrollment,
experiences
of
providing
information
to parents,
and
perceptions
of parent
understandi
ng

Individual,
Interpersona
l

astrocytoma
diagnosis, and
greater distance
from cancer
center.
61.6% of HCPs
stated they did not
try to influence
parents’ decisions
about participation
in early phase
trials, but 23.3%
stated that they
told parents that
their child would
benefit. The main
impediment in
obtaining consent
(32%) was
parents’ desire to
try anything. Many
parents seemed to
misunderstand
fundamental
concepts about
trials. 25.2% of
HCPs believed
that unclear
information
affected parents’
decisions and that
these decisions
were influenced by
their beliefs that
the trials was the
best hope, trust in
the HCP, and

Shah et
al., 2014

Assess CT
recruitment of
children in Great
Britain diagnosed
with leukemia
during 1980–2007
and evaluate
factors that may
influence
recruitment

Great
Britain

0-14
years

Acute
lympho
blastic
leukem
ia(ALL
) and
Acute
Myeloi
d
Leuke
mia(A
ML)

9147 ALL
and 1466
AML
patients
who were
eligible for
national
CTs

Unspecifi
ed
number
of sites/
20 CTs/
Phase
unspecifi
ed

QuantitativeNational
Registry of
Childhood
Tumours
linked to
birth
registrations,
Children’s
Cancer and
Leukaemia
Group
records,
Hospital
Episode
Statistics and
Medical
Research
Council
clinical trial
registers

Birth
weight,
congenital
malformati
on,
socioecono
mic status,
and
ethnicity

Individual

Shochat
et al.,
2001

Understand the
utilization of
oncology CTs by

United
States

</=21
years
old

Unspec
ified

5,141
children

251
hospitals/
Unspecifi

QuantitativeSurveys from
>200 hospital

Disease,
age, sex,
race,

Individual
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perceived medical
benefit.
Recruitment rates
for ALL varied
significantly with
congenital
malformation
(Down syndrome
61%, other
malformations
80%, none 82%;
p<0.001) and
ethnicity
(South Asian 78%,
other minority
groups 80%, white
85%; p<0.001).
Rates for AML
varied with birth
weight
(< 2500 g 48%,
2500–4000 g 69%,
>4000 g 67%;
p=0.001) and
congenital
malformation
(Down syndrome
28%, other
malformations
56%, none 63%;
p<0.001). For
ALL and AML, no
patters by SES
were found.
The following had
highest CT
participation: those

children in 1987
and 1992

Simon et
al., 2006

Explore how
altruism is
discussed in the
clinical research
setting and
whether it has any
effect on CT
participation

United
States

1-18
years

Acute
lympho
blastic
leukem
ia
(ALL)
or
acute
myeloi
d
leukem
ia
(AML)

140 consent
sessions
with
parents

ed
number
of trials
and phase

cancer
registries

insurance,
and
geographic
al region

6
institutio
ns that
routinely
treat
pediatric
leukemia/
at least 4
CTs/
Phase III

Qualitative/A
udiotaped
informed
consent
sessions and
interviews

Discussion
of altruism

61

Individual,
interpersona
l

treated at pediatric
centers (53.8%)
compared to other
institutions
(25.1%) and ≤5
years old (63.7%;
others, 42.0%).
Adolescents had
the lowest
participation. Type
of insurance did
not affect protocol
participation but
patients who
lacked insurance
had lower rates of
participation.
White,
non-Hispanic
patients had the
lowest
participation rates.
Enrollment rate
was not higher
among those with
consent session
that involved
altruistic
discussion.
Altruism was
discussed in most
consent sessions,
was introduced
most frequently by
the clinician, and
was multi-thematic
most often

Surun et
al., 2018

Explore access to
early-phase
pediatric oncology
CTs for refractory
solid tumors and
identify reasons
for lack of
invitation or
participation

France

Below
18
years
of age

Solid
tumors
and
lympho
mas
(leuke
mia
exclude
d)

100
children

1 site/
Unspecifi
ed
number
of trials/
Phases I
and II

Quantitativeretrospective
chart review

Reasons for
not inviting
patients to
participate,
parents’
refusal,
inclusion
failure

Trial,
individual,
interpersona
l,
organization
al

Thomas
et al.,
2018

Evaluate if cancer
CT availability is
associated with
low enrollment of
early AYAs and
determine the

United
States

0-20
years

Unspec
ified

216
patients
(58 early
AYAs and
158
children)

1
academic
children’
s
hospital/
26 CTs/

Quantitativeprospective
observational
cohort study

Age, sex,
cancer
type,
ethnicity

Individual,
organization
al
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focusing on
benefits to science.
52 patients were
asked to
participate
in an early-phase
trial(s). Twenty
parents declined,
primarily due to
concerns about
decline in quality
of life or
constraints.
Fourteen patients
were not included
on trial due to
clinical
deterioration. Five
patients had no
available earlyphase trials. 43
patients were not
enrolled mainly
due to exclusion
criteria, desire for
standard treatment,
constraints,
psychological
reasons, and
follow-up in
another hospital.
No significant
difference in CT
existence or
availability at the
site was found
between children

effects of age and
other factors upon
enrollment

Mostly
phase III

Tulstrup
et al.,
2016

Examine if type of
trial
(intensification vs.
reduction) with
different toxicity
profiles is
associated with
parents’ and
adolescents’
decisions about
CT enrollment

Nordic
countri
es

1-17
years

ALL

1,853
patients

Unspecifi
ed
number
of sites/
3 CTs/
Phase III

Quantitativeretrospective
cohort study/
Nordic
Society of
Paediatric
Haematology
and
Oncology
database

Trial type

Trial,
individual

Unguru
et al.,
2010

Investigate
younger and older
children’s
understanding of
oncology research
and their decisionmaking related to
it
Examine why
parents agreed to
have their child
with incurable
cancer participate
in a CT during
palliative period

United
States

7-18
years

Several
types

37 children
with cancer

QuantitativeQuality-ofassent
instrument

Understand
ing and
preferences
of research
participatio
n

Individual

Netherl
ands

3-15
years at
death

Unspec
ified

24 parents
of 16
deceased
children

1
children’
s medical
center/Un
specified
number
of CTs
and phase
1
children’
s
hospital/
Unspecifi
ed

Quantitativeretrospective
crosssectional/Que
stionnaires

Reasons for
CT
participatio
n

Individual

van der
Geest et
al., 2016
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and eAYAs.
Overall, there was
a significantly
lower likelihood of
eAYAs, nonHispanics, and
patients with solid
tumors to be
enrolled.
Parents of children
preferred
intensification, but
parents of
adolescents
preferred
reductions.
Adolescents were
more likely to
decline
intensification
trials than
children.
More children
(73%) participated
in CTs to help
children in the
future with cancer
than to get well
personally (60%).
The most frequent
reasons for CT
participation were
treatment for
future patients (n =
16), hope for a
cure (n = 9), and

Winesto
ne et al.,
2019

Identify patient
and institutional
factors associated
with enrollment on
AAML1031

United
States

0 - >15
years

Acute
myeloi
d
leukem
ia
(AML)

370
children
at tertiary
care
hospitals
associated
with
Children’s
Oncology
Group
(COG)

Woodga
te &
Yanofsk
y, 2010

Understand
Canadian parents’
decisions about
their children’s
participation
in cancer CTs

Canada

6
month15
years at
diagnos
is and 3
-17

Unspec
ified

31 parents
from 30
families

number
of CTs/
Phase
unspecifi
ed
Unspecifi
ed
number
of sites/
1 CT/
Phase III

1
outpatien
t
pediatric
cancer
center/

64

prolongation of
child’s life (n = 6).

Quantitative retrospective
cohort/Pediat
ric
Health
Information
System
database
(PHIS)

Race/ethnic
ity, sex,
age,
insurance
type, acuity
at
presentatio
n, region,
zip-code
poverty,
zip-based
low
education

Individual

QualitativeDescriptive/I
nterviews

Reasons for
CT
participatio
n

Individual,
interpersona
l

The following
were less likely to
enroll
non-Hispanic
Black patients
compared to nonHispanic White
patients, patients
with multi-system
failure versus no
system failure, and
patients living in
zip codes with
lower poverty
compared to zip
codes with higher
poverty, but this
varied by
race/ethnicity.
Enrollment rates
were similar
across all age
categories except
infants who had a
lower rate.
Six themes were
noted: surrealness,
the child’s best
interest, benefit to
future families of
children with
cancer, acceptance

years at
time of
study

Unspecifi
ed
number
of CTs/
Phase
unspecifi
ed

CT(s) = clinical trial(s)

65

of decision, single
decision among
several choices,
trust.

Table 3. Socioecological Levels Addressed
Author(s), Year
Aristizabalet
etal., 2015
Barrera et al.,
2005
Byrne-Davis et
al., 2010
Crane, Haase &
Hickman, 2019
Deatrick, Angst
& Moore, 2002
Dechartres et
al., 2011
DeVries et al.,
2010
Dodgshun et
al., 2014
Donnelly et al.,
2017
Eiser et al.,
2005
Hinds et al,
2005
Ingersgaard et
al., 2018
Johnston et al.,
2010
Lena et al.,
2019
Lund et al.,
2009
Miller et al.,
2013
Miller et al.,
2014
Nooka et al.,
2016
Oppenheim et
al., 2005
Pole et al., 2017
Robertson et
al., 2019
Shah et al.,
2014
Shochat et al.,
2001
Simon et al.,
2006
Surun et al.,
2018
Thomas et al.,
2018
Tulstrup et al.,
2016
Unguru et al.,
2010
van der Geest
et al., 2016
Woodgate &
Yanofsky, 2010

Trial

Individual
X

Interpersonal

Organizational

X

X

X

X
X
X
X

X
X

X

X
X

X

X

X

X
X
X
X

X

X
X
X
X
X
X
X
X

X
X

X
X

X
X

X

X

X

X

X

X
X

X

X
X
X
X

X

X
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Trial-level Factors Affecting Accrual and Completion of Oncology Clinical Trials: A
Systematic Review
Abstract
Background: Cancer is the second-leading cause of death in the United States. Clinical
trials translate basic science discoveries into treatments needed by cancer patients.
Inadequate accrual of trial participants is one of the most significant barriers to the
completion of oncology clinical trials.
Objective: The purpose of this study was to investigate trial-level factors that affect
accrual and/or completion of oncology clinical trials, identify gaps in the literature, and
indicate opportunities for future research.
Design: A systematic review of the literature on trial-level factors that affect accrual
and/or completion of oncology clinical trials was performed. Searches in PubMed and
Scopus identified 6,582 studies. Based on eligibility criteria, 16 studies were selected for
the review. Results were analyzed according to the following: a) background factors, b)
disease-related, c) treatment-related, and d) trial design.
Results: Background factors that were investigated in relation to oncology clinical trial
accrual and/or completion included sponsor, number and location of participating
institutions, competing trials, time of trial opening, and fast-track status. Disease-related
factors included the annual incidence and type(s) of targeted cancer. Several types of
treatment such as drugs, radiation and surgery were examined in the studies. Trial design
factors included trial development time, eligibility criteria, randomization, sample size,
trial phase, placebo use, and required protocol procedures and their timing.
Conclusion: With low patient participation rates in oncology clinical trials that hold
promise for future treatments, it is imperative that trial-level factors affecting accrual be
identified and addressed to facilitate the completion of trials.
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Trial-level Factors Affecting Accrual and Completion of Oncology Clinical Trials: A
Systematic Review
1. Introduction
Cancer is the second-leading cause of death in the United States with
approximately 606,520 deaths expected in 2020 (American Cancer Society [ACS], 2020).
As pressure has escalated to expeditiously translate basic science discoveries into
treatments that are urgently needed by cancer patients, the increased number of oncology
clinical trials and exorbitant costs of conducting these trials have resulted in challenges to
their completion. According to ClinicalTrials.gov, approximately 2,800 oncology clinical
trials opened in 2015. This number grew to over 4,600 in 2019 (National Library of
Medicine [NLM], 2020). The median cost of clinical trials for oncology drugs approved
by the Federal Drug Administration (FDA) in 2015-2017 was $37.1 million per trial
(interquartile range = $17.0 - $60.4 million) (Hsiue et al., 2020).
With growth in the number of oncology clinical trials and limited resources to
support the conduct of these trials, inadequate accrual of trial participants has become one
of the most significant barriers to the completion of clinical trials. Only 3-8% of
oncology patients participate in clinical trials (ACS Cancer Action Network, 2018). In
addition, approximately 20% of oncology clinical trials fail to complete because of
inadequate accrual (ACS Cancer Action Network, 2018). Patient accrual is a significant
metric in determining the success of a clinical trial, as achieving the targeted sample size
is required for valid results (Melnyk & Morrison-Beedy, 2012). Clinical trials are too
frequently terminated early or extended due to inadequate accrual. This adversely impacts
the financial and other resources of cancer trial sponsors and participating sites (Steinman
et al., 2017). Most importantly, trials that are delayed or terminated early impede the
ultimate goal of providing effective cancer therapies to patients who urgently need them.
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In 2010, the Institute of Medicine (IOM) called for a substantial improvement in
the efficiency, completion, and prioritization of clinical trials (IOM, 2010). To
accomplish these objectives, precise predictions about a trial’s accrual and completion are
vital in this time of limited research funding for governmental, academic, and corporate
entities (Schroen et al., 2010). These precise predictions to meet the IOM’s objectives are
only possible through a comprehensive understanding of the factors that affect accrual
and completion of oncology clinical trials. The literature demonstrates that factors
impacting accrual and completion of oncology clinical trials operate at the individual,
interpersonal, organizational, community, and policy levels. Although many researchers
have investigated factors at these levels and developed interventions such as patient
navigation and communication training to address barriers, accrual and completion of
clinical trials remain inadequate (Ahaghotu et al., 2016; Fouad et al., 2016; Hurd et al.,
2017; Ling et al., 2000; National Conference of State Legislatures , 2017; Wuensch et al.,
2017; Yusuf, 2004). It is unclear whether studies have adequately explored factors at the
trial level that may affect successful accrual and trial completion, e.g., eligibility criteria,
planned sample size, phase of study, study design, and use of randomization.
The purpose of this systematic review was to examine the empirical literature to
investigate trial-level factors that affect accrual and/or completion of oncology clinical
trials, identify gaps in the literature, and indicate potential opportunities for future
research. The following research question guided the review: Among studies that
analyzed large data sets of clinical trials, which trial-level factors influenced accrual
and/or completion of oncology trials?
2. Methods
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The authors consulted with a medical reference librarian to determine the best
approach to search the literature for applicable studies. The PRISMA statement guided
the systematic selection of literature included in the sample, and a PRISMA flow chart
detailing the process was created (see Figure 1) (Moher et al., 2009). PubMed and Scopus
databases were searched on February 24, 2020 for relevant publications. There were no
date delimiters. The following search terms with appropriate Boolean operators in titles
and abstracts were applied: (cancer OR oncology) AND (“clinical trials” OR “clinical
research trials” OR “therapeutic trials”) AND (enrollment OR accrual OR recruitment)
AND (“eligibility criteria” OR inclusion OR exclusion OR methodology OR design OR
“randomized controlled trials” OR “randomized control trials” OR RCTs OR barriers
OR challenges OR facilitators OR “facilitating factors” OR factors OR correlates OR
pragmatic OR feasibility). Publications were limited to the English language published in
peer-reviewed journals. The reference lists of retrieved publications were also hand
searched for additional applicable primary sources.
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Fig. 1. Flow diagram for literature selection and inclusion.

The initial search produced 6,582 citations (PubMed = 1,109 and Scopus =
5,473). Five additional citations for peer-reviewed articles were identified from hand
searching. The titles and abstracts of the publications were evaluated for relevancy based
on inclusion and exclusion criteria. Studies were included if they were: a) empirical
studies that analyzed trial-level factors that influenced accrual and/or completion of
oncology trials and b) studies that analyzed data from state, regional, national, or
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international clinical trial databases. Excluded were studies that investigated both
oncological and non-oncological clinical trials, utilized a clinical trials database specific
to a single institution or network of local institutions, or only examined individuals’
perceptions of trial-level factors that influenced accrual and/or completion of oncology
clinical trials. Also excluded were qualitative studies, literature reviews, meta-analyses,
dissertations, narratives, commentaries, workshop proceedings, and expert
recommendations addressing trial-level factors. Upon evaluation, 6,555 citations were
removed due to ineligibility based on the review of titles and abstracts. Of the 32
remaining full-text publications, 16 met criteria to be included in the study sample. Of
note, Scopus did not contain any eligible publications that were not already found in
PubMed.
The results and discussion of this review were organized according to the themes
of Bennette et al.’s (2016) conceptual model of trial-level factors associated with low trial
accrual. The model’s main themes encompass the following: a) background factors, b)
disease-related, c) treatment-related, and d) trial design. Background includes factors
such as competition from other clinical trials and insurance coverage of patient
procedures associated with clinical trials. Disease-related include factors such as annual
incidence of cancer and cancer stage. Treatment-related include factors such as type of
treatment (e.g. chemotherapy or surgical) and use of a single modality (e.g. radiation) as
opposed to multiple modalities (e.g. chemotherapy and radiation). Trial design includes
factors such as eligibility criteria and use of randomization.
3. Results
3.1 General Overview
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Trial-related factors that impact a study’s accrual and/or completion were
examined in several contexts such as study design, population, type of cancer, sample
size, trial phase, and database (Appendix 1). Fifteen studies were quantitative, and one
study had a mixed methods design. All studies (n = 16) were at level 4 (e.g. retrospective
cohort study) according to Melnyk’s hierarchy of evidence (Melnyk & Morrison-Beedy,
2012). Also, all studies examined oncology clinical trials for adults, with only three
including trials for pediatrics. The majority of the studies (n = 10) did not limit inquiry to
a specific type(s) of cancer. Three studies specified multiple types of cancer. The
remaining studies (n = 3) specified one type of cancer, two of which were lung cancer.
Sample size ranged from 16 to 12,875 clinical trials. Almost half of the studies (n=7)
included a sample of phase I, II, and III trials. Most of the remaining studies had a sample
of phase I and II trials (n = 2) or phase II and III trials (n = 3). Two studies had a sample
of only phase III trials. All studies (n = 16) used a national database(s) as the source of
clinical trial data. The most commonly used database (n = 8) was ClinicalTrials.gov.
Only one study utilized a theoretical or conceptual framework, which was Bennette et
al.’s (2016) conceptual model of trial-level factors associated with low trial accrual.
3.2 Conceptual Model of Trial-Level Factors Associated with Low Trial Accrual
To organize the results and discussion, the authors of this systematic review
utilized Bennette et al.’s (2016) model that conceptualizes trial-level factors associated
with low trial accrual according to themes. Of the 16 studies included in the final
analysis, the following themes were addressed: background factors (n = 10), 8 diseaserelated (n = 11), 5 treatment-related (n = 8), and trial design (n = 14).
3.2.1 Background Factors
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Background factors affecting oncology clinical trial accrual and/or completion
were reported in the literature. Sponsor/funder was one of the examined background
factors. Amongst published phase III oncology clinical trials, industry sponsored trials
were among the fastest accruing (Ruther et al., 2015). Also, with poor accrual being the
most common cause of early terminated clinical trials, industry sponsored immune
checkpoint inhibitor trials were significantly less likely to terminate early compared with
those that were sponsored by federal and academic institutions (Khunger et al., 2018).
Worldwide, industry sponsored trials were also significantly more likely to attain accrual
sufficiency than government funded trials (Paul et al., 2019). Consequently, government
sponsorship was a predictor of study failure of randomized clinical trials in radiation
oncology (Nguyen et al., 2018).
Clinical trial development time was another examined background factor. Cheng
et al. (2010) measured trial development time from initial submission of the trial to the
NCI Cancer Therapy Evaluation Program (CTEP) to the opening of the trial. Oncology
clinical trials developed in < 12 months were significantly more likely to meet accrual
targets than those developed in 12-18 months. In contrast, oncology clinical trials
developed in > 24 months were significantly less likely to meet accrual targets than those
developed in < 12 months and 12-18 months.
Other background factors affecting oncology clinical trial accrual and/or
completion were the number and location of participating institutions. Clinical trials
conducted at a single institution were more likely to fail to complete than those conducted
at multiple institutions (Nguyen et al., 2018; Stensland et al., 2014). Regarding location
of participating sites, data from one study suggested that trials performed outside of the
United States or both within and outside of the United States were more likely to

76

complete than those conducted solely in the United States (Stensland et al., 2014).
Findings from another study demonstrated that the continental location of the principal
investigator and trials conducted internationally were not significantly associated with
study failure (Nguyen et al., 2018). Multinational trials were among the fastest accruing.
However, there were no significant differences in accrual time between trials conducted
in the United States compared to Europe among phase III oncology clinical trials (Ruther
et al., 2015).
Competing trials, time of trial opening, and fast-track status were background
factors that were investigated in relation to oncology clinical trial accrual and/or
completion. Among adult National Clinical Trials Network (NCTN) (cooperative group)
cancer clinical trials, the number of competing trials was a predictor of low accrual, with
a higher number of competing trials associated with low accrual (Bennette et al., 2016).
Nguyen et al. (2018) examined completed and incomplete randomized clinical trials in
radiation oncology that opened in consecutive time periods. Significantly more trials
failed during each consecutive time period (11.8% before 2007, 34% in 2007-2008, and
39.5% in 2009-2012). Hernandez-Torres et al. (2019) found trial start date prior to 2003
was associated with lower accrual of older adults. Fast track review status designated by
the Food and Drug Administration (FDA) was not associated with low accrual (Bennette
et al., 2016).
3.2.2 Disease-related
Lower annual incidence of the targeted type(s) of cancer and larger required
enrollment fraction of the eligible patient population were predictors of low accrual
(Bennette et al., 2016). Among NCI Cooperative Group phase III clinical trials, fewer
breast cancer trials terminated due to inadequate accrual (Korn et al., 2010). Also, Ruther
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et al. (2015) found the fastest accruing trials among phase III oncology clinical trials
were those for breast cancer. However, Hernandez-Torres et al. (2020) demonstrated
breast cancer clinical trials were associated with lower accrual of older adults. Among the
older population, clinical trials for central nervous system cancers were associated with
higher accrual (Hernandez-Torres et al., 2020). There was no significant difference in
adequate accrual between urological and nonurological trials. However, kidney cancer
trials accrued the best, whereas bladder cancer trials accrued the worst among urological
trials (Paul et al., 2019). Predictors of low accrual were trials for common solid cancers
as opposed to rare solid or liquid tumors and those with inclusion criteria that targeted
multiple types of cancer (Bennette et al., 2016).
There were mixed results for the association between accrual and metastatic
disease. In two studies, metastatic disease, compared to nonmetastatic disease, was a
predictor of low accrual (Bennette et al., 2016; Lemieux et al., 2008). Also, early stage
cancer was significantly associated with enrollment of older persons (Gross et al., 2005).
However, in another study accrual was better for trials that involved advanced disease
(Lyss & Lilenbaum., 2009).
3.2.3 Treatment-related
Treatment-related factors were investigated in the literature. Clinical trials that
investigated immune checkpoint inhibitors were less likely to terminate early compared
to those that investigated other types of oncology drugs, but the results were not
statistically significant (Khunger et al., 2018). Predictors of low accrual included nontargeted therapy and radiation therapy (Bennette et al., 2016). Accrual was poorer for
Radiation Therapy Oncology Group trials than other cooperative groups and for
multimodality trials that did not primarily include systemic treatment (Lyss & Lilenbaum,
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2009). Whereas Bennette et al. (2016) found the use of an investigational new drug to be
a predictor of low accrual, other researchers (Korn et al. 2010; Lyss & Lilenbaum, 2009)
found no significant difference in inadequate accrual between clinical trials that involved
a new investigational therapy and those that did not. Clinical trials involving standard
therapy, with or without a new therapy, had better accrual than those that did not
incorporate standard therapy (Lyss & Lilenbaum, 2009). Trials that compared surgery to
other types of therapies such as drugs were associated with low accrual and/or trial
failure, and multimodality clinical trials were associated with low accrual (Bennette et al.,
2016; Nguyen et al., 2018).
3.2.4 Trial Design
Our findings suggest eligibility criteria, randomization, sample size, trial phase,
placebo use, and required protocol procedures and their timing affect accrual and/or
completion of oncology clinical trials. The main reported reasons for slow accrual for
phase I oncology clinical trials were safety/toxicity (48%), design/protocol issues (42%)
and eligibility criteria (41%). In addition, the main reasons for slow accrual for phase II
oncology clinical trials were eligibility criteria (35%) and design/protocol issues such as
required procedures, treatment schedule, and overall complexity of the trial (33%)
(Massett et al., 2016). Increased trial complexity defined by a higher number of targeted
diseases in inclusion criteria, interventions and study locations was associated with low
accrual (Bennette et al., 2016).
Sample size and phase of the clinical trial were two trial design factors that
affected accrual and/or completion of oncology clinical trials, although with mixed
results in studies. Bennette et al. (2016) found larger sample size was a predictor of low
accrual. However, Khunger et al. (2016) demonstrated the sample size goal (not reported)
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was higher for completed trials with a median sample goal of 47 compared with that of
terminated trials with a median of 9. They also found phase II and phase III trials were
significantly less likely to terminate early compared with phase I trials, with low accrual
being the most common reason for early termination for all trials. However, Bennette et
al. (2016) demonstrated phase III was a predictor of low accrual. Other studies did not
show accrual varied by trial phase (Paul et al., 2019).
Eligibility is another trial design factor that affects oncology clinical trial accrual.
Overall, eligibility criteria that place burdens on patients, such as those that require the
collection of tissues that are not involved with standard of care, were associated with low
accrual (Bennette et al., 2016). In a study of phase I to III molecular trials, the total
number of eligibility criteria was significantly associated with the enrollment period’s
duration in trials that had at least 35 enrolled patients (Kim et al., 2015).
Specific types of eligibility criteria, which have the potential to considerably limit
accrual, were examined in the literature. In a study utilizing ClinicalTrials.gov, the
following exclusion criteria were in early phase clinical trials for breast, colorectal, or
lung cancers: age > 75 years (6%), history of prior malignancies (86%), autoimmune
disease with exceptions of vitiligo and alopecia (48%), any central nervous system (CNS)
metastasis (38%), symptomatic CNS metastasis (34%), human immunodeficiency virus
(31%), hepatitis B or C (21%), and atrial fibrillation (20%). Renal and hepatic eligibility
criteria were prevalent, such as creatinine <1.5 of the upper limit of normal (ULN)
(35%). Compared to targeted therapy clinical trials, chemotherapy clinical trials were
more likely to have exclusion criteria pertaining to CNS metastasis and history of other
malignancies. Industry-sponsored trials were more likely to have liver function exclusion
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criteria than those with other types of sponsors such as the NCI or universities (Duma et
al., 2019).
Other specific types of eligibility criteria were examined in the literature. In a
study of Eastern Cooperative Oncology Group (ECOG) -affiliated lung cancer clinical
trials, 80% excluded prior cancer diagnosis: active cancer (16%), any prior cancer (14%),
within 5 years (43%), and within 2-3 years (7%). These exclusions were more common
for phase II and III clinical trials (85%) compared to pilot/phase I clinical trials (25%).
Estimated proportion of excluded prior lung cancer patients was up to 18% (>5% for 2/3
of clinical trials and >10% for approximately 1/3 of clinical trials). Exclusion criteria
related to prior cancer treatment were present in 39% (20) of clinical trials, with 29% (15)
excluding chemotherapy or other therapy and 10% (5) excluding both that and
radiotherapy (Gerber et al., 2014). Although in one study (Bennette et al., 2016)
performance status (function, symptom burden, need for care) in exclusion criteria was
not found to be associated with poor accrual in adult oncology clinical trials, performance
status in exclusion criteria was significantly associated with enrollment of older persons
in another study (Gross et al., 2005). However, exclusion criteria related to renal
dysfunction were associated with lower accrual of older adults (Hernandez-Torres et al.,
2020).
Randomization and use of placebo were other trial factors studied regarding
accrual and/or trial completion. Bennette et al. (2016) found the use of randomization to
be associated with low accrual. This was further supported by pediatric nonrandomized
clinical trials having adequate accrual (Korn et al., 2010). However, in another study,
randomization was not found to affect accrual or the early termination of studies (Paul et
al., 2019). The use of a placebo also had mixed results. In a study of breast cancer clinical
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trials by Lemieux et al. (2008), trials with no placebo were associated with better
recruitment than those with a placebo. However, Bennette et al. (2016) found no
associations between low accrual and placebo use. Also, Ruther et al. (2015) reported
there were no significant differences in accrual time between placebo and non-placebo
use in published phase III oncology clinical trials.
Required protocol procedures and their timing affected accrual in oncology
clinical trials. The requirement of obtaining a tissue sample to assess eligibility was a
predictor of low accrual (Bennette et al., 2016). Better recruitment was associated with an
allowed 12 week or more interval vs. less time from diagnosis, surgery, or end of
previous therapy for nonmetastatic clinical trials (Lemieux et al., 2008). There was no
association between blinding and length of follow-up and poor accrual (Bennette et al.,
2016).
Other trial design factors were investigated in the literature. There were no
associations for accrual related to age group, sex, intervention model, therapeutic
compared with nontherapeutic treatment, masking compared with open label, primary
purpose, and specialty (Paul et al., 2019). Among randomized clinical trials in radiation
oncology, lack of accrual was the main reason for trial failure, and a safety endpoint as an
outcome was associated with trial failure (Nguyen et al., 2018).
4. Discussion
In this systematic review, we examined the empirical literature to investigate triallevel factors that affect accrual and/or completion of oncology clinical trials, identified
gaps in the literature, and suggest potential opportunities for future research. One of the
most striking findings was the limited number of studies that utilized large databases, lest
ClinicalTrials.gov, to examine trial-level factors that affect accrual and/or completion of
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oncology clinical trials. Researchers are no longer limited to studying clinical trials
merely as a single trial or trials which involved a single or few institutions.
ClinicalTrials.gov allows researchers to investigate clinical trials as an enterprise since it
is the largest and most comprehensive clinical trial database in the world (Fain, 2018).
There was the lack of a standard definition of adequate or inadequate accrual. For
example, Paul et al. (2019) appeared to define insufficient accrual as anything less than
100% of the trial’s minimum projected sample size whereas Bennette et al. (2016)
defined low accrual as less than 50% of the target sample size. Different definitions for
the outcome variable of adequate or inadequate accrual may partially explain discrepant
results in the examined studies’ results.
Background factors that were investigated in relation to oncology clinical trial
accrual and/or completion included sponsor, number of participating institutions, location
of the institutions, competing trials, time of trial opening, and fast-track status. The
literature consistently demonstrated that industry-sponsored trials outperformed trials
sponsored by other entities in accrual and completion. The pharmaceutical industry may
have more financial resources to manage clinical trials at multiple worldwide institutions
and invest in accrual strategies such as advertising and participant incentives such as
travel reimbursements. Unsurprisingly, a higher number of NCTN-sponsored competing
trials was associated with low accrual. Fast track review status designated by the FDA
was not associated with low accrual which would be expected, given that fast tracking
involves having study sponsors and the FDA working closely together to prioritize and
expedite the conduct of clinical trials to get the investigational therapy approved and
released to the market.
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The type of cancer and its annual incidence were disease-related factors that were
investigated. Except among the older population, clinical trials for breast cancer trials
consistently outperformed those for other types of cancers in accrual, possibly resulting
from the high incidence of breast cancer and public awareness campaigns for these
clinical trials. Predictors of low accrual were common solid cancers as opposed to rare
solid or liquid tumors. Overall, there are more standard therapies available for common
solid cancers than liquid and rare solid tumors. Therefore, patients with common solid
cancers have more standard therapy options and do not have to rely on an investigational
therapy, resulting in lower accrual in clinical trials.
Several types of treatment were examined in the studies. Clinical trials involving
radiation and surgery face challenges with accrual and/or completion. Patients may
choose drug regimens, whether as standard therapy or in trials involving only drugs, to
avoid the invasiveness and potential complications of a surgical procedure. Also, the
proposed surgical procedure in a clinical trial may not have established efficacy in itself
or compared to marketed drugs. In addition, patients may prefer drug regimens over
radiation clinical trials because they do not want to complete frequent visits to a radiation
facility as radiation therapy often entails daily administrations for many weeks. There
were mixed results about accrual between clinical trials that involved a new
investigational therapy and those that did not, likely due to the difference in toxicity
profiles of the investigational agents.
The following trial design factors were investigated: trial development time,
eligibility criteria, randomization, sample size, trial phase, placebo use, and required
protocol procedures and their timing. Eligibility criteria was the most frequently
investigated factor. Although they are necessary to exclude patients who have negative
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prognostic factors and a high risk of adverse events, eligibility criteria can adversely
impact accrual and/or trial completion. Each eligibility criterion needs to be evaluated to
ensure it is supported by the scientific literature and not included just because it was
contained in previous protocols (Malik & Lu, 2019). Duma et al. (2019) also
recommends eligibility criteria to be relaxed once a drug’s toxicity profile is better
understood.
Although trial-level factors that affect accrual and completion of oncology clinical
trials have been discussed in publications, there remain gaps in the literature. Several
trial-level factors have not yet been investigated utilizing ClinicalTrials.gov outside of
studies that are sponsored by NCTN, focus on urological and non-urological solid
cancers, and investigate radiation. These trial-level factors include primary purpose,
randomization, blinding, and placebo use. In addition, there is a need for studies that
characterize the relative importance of various trial-level factors driving clinical trial
accrual and/or trial completion and to test the impact of including and excluding these
driving trial-level factors on accrual. Research is needed to determine if trial protocols
developed to minimize the inclusion of trial-related factors known to be significant
barriers result in successful accrual. The reviewed studies did not indicate if some trialrelated factors were more influential than others based on the type of cancer targeted in
clinical trials. In addition, although this systematic review examined diverse trial-related
factors, the review did not address influential trial-related factors specific to patient
demographics, except for older adults. Trial-related factors may differ in the way they
affect accrual in clinical trials focused on different types of cancers or populations, such
as pediatrics. Interventions to improve accrual may need to be tailored to clinical trials
for specific types of cancers and populations.
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Studies utilizing a mixed methods design may increase knowledge about triallevel factors that affect accrual and/or study completion. Mixed methods studies could
explore participants’ views of, and experiences with, trial-related factors to improve
accrual and/or trial completion. This knowledge could assist researchers in developing
and implementing efficient trial designs and effective interventions to increase accrual
and completion of oncology clinical trials. These data would be helpful in determining
which trial-related factors are modifiable.
We found that several of the examined studies had conflicting results about the
association between trial-level factors and accrual and/or completion of oncology clinical
trials. Therefore, more research is required to further elucidate these associations. Only
eight of the sample articles utilized ClinicalTrials.gov, thus future researchers should
consider use of this database when studying trial-level factors that affect accrual as
having a larger sample sizes of clinical trials would increase generalizability of results.
Furthermore, clinical trials for different types of cancer encounter distinct challenges to
successful accrual. The majority of studies included in this systematic review did not
specify a specific cancer, so future research is vital to address trial-level barriers to
accrual associated with individual types of cancer. Also, since most of the studies in this
review focused on adult oncology clinical trials, similar research is needed for clinical
trials for other populations such as pediatrics. Finally, focused efforts on the development
and implementation of interventions to address the trial-level factors that adversely
impact accrual are needed. This research will need to involve careful reflection about the
modifiability of trial-level factors. Improved accrual may contribute to successful
completion of oncology clinical trials in a timely manner, reducing the waste of financial
and other resources.
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This systematic review has limitations. The literature search may not have
included all available studies in the published literature because additional terms
describing trial-level factors may have been omitted inadvertently. Moreover, since one
investigator conducted the review, selected studies included in the final review could not
be assessed for inter-rater reliability based on the inclusion and exclusion criteria.
5. Conclusion
With low patient participation rates in the increasing number of oncology clinical
trials, it is imperative that trial-level factors affecting accrual be identified and
interventions addressing these challenges be developed to facilitate the completion of
trials. Following a theory-based evaluation and synthesis of research on trial-related
factors that influence accrual in oncology clinical trials, this systematic review identified
gaps in research in this area. To address the gaps in the literature, theoretically-based
studies evaluating the association between trial-level factors and accrual/trial completion
should be conducted. The use of theory guides the evaluation, analysis, and organization
of data. In addition, researchers should simultaneously address background, diseaserelated, treatment-related, and trial design factors that influence accrual using innovative
approaches, focusing on specific types of cancer and populations.
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Appendix 1. Literature matrix for trial-level factors affecting accrual and/or completion of oncology clinical trials

Author, Date

Bennette et al.,
2016

Study Purpose(s)
Specific to Trial Factors
and Accrual
Evaluate associations and
predictors between triallevel factors and low
accrual in adult
cooperative group cancer
CTs (clinical trials)

Type(s) of
Cancer
Multiple

Sample
Description,
Size
787
interventional,
late phase,
cooperative
group adult
oncology CTs
that started in
2000-2011

Phase(s) of
CTs

Database

II, III

Aggregate
Analysis of
ClinicalTrials.g
ov (AACT),
Drugs@FDA
Database,
Surveillance,
Epidemiology,
and End Results
(SEER)
Program

94

Trialrelated
Factors
Number of
competing
trials,
treatment
setting,
intervention
modality,
therapeutic,
targeted
therapy,
new
investigatio
nal agent,
priority
status,
metastatic
setting,
clinical
setting,
sample
size,
randomized
design,
phase,
placebo,
number of
intervention
s, more
than one
condition,
blinded,
number of
participatin
g sites,
eligibility
limited by
performanc

Results Specific to Trial Factors

-Predictors of low accrual included the following: higher
number of competing trials, phase III, higher enrollment
percentage of eligible population, non-targeted therapy,
radiation therapy, lower annual incidence of clinical
condition, tissue sample required to assess eligibility,
non-new investigational drug, metastatic setting, sample
size, more than one condition, and common solid cancer.
-Other factors associated with low accrual were
multimodality, surgery, arduous eligibility criteria,
randomization, and trial complexity including number of
interventions, number of study locations, and more than
one disease.
-There were no associations between low accrual and
placebo use, length of follow-up, fast track review,
blinding, and eligibility limited by performance status.

Cheng et al.,
2010

Investigate trial
development time on
accrual to oncology CTs

Multiple

419 therapeutic,
non-pediatric
oncology CTs
activated
between 20002004 and
sponsored by
National Cancer
Institute (NCI)
Cancer Therapy
Evaluation
Program
(CTEP)
1,103 early
phase
therapeutic
cancer CTs
from 20002015

I, I/II, II, III

CTEP Protocol
and Information
Office database
with input from
Clinical Data
Update System
and Clinical
Trials
Monitoring
Service

Duma et al.,
2019

Identify comorbidities
that adversely impact
recruitment of patients
with breast, colorectal, or
lung cancers in early
phase CTs

Breast,
colorectal,
lung

I, Ib/II, II

ClinicalTrials.g
ov

Gerber et al.,
2014

Determine prevalence of
prior cancer-related
exclusion criteria and
their impact on lung
cancer CT accrual

Lung

51 lung cancer
CTs sponsored
or endorsed by
the Eastern
Cooperative
Oncology
Group (ECOG)
thoracic
committee

I/pilot, II, III

ECOG thoracic
committee
website; linked
Surveillance,
Epidemiology,
and End Results
(SEER)Medicare
database

Gross et al.,
2005

Ascertain the effect of
protocol factors on
enrollment of older
patients in cancer CTs

Lung, breast,
colorectal,
prostate

36,167 patients
enrolled in 33
National Cancer
Institute (NCI)sponsored

Unspecified

NCI Clinical
Trial
Evaluation
Program
database; NCI
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e status,
eligibility
limited by
age
Trial
developme
nt time

Trial phase,
target
disease,
anticancer
therapy,
line of
therapy,
location,
sponsor,
inclusion
and
exclusion
criteria (age
limits,
comorbiditi
es, organ
function)
Eligibility
criteria
related to
prior cancer
and its
treatment

Cancer
type,
performanc
e status,
comorbiditi

-CTs developed in < 12 months were significantly more
likely to meet accrual targets than those developed in 1218 months.
-CTs developed in > 24 months were significantly less
likely to meet accrual targets.

-The CTs had the following exclusion criteria: age > 75
years (6%), history of prior malignancies (86%),
autoimmune disease with exceptions of vitiligo and
alopecia (48%), any central nervous system (CNS)
metastasis (38%), symptomatic CNS metastasis (34%),
human immunodeficiency virus (31%), hepatitis B or C
(21%), and atrial fibrillation (20%).
-Renal and hepatic eligibility criteria were prevalent such
as creatinine <1.5 of the upper limit of normal (ULN)
(35%).
=Compared to targeted therapy CTs, chemotherapy CTs
were more likely to have exclusion criteria pertaining to
CNS metastasis and history of other malignancies.
-Trials sponsored by industry were more likely to have
liver function exclusion criteria than those with other types
of sponsors.
=41 (80%) of ECOG -affiliated lung cancer CTs excluded
prior cancer diagnosis: active cancer (16%), any prior
cancer (14%), within 5 years (43%), within 2-3 years
(7%)).
-Estimated proportion of excluded prior lung cancer
patients was up to 18% ( >5% for 2/3 of CTs and>10%
for approximately 1/3 of CTs).
-Exclusion criteria related to prior cancer treatment were
present in 20 (39%) of CTs, with 15 (29%) excluding
chemotherapy or other therapy and 5 (10%) excluding
both that and radiotherapy.
-Cancer type (early stage) and performance status in
exclusion criteria were significantly associated with
enrollment of older persons.

cooperative
group cancer
CTs in 19962002
69 Canadian
Cancer Trials
Group studies
that started in
1990-2010

es excluded
stage

HernandezTorres et al.,
2020

Determine if exclusion
criteria are associated
with low accrual of older
adults to cancer CTs

Multiple

Khunger et al.,
2018

Ascertain the frequency
and factors associated
with withdrawal and early
termination of oncology
CTs, focusing on immune
checkpoint inhibitor (ICI)
trials

Multiple

12,875 adult,
interventional,
randomized
oncology trials;
350 ICI trials
(2011 to 2015)

I, I/II, II, II/III,
III

ClinicalTrials.g
ov

Type of
cancer, type
of
treatment,
sponsor,
phase,
accrual
goal

Kim et al.,
2015

Investigate implications
of eligibility
criteria in phase I to III
molecular trials

Multiple

I, II, III (only II
and III in final
analysis)

Use of
ClinicalTrials.g
ov was not
successful;
Manual review
of trials

Number
and
characterist
ics of
eligibility
criteria

Korn et al.,
2010

Examine accrual for
National Cancer Institute
(NCI) Cooperative Group
phase III CTs between
2000-2007

Multiple

67 CTs
conducted by
Novartis
Oncology
in the United
States from
2006 to 2013
191 CTs
activated in
2000-2007

III

Unspecified

Disease
site, use of
randomizati
on, use of
investigatio
nal new
drug

Identify protocol
characteristics of breast
cancer CTs associated
with poor recruitment

Breast

I, II (or I and
II), III (or (II
and III)

Questionnaires
to cooperative
groups and
pharmaceutical
companies;
missing data
obtained from

Phase,
randomizati
on, control
group,
blinding,
intervention
,

Lemieux et al.,
2008

III and
randomized
phase II

Physician Data
Query (PDQ)
clinical trial
database
Canadian
Socioeconomic
Management
System
database

*includes 42
pediatric CTs

688 CTs
opened between
1997-2002 in
Ontario
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CT start
date, cancer
type, and
exclusion
criteria

=The following CT factors were associated with lower
accrual of older adults: start date prior to 2003, breast
cancer indication, and exclusion criteria related to renal
dysfunction.
=Central nervous system CTs were associated with higher
accrual of older adults.
- Low accrual was the most common reason for early
termination for all trials.
-5% of CTs were early terminated, and 3.5% were
withdrawn.
- 4% of ICI trials were early terminated, and 1.4% were
withdrawn.
- ICI trials were less likely to early terminate compared
with all other oncology drug trials, but the results were
not statistically significant.
- Institution-sponsored trials were significantly more
likely to early terminate compared with industry
sponsored trials.
- Phase II and phase III trials were significantly less
likely to early terminate compared with phase I trials.
- The accrual goal was higher for completed trials with a
median 47 compared with terminated trials with a median
9.
Overall, the total number of eligibility criteria did not
affect enrollment duration. However, it was significantly
associated with the enrollment period’s duration in trials
that had at least 35 patients.

An estimated 22.0% of all adult and pediatric CTs would
be terminated due to inadequate accrual, with 1.7%
(2,991) of the total enrolled accrued patients being on
these CTs. Fewer breast cancer CTs terminate due to
inadequate accrual. 2 of 42 pediatric trials had poor
accrual. None of the pediatric nonrandomized CTs had
inadequate accrual. There was no significant difference in
inadequate accrual between CTs that involved an
investigational new drug and those that did not.
The following protocol factors were associated with
better recruitment: no placebo vs. placebo, nonmetastatic
vs. metastatic, and allowed 12 week or more interval vs.
less from diagnosis, surgery, or end of previous therapy
for nonmetastatic CTs.

publications
(ClinicalTrials.
gov and
websites for
cooperative
groups and
pharmaceutical
companies were
used only to
verify if trials
should be
included if no
completed
questionnaire
received)

Lyss &
Lilenbaum,
2009

Ascertain accrual patterns
among cooperative group
non-small cell lung
cancer CTs

Non-Small
Cell Lung

Massett et al.,
2016

Determine reasons for
slow accrual in early
phase trials sponsored by
the National Cancer
Institute

Multiple

16 randomized
CTs sponsored
by the main
cooperative
groups in North
America that
closed accrual
between 20002005
135 corrective
action plans
from 20112013
*11 (8%) were
pediatric trials
and 5 (4%)

II, III

Community
Oncology and
Prevention
Trials Research
Group;
National Cancer
Institute of
Canada

I, II

Corrective
action plans and
NCI Cancer
Therapy
Evaluation
Program
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intervention
available
outside the
study,
sponsor,
location,
number of
participatin
g sites,
menopausal
status,
metastasis,
minimal
age limit,
maximal
age limit,
number of
eligibility
criteria,
premature
dosing,
maximum
interval
between
diagnosis/s
urgery/end
of therapy
and
enrollment,
extra
baseline
tests, extra
follow-up
tests
Extent of
disease,
trial phase,
# of
modalities

Study
design/prot
ocol,
eligibility

-Accrual was poorer for Radiation Therapy Oncology
Group trials than other cooperative groups and for
multimodality trials that did not primarily include
systemic treatment.
-Accrual was better for trials that involved advanced
disease.
-CTs involving standard therapy regardless of the
inclusion of a new therapy had better accrual.
-The main reported reasons for slow accrual for phase I
CTs were safety/toxicity (48%), design/protocol issues
(42%) and eligibility criteria (41%). The main reasons
for phase II CTs were eligibility criteria (35%) and
design/protocol issues (33%).

Nguyen et al.,
2018

Compare characteristics
of completed and
incomplete randomized
CTs in radiation oncology
and identify predictors of
trial failure

Multiple

Paul et al.,
2019

Determine predictors of
adequate accrual in
urological and
nonurological solid
cancer trials

Prostate,
colorectal,
kidney,
bladder,
testicular,
breast, lung

were for trials
for both adults
and children
134 trials that
were registered
from 20072010

326 trials in
2000-2006

(CTEP)
database
I, II, III

ClinicalTrials.g
ov

III and IV

ClinicalTrials.g
ov;
International
Standard
Randomised
Controlled Trial
Number
Registry
(United
Kingdom
based); online
databases such
as PubMed and
Google Scholar
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Cooperativ
e group
involvemen
t, sponsor,
PI location,
number of
open
institutions,
internationa
l study, PI’s
h-index,
disease site,
age, sex,
main
comparator
s, number
of study
arms,
masking,
blinding,
primary
purpose,
anticipated
enrollment,
final
enrollment,
primary
outcome
Age group,
nonrandomi
zed vs
randomized
, funding
source, sex,
intervention
model,
therapeutic
vs
nontherape
utic,
masking vs
open label,
primary
purpose,
specialty,
phase

-Lack of accrual (57.5%) was the main reason for trial
failure
-Significantly more trials failed with each consecutive
time period (11.8% before 2007, 34% in 2007-2008, and
39.5% in 2009-2012).
-Predictors of failure were surgical comparator,
government sponsorship, safety endpoint, and studies
starting after 2006 via univariate analysis.
-Via multivariate analysis, predictor of failure was
surgical trials, and predictor of trial success was
behavioral trials.

-63% of trials reported sufficient accrual.
-There was no significant difference in adequate accrual
between urological and nonurological trials.
-Kidney cancer trials accrued the best whereas bladder
cancer trials accrued the worst.
-Compared to government funded trials, industry
sponsored trials were significantly more likely to attain
adequate accrual.
-No other factors (e.g. age group, nonrandomized vs
randomized, intervention model, therapeutic vs
nontherapeutic, masking vs open label, primary purpose,
specialty, phase) were significantly associated with
sufficient accrual.

Ruther et al.,
2015

Determine accrual speed
in published phase III
oncology CTs across
geographical locations
and identify its influential
factors

Multiple

Stensland et
al., 2014

Evaluate study factors
associated with trials that
fail to complete

Multiple

546 phase III
oncology
therapeutic
CTs published
in 2006-2010
*included 4%
pediatric/young
adult CTs
7776 adult
interventional
cancer trials

III

OVID-Medline

Country,
type of
cancer,
funder,
arms, and
result

-The fastest accruing CTs were those that had the
following characteristics: multinational, breast cancer
indication, industry sponsorship, and equivalency.
-There were no significant differences in accrual time
between placebo and non-placebo CTs and those CTs
conducted in the United States versus Europe.

I/II, II, III

ClinicalTrials.g
ov

Number of
sites,
sponsor,
location

-The most common reason for CTs to fail to complete
was poor accrual (39%).
-The following trials were more likely to not complete:
---Single center versus multicenter trials
---Industry-sponsored versus federally funded trials
-Trials performed outside of the United States or both
within and outside of the United States were more likely
to complete than those conducted solely in the United
States.

CT=clinical trials
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Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Poor
Accrual: An Exploratory Analysis
Abstract
Background: Poor accrual is a significant barrier to the completion of pediatric oncology
clinical trials. Early terminated or prolonged trials have substantial financial implications
and hinder the availability of new effective pediatric cancer therapies in a timely manner.
The purposes of this study were to 1) describe patterns in the presence of variables and
completeness of data entry for variables in the ClinicalTrials.gov database over time for
pediatric oncology trials and 2) investigate trial-related factors that may affect early
termination of pediatric oncology clinical trials due to low accrual.
Procedure: ClinicalTrials.gov data were extracted from Aggregate Analysis of
ClinicalTrials.gov (AACT). Descriptive statistics and multiple logistic regression were
used to analyze the data.
Results: The number of variables increased with each subsequent period, except the most
recent period (150, 159, 160 and 139, respectively). Of the 160 examined variables, 129
(81%) variables had 100% of applicable data in each period. None of the following
clinical trial characteristics were associated with or predictive of early termination of
pediatric oncology trials due to low accrual: enrollment, primary purpose, intervention
type, phase, interventional model, allocation, arm type, number of arms, masking,
primary end points, number of primary outcomes, sponsor, number of participating
facilities, and primary disease. However, odds for studies to terminate early were 3.9
times higher for those that used a data and safety monitoring committee compared to
those that did not (p=0.05)
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Conclusions: Knowledge of trial-level factors that may affect accrual and completion of
those trials may enable researchers to strategically design trials in a manner that
facilitates accrual and trial completion in an efficient manner.
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Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Poor
Accrual: An Exploratory Analysis
Introduction
Cancer is the second-leading cause of death among children in the United States,
exceeded only by injuries.1 In 2020, it was predicted that 11,050 children ages 0-14 years
old would be diagnosed with cancer, and 1,190 children in the same age group would die
from cancer.1 Besides death, ramifications of childhood cancer include long-term
complications from anticancer therapies such as secondary malignancies and financial
hardships for survivors and their families.2,3 As of 2019, only 34 drugs had been
approved by the United States Food and Drug Administration (FDA) for the treatment of
pediatric cancers.4 New effective anticancer therapies are necessary as evidenced by
cancer remaining a leading cause of death for children. The following types of cancers
account for almost 82% of childhood cancer deaths: brain (30.0%), leukemia (24.8%),
bone and articular (10.1%), endocrine (9.0%), and mesothelial/soft tissue (7.7%).5
Clinical trials afford new effective therapies for children with cancer by
establishing the safety and efficacy/effectiveness of drug discoveries. Alongside the need
for new effective cancer therapies for children, the number of pediatric oncology clinical
trials and their associated costs have substantially increased. According to the
ClinicalTrials.gov database, 32 pediatric oncology clinical trials were initiated in 2010
whereas this number grew to 137 in 2019.6 Clinical trials for FDA-approved oncology
drugs in 2015-2017 had a median cost of $37.1 million per trial (interquartile range =
$17.0 - $60.4 million).7
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Poor accrual is a significant barrier to the completion of pediatric oncology
clinical trials. For a study’s findings to be valid, an adequate sample size is required.8
Approximately 60% of children with cancer are treated in clinical trials.9 Consequently,
pediatric oncology clinical trials that are terminated early or prolonged due to poor
accrual adversely impact treatment outcomes; in addition, early termination or
prolongation of trials negatively affects the financial well-being of trial sponsors such as
governmental organizations, academic institutions and the pharmaceutical industry, along
with that of institutions participating in the trials.10 Most notably, early terminated or
prolonged trials hinder the release of new effective pediatric cancer therapies in a timely
manner.
The literature demonstrates that factors impacting accrual and completion of adult
oncology clinical trials operate at the trial, individual, interpersonal, organizational,
community, and policy levels.11-16 Trial level factors include the following: sponsor, trial
development time, number and location of participating institutions, sample size,
competing trials, time of trial opening, fast-track status, type of cancer, incidence of the
targeted cancer, and presence of metastases.11,17-27 Other trial level factors include type of
treatment, eligibility criteria, randomization, required procedures and their timing, use of
a placebo, and phase of study.11,18-26,28-32 However, a dearth of research exists about trial
level factors that may affect accrual in pediatric oncology clinical trials. Trial level
factors may differ between trials for pediatric and adult populations because these
populations differ in their biology, types of cancer, and cancer therapies.33
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As a result of a growing demand for transparency regarding clinical trials by the
government and public to facilitate drug development and safety, many sponsors are
required by federal regulations to register their trials on ClinicalTrials.gov.34 Registration
is required for clinical trials that involve an FDA investigational new drug application,
have at least one participating site in the United States, or involve a drug, biological, or
device produced in the United States and exported elsewhere.35,36 Before the
ClinicalTrials.gov database became accessible in 2000, researchers relied upon available
data from a single trial or multiple trials within a single institution to investigate triallevel factors. ClinicalTrials.gov now allows researchers to investigate clinical trials as an
enterprise. However, changes in regulations over the last two decades resulted in
discrepancies in the type and completeness of data that investigators submitted into the
database during that time frame.37 As a result, the amount of available data differs among
variables such as eligibility criteria and sample size and across different time periods.
To address the previously discussed gaps in knowledge of accrual and early
termination of pediatric oncology trials, this study aimed to: 1) describe patterns in the
presence of variables and completeness of data entry for variables in the
ClinicalTrials.gov database over time; and 2) investigate trial-related factors that may
affect early termination of pediatric oncology clinical trials due to low accrual.
Theoretical Framework
Bennette et al’s11 conceptual model of trial-level factors associated with low trial
accrual guided variable selection, data analysis and organization of results. The model
offers four critical domains for assessing trial-level factors associated with low trial
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accrual: background, disease-related, treatment-related, and trial design. Background
factors include factors such as greater competition from other trials and less state-level
coverage of clinical trial costs. Disease-related factors include factors such as less
advanced disease, solid tumor setting, less compelling scientific rationale, and lower
annual incidence of the eligible population. Treatment-related factors include factors such
as treatment in trials that are greatly different from standard of care, research question not
relevant to clinical practice, patient or provider preference for a particular treatment,
radiotherapy or surgical treatment, not an investigational new agent, more expensive
treatment, higher risk for toxicity, multimodality, and less compelling scientific rationale.
Trial design factors include factors such as strict or many eligibility criteria, randomized
design, placebo-controlled arm, greater trial complexity, and longer required follow-up.
Methods
To examine possible trial-related predictors of early termination of pediatric
oncology clinical trials due to low accrual, the authors utilized ClinicalTrials.gov data
which were extracted from Aggregate Analysis of ClinicalTrials.gov (AACT). The
researchers chose ClinicalTrials.gov because it is the largest and most comprehensive
database of clinical trials in the world.38
ClinicalTrials.gov Dataset Description
Maintained by the National Library of Medicine (NLM), ClinicalTrials.gov is a
database that includes information about clinical trials and other types of studies for
diverse illnesses, including cancer. This database, which is accessible by the public,
includes clinical trials sponsored by public and private entities, conducted in all states and
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216 countries. Sponsors or primary investigators provide both, the initial information and
periodic updates of the clinical trials.6
The National Institutes of Health (NIH) created ClinicalTrials.gov as a registry of
clinical trials that examine investigational drugs’ effectiveness for serious illnesses due a
mandate by the Food and Drug Administration Modernization Act of 1997 (FDAMA). In
2000, ClinicalTrials.gov became accessible to the public. Subsequently, the Amendments
Act of 2007 (FDAAA) required the database’s expansion to include other types of
clinical trials and additional information about the trials, including their results. The law
also instituted penalties for failure to provide the required information. In 2016, the Final
Rule for Clinical Trials Registration and Results Information Submission (42 CFR Part
11) further expanded the required information for clinical trials. Thus, because of laws,
the number of registered trials and amount of available information for these trials have
increased over time. In addition, over the years more sponsors and investigators have
provided their trial data due to other policies.36,37 For example, in 2005 the International
Committee of Medical Journal Editors instituted the requirement of clinical trial
registration for publication.39
Aggregate Analysis of ClinicalTrials.gov (AACT) Dataset Description
Aggregate Analysis of ClinicalTrials.gov (AACT) is a database that contains all
ClinicalTrials.gov data related to registered protocols and their results. Every day the data
in ClinicalTrial.gov are uploaded to AACT, a relational database.40 The AACT database
was chosen for this study because it allows ClinicalTrials.gov data to be more easily
downloaded and imported into statistical analysis software SPSS than the original files on
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the ClinicalTrials.gov website. The files on ClinicalTrials.gov are very large zipped files,
each containing a large number of sub-files in XML format that cannot easily be
imported into SPSS without use of XML syntax and/or purchase of an XML to SPSS
converter. In contrast, files in the AACT database have been converted to .txt,
simplifying and reducing steps for the user.
Data Analysis
SPSS Version 25 (Armonk, NY: IBM Corp, 2017) was used to perform analyses
of selected variables from the AACT dataset. The aims were to describe patterns in the
presence of variables and completeness of data entry for variables in the
ClinicalTrials.gov database over time and 2) investigate trial-related factors that may
affect early termination of pediatric oncology clinical trials due to low accrual. For both
aims, frequency distributions for all variables are reported in tables. For Aim 2, Chisquare statistics were obtained to determine whether a relationship between the potential
predictor variables (enrollment, primary purpose, intervention type, phase, interventional
model, allocation, arm type, number of arms, masking, primary end points, number of
primary outcomes, sponsor, number of participating facilities, primary disease, data
monitoring committee) and early termination of clinical trial due to low accrual exists.
Frequencies and percentages are reported. In addition, multiple logistic regression was
performed. Forward stepwise and forced entry multiple logistic regression were used to
add potential predictors sequentially into the model based on a significance level α of <
0.2 to reduce the chance of a false negative result (Type II error) since this was an
exploratory analysis.
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Results
Characteristics of Clinical Trials
A total of 474 pediatric interventional oncology trials were identified in the
AACT database. Of the different time periods examined in this study, most pediatric
oncology trials (n = 222) were initiated during 2008 – 2017. Most of the trials did not
specify any participating institutions within the United States (n = 258) and/or had a
status other than completed or terminated/withdrawn (n = 210). Of the total pediatric
interventional oncology trials, 105 were trials conducted in the United States that were
either completed (n = 87, 83%) or terminated/withdrawn due to poor accrual (n = 18,
17%). Most of these trials (n = 77, 73%) enrolled 100 or fewer subjects. Over half of the
trials (n = 62, 59%) had a primary aim to test a treatment, with drugs being the most
frequent type of intervention (n = 48, 46%). The most common phase of trial was II (n =
27, 26%), and 49 (47%) trials had a single group study design. Forty trials (38%)
involved randomization. Most trials had two arms (n = 41, 39%), with the majority of
trials (n = 73, 70%) having an experimental arm versus an active, sham, placebo, or no
intervention control arm. Most trials (n = 74, 70%) had no masking, i.e., neither study
participants nor raters obtaining assessments were blinded to the treatment assignment.
Almost half (n = 50, 48%) were sponsored internally by universities and hospitals. Even
though leukemia was the most frequent primary disease (n = 25, 24%), trials (n = 34,
32%) often included patients with multiple types of cancer. The majority of trials had > 1
participating facility (n = 56, 53%) and a data and safety monitoring committee (n = 51,
58%).
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Trials with a Given Variable Completed within Four Time Periods
The researchers aimed to describe patterns in the presence of variables and
completeness of data entry for variables in the ClinicalTrials.gov database over time.
Over time, new regulations mandated additional variables be captured within
ClinicalTrials.gov. The researchers examined the frequency and proportion of pediatric
oncology clinical trials with a given variable completed within four periods defined by
new regulations affecting data entry in ClinicalTrials.gov (see Table 1). The number of
initiated trials increased with each subsequent time period (n = 27 initiated before
21Nov1997 [Period I]; n = 120 between 21Nov1997 and 31Aug2008 [Period II]; n = 222
between 01Sep2008 and 17Apr2017 [Period III]), except the most recent time period (n =
98 between 18Apr2017 and 01May2020 [Period IV]), when the data were retrieved from
ClinicalTrials.gov. In addition, the number of variables increased with each subsequent
period, except the most recent period (150, 159, 160 and 139, respectively). Of the 160
examined variables, 129 (81%) variables had 100% of applicable data in each period. If a
variable was included in a period, that variable was not necessarily included in a
subsequent period, e.g. number of related serious events and sample size included in
analysis for each outcome for each study group. The third period had the most complete
data, with 99.6% compared with 84.4% in first period, 85.5% in the second, and 83.2% in
the fourth period. The most incomplete data in the fourth period pertain to final analyses
and results, e.g. sample size included in analysis for each outcome for each study group,
number of withdrawals/drops, and number of related serious events.
Association of Clinical Trial Characteristics with Early Termination of Pediatric
Oncology Trials
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No statistically significant associations between clinical trial characteristics and
early termination/withdrawal of pediatric oncology trials were observed (Table 4) except
for use of a data and safety monitoring committee. Though p is not below 0.05, the odds
of early termination/withdrawal were almost 4 times higher among trials with a data
monitoring committee than those without one (OR = 3.9, p = 0.05). Also, the odds of
termination/withdrawal of clinical trials with one primary outcome were almost 2 times
higher than those with two or more primary outcomes (OR = 1.73, p = .390). Also,
though not statistically significant, differences in proportions of enrollment and early
terminated/withdrawn trials were observed (93% vs 7%, p = .29). These findings should
be further investigated.
Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Low
Accrual
Multiple logistic regression modeling was used to examine whether
characteristics of clinical trials were predictive of early termination of pediatric oncology
trials due to low accrual (see Table 5) when combined. None of the clinical trial
characteristics were predictive of early termination of pediatric oncology trials due to low
accrual in these data.
Discussion
This study aimed to 1) describe patterns of the presence of variables and
completeness of data entry for variables in the ClinicalTrials.gov database over time and
2) investigate trial-related factors that may affect early termination of pediatric oncology
clinical trials due to low accrual. Despite the need for new, effective therapies for
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pediatric oncology patients, the number of clinical trials that can be conducted is
constrained by limited financial resources and willing participants. Therefore,
identification of trial-level factors associated with poor accrual is crucial, to minimize the
expenditure of valuable resources for the development and conduct of trials with a high
likelihood of failing to complete.17
Patterns of Presence of Variables and Completeness of Data Entry for Variables in
ClinicalTrials.gov Database
Patterns of the presence of variables and completeness of data entry for variables
in the ClinicalTrials.gov database differed over time. ClinicalTrials.gov did not exist
prior to 1997 so available data about initiated trials during this period were extremely
limited and entered retrospectively. The most recent period (18Apr2017-01May2020) had
fewer initiated clinical trials than the previous two periods which is due to this time
period consisting of only three years as opposed to the previous two periods which each
consisted of approximately 10 years. The number of required variables increased each
subsequent period until the third period due to increased regulations and policies
mandating increased transparency of clinical trials. The decline in completed data in the
most recent period is likely due to clinical trials initiated during this period still ongoing.
Information for many variables, such as number of adverse events and sample size
included in analysis for each outcome for each study group, is not available until after the
completion of a trial. With the continued growth in number of clinical trials and increased
regulations to facilitate transparency of clinical trials, ClinicalTrials.gov may become a
more robust database in the future.
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Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Low
Accrual
Unexpectedly, none of the examined trial characteristics were found to be
predictors of early termination of pediatric oncology trials: enrollment, primary purpose,
intervention type, phase, interventional study model, allocation, arm type, number of
arms, masking, primary end points, number of primary outcomes, sponsor, number of
participating facilities, primary disease, and data and safety monitoring committee. These
results are contrary to the literature that demonstrated trial-level factors impact accrual
and completion of adult oncology clinical trials.11,17-32 The difference in results compared
to available adult trials may be due to small number of examined pediatric oncology
clinical trials which limits testing power. Also, the combination of several categories of
trial characteristics within variables necessary for analyses due to small frequencies in
some categories was a limiting factor. For example, the original plan was to analyze each
of the following types of interventions as has been done in studies of adult oncology
clinical trials: drugs, behavioral, biological, combination product, device, diagnostic test,
dietary supplement, genetic, procedure, and radiation. However, due to the small number
of trials in each category, all intervention types except drugs had to be combined for
testing. Even with combining categories, some of the resulting groups remained small
due to the small overall sample size as well as the imbalance between completed and
early terminated trials. The likelihood of type II errors increases with small groups,
possibly resulting in predictors not being identified.
Strengths
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This study has multiple strengths. Predictors of early termination of oncology
clinical trials due to poor accrual have been understudied in the pediatric population.
ClinicalTrials.gov is the largest database of clinical trials, thus this study’s results are
more generalizable than if the study had a sample consisting of trials conducted at a
single or few institutions. Also, this study analyzed clinical trials sponsored by both
cooperative groups and pharmaceutical companies as both operate differently. The
cooperative group program is part of a governmental agency, the National Cancer
Institute, and pharmaceutical companies are for-profit organizations.
Limitations
This study has limitations, several of which pertain to the ClinicalTrials.gov
database. Existing legislation does not require all types of clinical trials, such as phase I
trials, to be registered on ClinicalTrials.gov.36 In addition, data for all examined variables
are not present as the data are currently and/or were previously not required.35 The first
aim of this study was to describe patterns of the presence of variables and completeness
of data entry for variables in the ClinicalTrials.gov database over time. Results could
differ based on the cut-off dates for time periods as it takes time for laws and policies to
be fully implemented.19 The second aim of this study was to investigate trial-related
factors that may affect early termination of pediatric oncology clinical trials due to low
accrual. Results for the study’s second aim could differ based on the timing of the study
because sponsors and principal investigators can retrospectively update information in
ClinicalTrials.gov. Also, some of the groups within variables such as type of
interventions were small, possibly resulting in predictors not being identified. Additional
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legislation for required data submission to ClinicalTrials.gov and enforcement of the
current and future legislature could improve analyses. The use of only one clinical trials
database may have introduced bias since data in ClinicalTrials.gov may be inaccurate.25
Incorporating the use of another large database such as the European Union Drug
Regulating Authorities Clinical Trials Database (EudraCT) may lessen bias in future
research.
Limitations exist with the dependent variable of early termination of clinical trials
due to inadequate accrual. The imbalance between the numbers of completed trials and
trials terminated/withdrawn due to poor accrual is a limitation because it is more difficult
to identify predictors since the terminated/withdrawn group is so small. Reason for the
termination or withdrawal of a clinical trial is not a required field by ClinicalTrials.gov,
thereby possibly introducing selection bias.20 Also, all cases of early termination due to
inadequate accrual may not have been captured for the analysis. For example, sponsors
may have reported the reasons for termination or withdrawal as “cancellation of trial by
sponsor” or “inadequate budget.” Both of these reasons may have been related to poor
accrual. Also, often there are multiple reasons for a trial to be terminated or withdrawn.27
For example, a trial may be terminated for both poor accrual and inadequate budget and
yet only one reason is entered into ClinicalTrials.gov.
Other limitations are related to confounding variables. The effects of variables at
the individual, interpersonal, organizational, community and policy levels were not
addressed in this study. Furthermore, this study did not assess trial-level factors that other
researchers have found that significantly impact accrual and or early study termination
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due to inadequate accrual, such as disease incidence, eligibility criteria, and tissue
testing.11,41
Implications
This study has several implications. Identification of modifiable trial-level factors that are
associated with inadequate accrual may enable future trials to be designed in a manner
that facilitates accrual and their completion.11,17 Meanwhile, healthcare providers can
provide patient education about non-modifiable trial-level factors to possibly increase
acceptance and trial participation.17,22 Sponsors and institutions can prioritize clinical
trials that have trial-level factors that are associated with accrual and trial completion. If
sponsors and institutions develop and/or select trials with trial-level factors that are
associated with inadequate accrual or early termination, they will be aware in advance
that increased resources and interventions will likely be required for successful trial
completion.11,41 Sponsors should ensure the reason for early study terminations is
documented in ClinicalTrials.gov so these data are available for future research
endeavors about trial-level factors associated with early termination of clinical trials.
Future Research
Future research is needed pertaining to trial-level factors associated with early
termination of pediatric oncology clinical trials due to inadequate accrual. Research can
advance study findings by including pediatric oncology clinical trials conducted
throughout the world, rather than focusing on just those conducted within the United
States. Also, variables such as eligibility criteria in the ClinicalTrials.gov that were not
investigated in this study but may be associated with early termination of pediatric
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oncology clinical trials due to inadequate accrual, such as eligibility criteria, should be
considered for future study. Finally, research can be conducted to determine if
interventions such as patient education regarding non-modifiable trial-level factors can
improve accrual and completion of pediatric oncology clinical trials.
Conclusions
New, effective anticancer therapies for children are necessary as evidenced by cancer
being the second-leading cause of death among children in the United States. Yet, limited
financial and human resources exist for the conduct of clinical trials. Therefore, sponsors
and institutions must develop and prioritize clinical trials that have a high likelihood of
accruing and completing. The identification of trial-level factors that are associated with
accrual and/or trial completion is crucial for this to occur. This study identified patterns
in the presence of variables and completeness of data entry for variables in the
ClinicalTrials.gov database over time. It also investigated trial-related factors that may
affect early termination of pediatric oncology clinical trials due to low accrual. Findings
of trial characteristics included in this study suggest they are not predictive of early
termination of pediatric oncology trials, possibly due to the small number of available
trials. However, the authors did not include evaluation of trial inclusion/exclusion criteria
and trial complexity because these variables were not readily available in the database,
and these factors may be important drivers of failure to accrue/complete clinical trials
based on the existing literature. Future studies may evaluate these factors and examine a
larger number of clinical trials to further understand trial-level factors associated with
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accrual and/or pediatric oncology trial completion and strategies to address the trial-level
factors that have a negative impact.
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TABLE 1 Frequency and proportion of trials with a given variable completed within four
periods
Period for start date
Variable
Before
21Nov199701Sep200818Apr201721Nov1997 31Aug2008
17Apr2017
01May2020
(n=27)
(n=120)
(n=222)
(n=98)
I
II
III
IV
Sample size at baseline 4 (14.8%)
23 (19.2%)
30 (13.5%)
0 (0%)
for each study group
Baseline type of units of 27 (100%)
120 (100%)
222 (100%)
98 (100%)
measure of sample
Baseline parameter for
4 (14.8%)
23 (19.2%)
29 (13.1%)
0 (0%)
units of measure of
sample
Brief description of
27 (100%)
120 (100%)
222 (100%)
98 (100%)
study
Intervention MeSH
27 (100%)
120 (100%)
222 (100%)
98 (100%)
terms
Number of facilities
27 (100%)
113 (94.2)
190 (85.6%)
89 (90.8%)
Number of related non- 4 (14.8%)
23 (19.2%)
30 (13.5%)
0 (0%)
serious events
Number of related
4 (14.8%)
23 (19.2%)
30 (13.5%)
0 (0%)
serious events
Year of registration
27 (100%)
120 (100%)
222 (100%)
98 (100%)
Number of months
15 (55.6%) 79 (65.8%)
144 (64.9%)
10 (10.2%)
between start date and
primary completion
date
Results reported
27 (100%)
120 (100%)
222 (100%)
98 (100%)
Number of months
4 (14.8%)
23 (19.2%)
30 (13.5%)
0 (100%)
between primary
completion date and
first received results
date
Study has at least one
27 (100%)
120 (100%)
222 (100%)
98 (100%)
facility in USA
Study has just one
27 (100%)
120 (100%)
222 (100%)
98 (100%)
facility
Minimum age
7 (25.9%)
54 (45.0%)
161 (72.5%)
77 (78.6%)
converted to an integer
Maximum age
27 (100%)
120 (100%)
222 (100%)
98 (100%)
converted to an integer
Part of minimum age
27 (100%)
120 (100%)
222 (100%)
98 (100%)
info that specifies units
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Part of maximum age
info that specifies units
Number of primary
outcomes
Number of secondary
outcomes
Number of other
outcomes
Condition MeSH terms
Conditions under study
Country where facility
located
Type of arm
Date when results were
first received
Descriptions of design
groups
Are results primary or
secondary outcomes
Measure used
Time frame in which
events were reported
Description of design
outcomes
Type of allocation
Interventional model
Observational model
Primary purpose
Observational timing
Type of masking
Description of
intervention
Was subject masked?
Was caregiver masked?
Was investigator
masked?
Was outcome accessor
masked?
Detailed description of
protocol
Uploaded documents
Link for study-related
documents

27 (100%)

120 (100%)

222 (100%)

98 (100%)

15 (55.6%)

98 (81.7%)

220 (99.1%)

98 (100%)

9 (33.3%)

59 (49.2%)

158 (71.2%)

65 (66.3%)

0 (0%)

0 (0%)

9 (4.1%)

7 (7.1%)

27 (100%)
27 (100%)
27 (100%)

120 (100%)
120 (100%)
120 (100%)

222 (100%)
222 (100%)
222 (100%)

98 (100%)
98 (100%)
98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
27 (100%)
27 (100%)
27 (100%)
27 (100%)
27 (100%)
27 (100%)

120 (100%)
120 (100%)
120 (100%)
120 (100%)
120 (100%)
120 (100%)
120 (100%)

222 (100%)
222 (100%)
222 (100%)
222 (100%)
222 (100%)
222 (100%)
222 (100%)

98 (100%)
98 (100%)
98 (100%)
98 (100%)
98 (100%)
98 (100%)
98 (100%)

27 (100%)
27 (100%)
27 (100%)

120 (100%)
120 (100%)
120 (100%)

222 (100%)
222 (100%)
222 (100%)

98 (100%)
98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)
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Period of drops and
withdrawals
Reasons for drops or
withdrawals
Number of drops or
withdrawals
Sampling method
Gender
Minimum age
Maximum age
Were healthy volunteers
eligible?
Brief description of
eligible patients
Inclusion and exclusion
criteria
Study status
Name of facility
Facility’s city
Facility’s state
Facility’s zip code
Facility’s country
Terms or phrases
synonymous with
intervention
Intervention or
exposure
Name of specific
intervention
Description of
intervention
URL for intervention
Description of URL for
study
Period of study when
study was not
completed
Outcome count
Type of non-inferiority
Description of noninferiority
Parameter type of
outcome

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

1 (3.7%)

20 (16.7%)

26 (11.7%)

0 (0%)

27 (100%)
27 (100%)
27 (100%)
27 (100%)
27 (100%)

120 (100%)
120 (100%)
120 (100%)
120 (100%)
120 (100%)

222 (100%)
222 (100%)
222 (100%)
222 (100%)
222 (100%)

98 (100%)
98 (100%)
98 (100%)
98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
27 (100%)
27 (100%)
27 (100%)
27(100%)
27 (100%)
27 (100%)

120 (100%)
120 (100%)
120 (100%)
120 (100%)
120 (100%)
120 (100%)
120 (100%)

222 (100%)
222 (100%)
222 (100%)
222 (100%)
222 (100%)
222 (100%)
222 (100%)

98 (100%)
98 (100%)
98 (100%)
98 (100%)
98 (100%)
98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

4 (14.8%)
27 (100%)
27 (100%)

23 (19.2%)
120 (100%)
120 (100%)

30 (13.5%)
222 (100%)
222 (100%)

0 (0%)
98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)
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Parameter value of
outcome
p value modifier
p value
One- or two-sided
confidence level
Confidence interval
Confidence interval
lower limit
Confidence interval
higher limit
p value description
Statistical method
Statistical method
description
Description of estimates
Description of groups
Units for outcome
Sample size included in
analysis for each
outcome for each study
group
Title of outcome
measurement
Description of outcome
measurement
Units of outcome
measurement
Parameter type of
outcome measurement
Parameter value of
outcome measurement
Dispersion type of
outcome measurement
Dispersion value of
outcome measurement
Lower limit of outcome
measurement
Upper limit of outcome
measurement
Outcome type
Outcome title
Outcome description

0 (0%)

6 (5.0%)

9 (4.1%)

0 (0%)

27 (100%)
0 (0%)
27 (100%)

120 (100%)
7 (5.8%)
120 (100%)

222 (100%)
9 (4.1%)
222 (100%)

98 (100%)
0 (0%)
98 (100%)

0 (0%)
0 (0%)

5 (4.2%)
3 (2.5%)

8 (3.6%)
8 (3.6%)

0 (100%)
0 (0%)

0 (0%)

4 (3.3%)

8 (3.6%)

0 (0%)

27 (100%)
27 (100%)
27 (100%)

120 (100%)
120 (100%)
120 (100%)

222 (100%)
222 (100%)
222 (100%)

98 (100%)
98 (100%)
98 (100%)

27 (100%)
27 (100%)
27 (100%)
4 (14.8%)

120 (100%)
120 (100%)
120 (100%)
23 (19.2%)

222 (100%)
222 (100%)
222 (100%)
30 (13.5%)

98 (100%)
98 (100%)
98 (100%)
0 (0%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

4 (14.8%)

23 (19.2%)

27 (12.2%)

0 (0%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

0 (0%)

7 (5.8%)

11 (5.0%)

0 (0%)

0 (0%)

6 (5.0%)

5 (2.3%)

0 (0%)

0 (0%)

6 (5.0%)

5 (2.3%)

0 (0%)

27 (100%)
27 (100%)
27 (100%)

120 (100%)
120 (100%)
120 (100%)

222 (100%)
222 (100%)
222 (100%)

98 (100%)
98 (100%)
98 (100%)
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Timeframe of outcome
Outcome population
Units of outcome
Dispersion type
outcome
Parameter type of
outcome
Details of recruitment
Details of preassignment
Date of adverse event
Time frame in which
adverse events were
reported
Type of adverse event
Where did adverse
event terminology come
from
Type of adverse event
assessment
Number of subjects
with adverse events
Number of subjects at
risk for adverse events
Description of adverse
event
Number of adverse
events
Organ system affected
by adverse event
Terminology used to
describe adverse events
Frequency threshold of
adverse event
Type of result reported
Title of group for which
results were reported
Description of group for
which results reported
Type of sponsor
Was sponsor the lead or
collaborator?
Name of sponsor

27 (100%)
27 (100%)
27 (100%)
27 (100%)

120 (100%)
120 (100%)
120 (100%)
120 (100%)

222 (100%)
222 (100%)
222 (100%)
222 (100%)

98 (100%)
98 (100%)
98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

4 (14.8%)

23 (19.2%)

30 (13.5%)

0 (0%)

4 (14.8%)

23 (19.2%)

30 (13.5%)

0 (0%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

0 (0%)

9 (7.5%)

10 (4.5%)

0 (0%)

27(100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

4 (14.8%)

23 (19.2%)

30 (13.5%)

0 (0%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)
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Date study was first
submitted to
ClinicalTrials.gov
Date results were first
submitted to
ClinicalTrials.gov
Date of last submission
to ClinicalTrials.gov
Submission date of
version of record that
met quality control
criteria
Date that submission
was made public on
ClinicalTrials.gov
Is study first posted date
an estimate or actual
date
Is results first posted
date an estimate or
actual date
Is last update posted
date an estimate or
actual date
Date study started
Is start date an estimate
or the actual date?
Study completion date
Is completion date an
estimate or the actual
date?
Primary completion
date
Is primary completion
date an estimate or the
actual date?
Type of study
Acronym for study
name
Brief title of study
Official title of study
Overall status of study
Why study was stopped

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
27 (100%)

120 (100%)
120 (100%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)
27 (100%)
27 (100%)
27 (100%)

120 (100%)
120 (100%)
120 (100%)
120 (100%)

222 (100%)
222 (100%)
222 (100%)
222 (100%)

98 (100%)
98 (100%)
98 (100%)
98 (100%)
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Last reported status of
study
Phase of trial
Actual or anticipated
enrollment number
Is enrollment number
actual or anticipated
number
Source of study data
Number of arms
Number of groups
Does study have
expanded access
Does study have a data
monitoring committee
Does study involve a
FDA-regulated drug
Does study involve a
FDA-regulated device
Product manufactured
in and exported from
US
Is there a plan to share
ipd
Description of plan to
share ipd
PubMed ID
Study references
Citation for study
references

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
25 (92.6%)

120 (100%)
108 (90.0%)

222 (100%)
222 (100%)

98 (100%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)
9 (33.3%)
1 (3.7%)
27 (100%)

120 (100%)
57 (47.5%)
14 (11.7%)
120 (100%)

222 (100%)
162 (73.0%)
30 (13.5%)
222 (100%)

98 (100%)
73 (74.5%)
13 (13.3%)
98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

27 (100%)

120 (100%)

222 (100%)

98 (100%)

11 (40.7%)
27 (100%)
27 (100%)

26 (21.7%)
120 (100%)
120 (100%)

37 (16.7%)
222 (100%)
222 (100%)

6 (6.1%)
98 (100%)
98 (100%)
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TABLE 2 Frequency and proportion of trials with a given variable completed within four
periods
Period for start date
Variable
Before
21Nov1997- 01Sep2008- 18Apr201721Nov1997 31Aug2008 17Apr2017 01May2020
(n=27)
(n=120)
(n=222)
(n=98)
I
II
III
IV
Results reported
27 (100%) 120 (100%) 222 (100%) 98 (100%)
Yes
4 (14.8)
23 (19.2%) 30 (13.5%) 0 (0%)
No
23 (85.2%) 97 (80.8%) 192
98 (100%)
(86.5%)
Study has at least one facility 27 (100%) 113 (94.2%) 190
89 (90.8%)
in USA
(85.6%)
Yes
15 (55.6%) 71 (59.2%) 89 (40.1%) 38 (38.8%)
No
12 (44.4%) 42 (35.0%) 101
51 (52.0%)
(45.5%)
Study has just one facility
27 (100%) 120 (100%) 222 (100%) 98 (100%)
Yes
13 (48.1%) 38 (31.7%) 117
62 (63.3%)
(52.7%)
No
14 (51.9%) 82 (68.3%) 105
36 (36.7%)
(47.3%)
Type of arm
9 (33.3%)
57 (47.5%) 162
73 (74.5%)
(73.0%)
Active Comparator
1 (3.7%)
5 (4.2%)
18 (8.1%)
12 (12.2%)
Experimental
8 (29.6%)
45 (37.5%) 121
55 (56.1%)
(54.5%)
No Intervention
0 (0%)
3 (2.5%)
5 (2.3%)
1 (1.0%)
Placebo Comparator
0 (0%)
0 (0%)
3 (1.4%)
0 (0%)
Sham Comparator
0 (0%)
0 (0%)
1 (0.5%)
0 (0%)
Other
0 (0%)
4 (3.3%)
14 (6.3%)
5 (5.1%)
Are results primary or
15 (55.6%) 98 (81.7%) 220
98 (100%)
secondary outcomes
(99.1%)
Primary
15 (55.6%) 93 (77.5%) 216
93 (94.9%)
(97.3%)
Secondary
0 (0%)
5 (4.2%)
3 (1.4%)
5 (5.1%)
Other
0 (0%)
0 (0%)
1 (0.5%)
0 (0%)
Type of allocation
8 (29.6%)
52 (43.3%) 100
42 (42.9%)
(45.0%)
Non-Randomized
1 (3.7%)
20 (16.7%) 25 (11.3%) 11 (11.2%)
Randomized
7 (25.9%)
32 (26.7 %) 75 (33.8%) 31 (31.6%)
Interventional model
10 (37.0%) 62 (51.7%) 164
73 (74.5%)
(73.9%)
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Crossover
Assignment
Factorial Assignment
Parallel Assignment
Sequential
Single Group
Assignment
Observational model
Case Control
Case-Control
Case-Crossover
Case-Only
Cohort
Family-Based
Other
Primary purpose
Basic Science
Device Feasibility
Diagnostic
Health Services
Research
Prevention
Supportive Care
Treatment
Other
Observational timing
Cross-Sectional
Retrospective
Prospective
Other
Type of masking
None (Open-Label)
Single
Double
Triple
Quadruple
Was subject masked?
Yes
Was caregiver masked?

0 (0%)

1 (0.8%)

5 (2.3%)

4 (4.1%)

0 (0%)
2 (7.4%)
0 (0%)
8 (29.6%)

1 (0.8%)
33 (27.5%)
0 (0%)
27 (22.5%)

0 (0%)
83 (37.4%)
0 (0%)
76 (34.2%)

1 (1.0%)
34 (34.7%)
1 (1.0%)
33 (33.7%)

2 (7.4%)
1 (3.7%)
0 (0%)
0 (0%)
0 (0%)
1 (3.7%)
0 (0%)
0 (0%)
24 (88.9%)

18 (15.0%)
1 (0.8%)
1 (0.8%)
0 (0%)
4 (3.3%)
12 (10.0%)
0 (0%)
0 (0%)
93 (77.5%)

25 (25.5%)
0 (0%)
7 (7.1%)
1 (1.0%)
1 (1.0%)
11 (11.2%)
0 (0%)
5 (5.1%)
73 (74.5%)

0 (0%)
0 (0%)
0 (0%)
0 (0%)

0 (0%)
0 (0%)
1 (0.8%)
0 (0%)

52 (23.4%)
3 (1.4%)
4 (1.8%)
1 (0.5%)
23 (10.4%)
17 (7.7%)
1 (0.5%)
3 (1.4%)
164
(73.9%)
2 (0.9%)
1 (0.5%)
4 (1.8%)
1 (0.5%)

0 (0%)
0 (0%)
24 (88.9%)

12 (10.0%)
9 (7.5%)
71 (59.2%)

10 (10.2%)
15 (15.3%)
33 (33.7%)

0 (0%)
2 (7.4%)
0 (0%)
0 (0%)
2 (7.4%)
0 (0%)
13 (48.1%)

0 (0%)
20 (16.7%)
2 (1.7%)
6 (5.0%)
11 (9.2%)
1 (0.8%)
47 (39.2%)

12 (44.4%)

64 (53.3%)

1 (3.7%)
0 (0%)
0 (0%)
0 (0%)
-

2 (1.7%)
5 (4.2%)
0 (0%)
2 (1.7%)
6 (5.0%)
6 (5.0%)
3 (2.5%)

24 (10.8%)
25 (11.3%)
102
(45.9%)
5 (2.3%)
55 (24.8%)
3 (1.4%)
20 (9.0%)
30 (13.5%)
2 (0.9%)
166
(74.8%)
125
(56.3%)
15 (6.8%)
12 (5.4%)
3 (1.4%)
11 (5.0%)
29 (13.1%)
29 (13.1)
13 (5.9%)
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1 (1.0%)
1 (1.0%)
6 (6.1%)
0 (0%)

7 (7.1%)
25 (25.5%)
7 (7.1%)
3 (3.1%)
14 (14.3%)
1 (1.0%)
73 (74.5%)
59 (60.2%)
4 (4.1%)
6 (6.1%)
1 (1.0%)
3 (3.1%)
9 (9.2%)
9 (9.2%)
6 (6.1%)

Yes
Was investigator masked?
Yes
Was outcome accessor
masked?
Yes
Sampling method
Non-Probability
Sample
Probability Sample
Gender
All

-

3 (2.5%)
4 (3.3%)
4 (3.3%)
5 (4.2%)

13 (5.9%)
23 (10.4%)
23 (10.4%)
27 (12.2%)

6 (6.1%)
8 (8.2%)
8 (8.2%)
8 (8.2%)

2 (7.4%)
2 (7.4%)

5 (4.2%)
20 (16.7%)
12 (10.0%)

27 (12.2%)
53 (23.9%)
46 (20.7%)

8 (8.2%)
25 (25.5%)
18 (18.4%)

0 (0%)
27 (100%)
27 (100%)

7 (7.1%)
98 (100%)
96 (98.0%)

Female
Male
Were healthy volunteers
eligible?
Yes
No

0 (0%)
0 (0%)
27 (100%)

Study status
Active, not recruiting
Completed
Not yet recruiting
Recruiting
Intervention or exposure

1 (3.7%)
0 (0%)
0 (0%)
0 (0%)
1 (3.7%)
25 (92.6%)

Behavioral
Biological
Combination Product
Device
Diagnostic Test
Dietary Supplement
Drug
Genetic
Procedure
Radiation
Other
Type of non-inferiority
Non-inferiority
Non-inferiority or
Equivalence
Superiority

0 (0%)
7 (25.9%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
16 (59.3%)
0 (0%)
2 (7.4%)
0 (0%)
0 (0%)
-

8 (6.7%)
7 (3.2%)
120 (100%) 222 (100%)
119 (99.2%) 214
(96.4%)
1 (0.8%)
6 (2.7%)
0 (0%)
2 (0.9%)
120 (100%) 221
(99.5%)
9 (7.5%)
17 (7.7%)
111 (92.5%) 204
(91.9%)
11 (9.2%)
52 (23.4%)
0 (0%)
2 (0.9%)
0 (0%)
0 (0%)
0 (0%)
2 (0.9%)
11 (9.2%)
48 (21.6%)
112 (93.3%) 202
(91.0%)
11 (9.2%)
35 (15.8%)
26 (21.7%) 13 (5.9%)
0 (0%)
0 (0%)
0 (0%)
7 (3.2%)
0 (0%)
1 (0.5%)
0 (0%)
4 (1.8%)
57 (47.5%) 95 (42.8%)
3 (2.5%)
13 (5.9%)
8 (6.7%)
7 (3.2%)
0 (0%)
5 (2.3%)
7 (5.8%)
22 (9.9%)
9 (7.5%)
11 (5.0%)
0 (0%)
1 (0.5%)
2 (1.7%)
2 (0.9%)

-

2 (1.7%)

0 (0%)

0 (0%)
27 (100%)

132

1 (0.5%)

2 (2.0%)
0 (0%)
95 (96.9%)
21 (21.4%)
74 (75.5%)
58 (59.2%)
0 (0%)
1 (1.0%)
3 (3.1%)
54 (55.1%)
91 (92.9%)
13 (13.3%)
2 (2.0%)
1 (1.0%)
7 (7.1%)
7 (7.1%)
0 (0%)
31 (31.6%)
1 (1.0%)
6 (6.1%)
0 (0%)
23 (23.5%)
0 (0%)
0 (0%)
0 (0%)

Superiority or Other
(legacy)
Other
One or two-sided confidence
interval
1-sided
2-sided
Outcome type
Primary
Secondary
Other-Prespecified
Type of adverse event
Serious
Other
Type of adverse event
assessment
Non-systematic
Assessment
Systematic
Assessment
Organ system affected by
adverse event
General disorders
Infections and
infestations
Investigations
Metabolism and
Nutrition
Musculoskeletal
Neoplasms benign,
malignant and unspecified
(including cysts and polyps)
Nervous
Pregnancy,
puerperium and perinatal
Product Issues
Psychiatric
Renal and urinary
Respiratory, thoracic
and mediastinal
Skin and
subcutaneous tissue

-

1 (0.8%)

4 (1.8%)

0 (0%)

-

4 (3.3%)
6 (5.0%)

3 (1.4%)
9 (4.1%)

0 (0%)
0 (0%)

4 (14.8%)
0 (0%)
4 (14.8%)
0 (0%)
4 (14.8%)
4 (14.8%)
0 (0%)
4 (14.8%)

2 (1.7%)
4 (3.3%)
23 (19.2%)
6 (5.0%)
17 (14.2%)
0 (0%)
23 (19.2%)
18 (15.0%)
5 (4.2%)
12 (10.0%)

0 (0%)
9 (4.1%)
30 (13.5%)
6 (2.7%)
23 (10.4%)
1 (0.5%)
222 (100%)
29 (13.1%)
1 (0.5%)
20 (9.0%)

0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)

0 (0%)

3 (2.5%)

2 (0.9%)

0 (0%)

4 (14.8%)

9 (7.5%)

18 (8.1%)

0 (0%)

4 (14.8%)

23 (19.2%)

30 (13.5%)

0 (0%)

0 (0%)
0 (0%)

3 (2.5%)
1 (0.8%)

0 (0%)
0 (0%)

0 (0%)
0 (0%)

0 (0%)
0 (0%)

1 (0.8%)
0 (0%)

0 (0%)
1 (0.5%)

0 (0%)
0 (0%)

0 (0%)
0 (0%)

0 (0%)
1 (0.8%)

1 (0.5%)
1 (0.5%)

0 (0%)
0 (0%)

2 (7.4%)
0 (0%)

0 (0%)
1 (0.8%)

1 (0.5%)
0 (0%)

0 (0%)
0 (0%)

0 (0%)
0 (0%)
1 (3.7%)
0 (0%)

0 (0%)
2 (1.7%)
0 (0%)
5 (4.2%)

1 (0.5%)
0 (0%)
1 (0.5%)
3 (1.4%)

0 (0%)
0 (0%)
0 (0%)
0 (0%)

0 (0%)

0 (0%)

1 (0.5%)

0 (0%)
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Surgical and medical
procedures
Total
Vascular
Type of result reported
Baseline
Outcome
Participant Flow
Reported Event
Type of sponsor
Industry
NIH
Other

0 (0%)

0 (0%)

1 (0.5%)

0 (0%)

0 (0%)
1 (3.7%)
4 (14.8%)
4 (14.8%)
0 (0%)
0 (0%)
0 (0%)
27 (100%)
0 (0%)
2 (7.4%)
25 (92.6%)

3 (2.5%)
6 (5.0%)
23 (19.2%)
21 (17.5%)
1 (0.8%)
1 (0.8%)
0 (0%)
120 (100%)
14 (11.7%)
4 (3.3%)
102 (85.0%)

0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
98 (100%)
18 (18.4%)
0 (0%)
80 (81.6%)

Was sponsor the lead or
collaborator?
Collaborator
Lead
Type of study
Interventional

27 (100%)

120 (100%)

10 (4.5%)
9 (4.1%)
30 (13.5%)
22 (9.9%)
6 (2.7%)
0 (0%)
2 (0.9%)
222 (100%)
46 (20.7%)
5 (2.3%)
171
(77.0%)
222 (100%)

0 (0%)
27 (100%)
27 (100%)
24 (88.9%)

1 (0.8%)
119 (99.2%)
120 (100%)
96 (80.0%)

0 (0%)
98 (100%)
98 (100%)
73 (74.5%)

Observational
Observational
(Patient Registry)
Overall status of study
Active, not recruiting
Completed

3 (11.1%)
0 (0%)

24 (20.0%)
0 (0%)

0 (0%)
222 (100%)
222 (100%)
166
(74.8%)
55 (24.8%)
1 (0.5%)

27 (100%)
0 (0%)
18 (66.7%)

120 (100%)
8 (6.7%)
77 (64.2%)

98 (100%)
7 (7.1%)
9 (9.2%)

Enrolling by
Invitation
Not yet recruiting
Recruiting
Suspended
Terminated
Withdrawn
Unknown Status
Last reported status of study
Active, Not
Recruiting
Not yet recruiting
Recruiting
Phase of trial

0 (0%)

0 (0%)

222 (100%)
24 (10.8%)
110
(49.5%)
1 (0.5%)

0 (0%)
1 (3.7%)
0 (0%)
1 (3.7%)
0 (0%)
7 (25.9%)
7 (25.9%)
7 (25.9%)

0 (0%)
2 (1.7%)
0 (0%)
7 (5.8%)
4 (3.3%)
22 (18.3%)
22 (18.3%)
12 (10.0%)

0 (0%)
34 (15.3%)
0 (0%)
21 (9.5%)
11 (5.0%)
21 (9.5%)
21 (9.5%)
1 (0.5%)

16 (16.3%)
57 (58.2%)
1 (1.0%)
1 (1.0%)
3 (3.1%)
1 (1.0%)
1 (1.0%)
0 (0%)

0 (0%)
0 (0%)
24 (88.9%)

1 (0.8%)
9 (7.5%)
96 (80.0%)

2 (0.9%)
18 (8.1%)
166
(74.8%)

0 (0%)
1 (1.0%)
73 (74.5%)
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98 (100%)

25 (25.5%)
0 (0%)

3 (3.1%)

Early Phase I
Phase 1
Phase 1/Phase 2
Phase 2
Phase 2/Phase 3
Phase 3
Phase 4
N/A
Number of arms

0 (0%)
0 (0%)
0 (0%)
11 (40.7%)
0 (0%)
10 (37.0%)
1 (3.7%)
2 (7.4%)
9 (33.3%)

1
2
3
4
5
7
8
9
11
12
Number of groups
1
2
3
4
Does study have expanded
access
No

6 (22.2%)
1 (3.7%)
0 (0%)
1 (3.7%)
0 (0%)
0 (0%)
0 (0%)
1 (3.7%)
0 (0%)
0 (0%)
1 (3.7%)
0 (0%)
1 (3.7%)
0 (0%)
0 (0%)
27 (100%)

3 (3.1%)
11 (11.2%)
7 (7.1%)
6 (6.1%)
0 (0%)
7 (7.1%)
5 (5.1%)
34 (34.7%)
73 (74.5%)

-

4 (1.8%)
27 (12.2%)
11 (5.0%)
37 (16.7%)
3 (1.4%)
14 (6.3%)
12 (5.4%)
58 (26.1%)
162
(73.0%)
19 (15.8%) 67 (30.2%)
28 (23.3%) 65 (29.3%)
3 (2.5%)
18 (8.1%)
3 (2.5%)
6 (2.7%)
1 (0.8%)
2 (0.9%)
2 (1.7%)
3 (1.4%)
1 (0.8%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
1 (0.5%)
0 (0%)
0 (0%)
14 (11.7%) 30 (13.5%)
6 (5.0%)
18 (8.1%)
6 (5.0%)
8 (3.6%)
2 (1.7)
3 (1.4%)
0 (0%)
1 (0.5%)
118 (98.3%) 221
(99.5%)
118 (98.3%) 221
(99.5%)
75 (62.5%) 199
(89.6%)
40 (33.3%) 89 (40.1%)
35 (29.2%) 110
(49.5%)
7 (5.8%)
38 (17.1%)

Does study have a data and
safety monitoring committee
Yes
No

11 (40.7%)

Does study involve a FDAregulated drug
Yes
No
Does study involve a FDAregulated device
Yes
No

-

3 (2.5%)
4 (3.3%)
7 (5.8%)

16 (7.2%)
22 (9.9%)
38 (17.1%)

21 (21.4%)
76 (77.6%)
97 (99.0%)

-

0 (0%)
7 (5.8%)

1 (0.5%)
37 (16.7%)

1 (1.0%)
96 (98.0%)

27 (100%)

5 (18.5%)
6 (22.2%)
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1 (0.8%)
13 (10.8%)
2 (1.7%)
32 (26.7%)
0 (0%)
27 (22.5%)
5 (4.2%)
16 (13.3%)
57 (47.5%)

31 (31.6%)
35 (35.7%)
2 (2.0%)
3 (3.1%)
1 (1.0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
1 (1.0%)
13 (13.3%)
2 (2.0%)
8 (8.2%)
2 (2.0%)
1 (1.0%)
97 (99.0%)
97 (99.0%)
84 (85.7%)
32 (32.7%)
52 (53.1%)
97 (99.0%)

Product manufactured in and
exported from US
Yes
No
Is there a plan to share ipd
Yes
No
Undecided

-

-

6 (2.7%)

90 (91.8%)

4 (14.8%)
0 (0%)
4 (14.8%)
0 (0%)

3 (2.5%)
0 (0%)
2 (1.7%)
1 (0.8%)

3 (1.4%)
3 (1.4%)
67 (30.2%)
20 (9.0%)
36 (16.2%)
11 (5.0%)

4 (4.1%)
4 (4.1%)
98 (100%)
8 (8.2%)
40 (40.8%)
17 (17.3%)
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TABLE 3 Characteristics [n (%)] of completed studies and studies terminated/withdrawn
due to poor accrual (total N=105)
Variable
Study status
Number of
(N=105)
studies
with data
Completed

n = 87
Enrollment
1-100
101-1,000
>1,000
Primary Purpose
Basic science
Device feasibility
Diagnostic
Health services research
Prevention
Screening
Supportive care
Treatment
Other
Intervention type
Behavioral
Biological
Combination product
Device
Diagnostic test
Dietary supplement
Drug
Genetic
Procedure
Radiation
Other
Phase
Early phase I
Phase I
Phase I/Phase II
Phase II
Phase II/Phase III
Phase III

Terminated/withd
rawn due to poor
accrual
n = 18

64 (79.0)
13 (16.0)
4 (4.9)

13 (92.9)
1 (7.1)
0 (0)

0 (0)
1 (1.2)
3 (3.6)
0 (0)
15 (17.9)
0 (0)
12 (14.3)
51 (60.7)
2 (2.4)

0 (0)
0 (0)
0 (0)
0 (0)
3 (16.7)
0 (0)
4 (22.2)
11 (61.1)
0 (0)

18 (20.7)
18 (20.7)
0 (0)
3 (3.4)
0 (0)
0 (0)
38 (43.7)
0 (0)
3 (3.4)
1 (1.1)
6 (6.9)

3 (16.7)
4 (22.2)
0 (0)
0 (0)
0 (0)
0 (0)
10 (55.6)
0 (0)
1 (5.6)
0 (0)
0 (0)

2 (2.3)
22 (25.3)
4 (4.6)
20 (23.0)
0 (0)
10 (11.5)

1 (5.6)
3 (16.7)
0 (0)
7 (38.9)
0 (0)
2 (11.1)
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95 (90.5)
77 (81.1)
14 (14.7)
4 (4.2)
102 (97.1)
0 (0)
1 (1.0)
3 (2.9)
0 (0)
18 (17.6)
0 (0)
16 (15.7)
62 (60.8)
2 (2.0)
105 (100)
21 (20.0)
22 (21.0)
0 (0)
3 (2.9)
0 (0)
0 (0)
48 (45.7)
0 (0)
4 (3.8)
1 (1.0)
6 (5.7)
105 (100)
3 (2.9)
25 (23.8)
4 (3.8)
27 (25.7)
0 (0)
12 (11.4)

Phase IV
Not applicable
Interventional Study Model
Crossover assignment
Factorial assignment
Parallel assignment
Sequential assignment
Single group assignment
Allocation
Non-randomized
Randomized
Arm type
Active comparator
Experimental
No intervention
Placebo comparator
Sham comparator
Other
Number of arms
1
2
3
4 or more
Masking
None (Open label)
Single
Double
Triple
Quadruple
End point of study
Safety
Efficacy
Safety and efficacy
Other, includes
bioavailability and
bioequivalence studies
Number of primary outcomes
1
>1
Sponsor
Children’s Oncology
Group (COG)
Industry

0 (0)
29 (33.3)

0 (0)
5 (27.8)

2 (2.7)
0 (0)
29 (39.7)
0 (0)
42 (57.5)

2 (11.8)
0 (0)
8 (47.1)
0 (0)
7 (41.2)

7 (16.7)
35 (83.3)

3 (27.3)
8 (72.7)

5 (6.8)
60 (81.1)
2 (2.7)
2 (2.7)
0 (0)
5 (6.8)

2 (12.5)
13 (81.3)
0 (0)
0 (0)
1 (6.3)
0 (0)

32 (43.2)
31 (41.9)
4 (5.4)
7 (9.5)

6 (37.5)
10 (62.5)
0 (0)
0 (0)

60 (80.0)
6 (8.0)
5 (6.7)
1 (1.3)
3 (4.0)

14 (77.8)
1 (5.6)
2 (11.1)
0 (0)
1 (5.6)

0 (0)
1 (4.8)
17 (81.0)
3 (14.3)

1 (100.0)
0 (0)
0 (0)
0 (0)

57 (73.1)
21 (26.9)

11 (61.1)
7 (38.9)

18 (20.7)

2 (11.1)

96 (91.4)
68(70.8)
28(29.2)
105 (100)
20 (19.0)

23 (26.4)

6 (33.3)

29 (27.6)
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0 (0)
34 (32.4)
90 (85.7)
4 (4.4)
0 (0)
37 (41.1)
0 (0)
49 (54.4)
53 (50.5)
10 (18.9)
43 (81.1)
90 (85.7)
7 (7.8)
73 (81.1)
2 (2.2)
2 (2.2)
1 (1.1)
5 (5.6)
90 (85.7)
38 (42.2)
41 (45.6)
4 (4.4)
7 (7.8)
93 (88.6)
74 (79.6)
7 (7.5)
7 (7.5)
1 (1.1)
4 (4.3)
22 (21.0)
1 (4.5)
1 (4.5)
17 (77.3)
3 (13.6)

Individual
Institution outside the
US (other than universities
and hospitals)
NIH
University/hospital
Number facilities
participating in trial
1
>1
Primary disease
Leukemia
Brain and spinal cord
Neuroblastoma
Wilm’s tumor
Lymphoma
Rhabdomyosarcoma
Retinoblastoma
Multiple types of cancer
Other
Data and safety monitoring
committee
Yes
No

0 (0)
1 (1.1)

1 (5.6)
0 (0)

1 (1.0)
1 (1.0)

3 (3.4)
42 (48.3)

1 (5.6)
8 (44.4)

4 (3.8)
50 (47.6)
105 (100)

40 (46.0)
47 (54.0)

9 (50.0)
9 (50.0)

23 (26.4)
16 (18.4)
4 (4.6)
1 (1.1)
1 (1.1)
1 (1.1)
5 (5.7)
30 (34.5)
6 (6.9)

2 (11.1)
4 (22.2)
1 (5.6)
0 (0)
0 (0)
0 (0)
3 (16.7)
4 (22.2)
4 (22.2)

49 (46.7)
56 (53.3)
105 (100)
25 (23.8)
20 (19.0)
5 (4.8)
1 (1.0)
1 (1.0)
1 (1.0)
8 (7.6)
34 (32.4)
10 (9.5)
88 (83.8)

38 (52.8)
34 (47.2)

13 (81.3)
3 (18.8)
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51 (58.0)
37 (42.0)

TABLE 4 Chi-square test of independence for completed and terminated/withdrawn study due to poor accrual
Variable
Study status
(N = 105)
Completed
Terminated # of studies
(n = 87)
or withdrawn with data
due to poor
X2
df
accrual
(n = 18)
Enrollment
81
14
95
1-100
64 (79.0)
13 (92.9)
1
>100
17 (21.0)
1 (7.1)
Primary Purpose
87
18
105
Treatment
51 (58.6)
11 (61.1)
.04
1
Other (basic science, device feasibility,
36 (41.4)
7 (38.9)
diagnostic, health services research, prevention,
screening, supportive care)
Intervention type
87
18
105
Drug
38 (43.7)
10 (55.6)
.85
1
Other (behavioral, biological, combination 49 (56.3)
8 (44.4))
product, device, diagnostic test, dietary
supplement, genetic, procedure, radiation)
Phase
87
18
105
Early (early phase I, phases I, I/II, II)
48 (55.2)
11 (61.1)
2
Late (phases II/III, III, IV)
10 (11.5)
2 (11.1)
Not applicable
29 (33.3)
5 (27.8)
Interventional Model
73
17
90
140

p-value

OR

95% CI
for OR

.294*

.29

.04-2.37

1.000

.90

.32-2.55

.439

.62

.22-1.72

.930*

**

**

Parallel group
Not parallel
Allocation**
Arm type
Experimental
Other (active comparator, no intervention,
placebo comparator, sham comparator, other)
Number of arms
1
>1
Masking
No (open label)
Yes
End point of study
Safety
Safety and efficacy
Efficacy
Other (includes bioavailability and
bioequivalence studies)
Number of primary outcomes
1
>1
Sponsor
Industry
University/hospital
Other (COG, individual, institution
outside US other than universities and hospitals,
NIH)

29 (39.7)
44 (60.3)

8 (47.1)
9 (52.9)

74
60 (81.1)
14 (18.9)

16
13 (81.3)
3 (18.8)

74
32 (43.2)
42 (56.8)
75
60 (80.0)
15 (20.0)
87
24 (27.6)
24 (27.6)
10 (11.5)
29 (33.3)

16
6 (37.5)
10 (62.5)
18
14 (77.8)
4 (22.2)
18
4 (22.2)
7 (38.9)
2 (11.1)
5 (27.8)

90

78
57 (73.1)
21 (26.9)
87
23 (26.4)
42 (48.3)
22 (25.3)

18
11 (61.1)
7 (38.9)
18
6 (33.3)
8 (44.4)
4 (22.2)

96

141

.31

1

.596

.74

.26-2.14

1

1.000*

.99

.25-3.95

1

.784

1.27

.42-3.86

1

1.00*

1.14

.33-3.98

3

.825*

**

**

1

.390

1.73

.59-5.04

2

.843*

**

**

53
90

.18
93

105

1.01
105

Number of participating facilities
1
>1
Primary disease
Single most common types (leukemia,
brain and spinal cord, neuroblastoma, Wilm’s
tumor, lymphoma, rhabdomyosarcoma,
retinoblastoma)
Other cancers and multiple types
Data and safety monitoring committee
Yes

87
40 (46.0)
47 (54.0)
87
51 (58.6)

18
9 (50.0)
9 (50.0)
18
10 (55.6)

36 (41.4)
72
38 (52.8)

8 (44.4)
16
13 (81.3)

105
49
56
105

88
51

.10

1

.800

.85

.31-2.35

.06

1

1.000

1.13

.41-3.15

4.36

1

.050

3.88

1.0214.78

No
34 (47.2)
3 (18.8)
37
*Fisher’s exact test performed because expected frequency < 5 in cells
** Risk Estimate statistics cannot be computed. They are only computed for a 2*2 table without empty cells.
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TABLE 5 Multiple logistic regression for completed and terminated/withdrawn study due
to poor accrual
Variables in the Equation
95% C.I. for OR
B
Data and Safety

S.E.

Wald

df

p value

OR

Lower

Upper

1.233

.709

3.019

1

.082

3.430

.854

13.779

1.418

1.091

1.690

1

.194

4.129

.487

35.019

Monitoring Committee
Enrollment
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Summary
Cancer is the second-leading cause of death among children in the United
States.[1] Clinical trials are the conduit to new effective therapies for children with
cancer because they ascertain whether new drug discoveries are safe and effective.[2]
However, inadequate accrual is a significant barrier to the completion of trials as only
two-thirds of children with cancer are treated on clinical trials.[3] More children with
cancer should be enrolled on clinical trials to enable successful completion of oncology
trials, thus facilitating timely availability of new effective therapies. The purposes of this
dissertation compendium underpin several gaps in the identification of 1) barriers to
enrollment in pediatric oncology clinical trials and 2) trial-level predictors of early
termination of pediatric oncology trials due to poor accrual. The synthesis of the findings
from the scoping and systematic reviews suggests associations between trial-level factors
and early trial termination of pediatric oncology trials due to poor accrual. The analysis
of pediatric clinical trials data reported in ClinicalTrials.gov did not demonstrate triallevel predictors of early trial termination of pediatric oncology trials due to poor accrual,
most likely due to not including important factors such as eligibility criteria and trial
complexity. Further research is recommended to examine the discrepancies between
findings of the literature reviews and exploratory analysis, with attention on the predictor
variables with larger effect sizes in the exploratory analysis. Future trials should be
designed considering trial-level factors such as eligibility criteria and interventional study
model that may affect accrual and completion of pediatric oncology trials.
Theoretical Frameworks
144

Two frameworks guided the literature searches and organization of
results/discussion in this dissertation compendium. The modified Socioecological Model
(SEM) addresses influential factors of clinical trial accrual at the trial,
individual/intrapersonal, interpersonal, organizational, community, and policy levels.[4]
The first manuscript demonstrated that factors impacting accrual and completion of
oncology clinical trials operate at multiple levels. Bennette et al.’s[5] conceptual model
of trial-level factors associated with low trial accrual has the following four critical
domains for assessing trial-level factors associated with low trial accrual: background,
disease-related, treatment-related, and trial design. The second and third manuscripts
identified trial-level factors within the four domains.
Manuscript #1: Scoping review: Barriers and facilitators to enrollment in pediatric
oncology clinical trials
The first manuscript in this dissertation, Barriers and Facilitators to Enrollment
in Pediatric Oncology Clinical Trials, investigated the literature to determine the
currently known barriers and facilitators to enrollment in oncology clinical trials for
children. Merely 60% of pediatric cancer patients receive therapy by participating in a
clinical trial.[3] Clinical trials are the means by which new potential therapies for cancer
and its symptoms are tested for their safety and efficacy before being marketed.[5] These
clinical trials often face obstacles to enrollment and completion due to their increasing
costs during a time when sponsors and participating sites have limited resources.[6,7]
Also, clinical trial enrollment is challenging due to the uncertainty of a new
intervention’s effectiveness and potential side effects, both known and unknown.
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Enrollment is important because a clinical trial’s success is based upon having an
adequate sample size to produce valid results.[8]
Accepted for publication in Pediatric Nursing journal, the scoping review was
directed by Arksey and O’Malley’s [9] methodological framework and ascertained
barriers and facilitators to enrollment in pediatric oncology clinical trials. Findings from
the review demonstrated trial-level barriers included lack of an available trial, trials
closed to accrual, and eligibility criteria. Individual factors associated with enrollment
included age, sex, race/ethnicity, insurance status, cancer characteristics, and motivation.
Interpersonal factors included parents’ desire for continuity of care by healthcare
providers, physicians’ discussions with parents and children about clinical trials, and
physicians’ attitudes about clinical trials. Organizational factors that influenced
enrollment included local availability of a clinical trial and continuity of care. No studies
of community or policy-level barriers and facilitators were found. The review’s findings
included a gap in theoretically based knowledge about trial-level barriers and facilitators
to enrollment in pediatric oncology clinical trials.
Manuscript #2: Trial-level Factors Affecting Accrual and Completion of Oncology
Clinical Trials: A Systematic Review
The second manuscript in this dissertation, Trial-level Factors Affecting Accrual
and Completion of Oncology Clinical Trials: A Systematic Review, explores the literature
to identify trial-level factors that affect accrual and/or completion of oncology clinical
trials, gaps in the literature, and prospects for research in the future. Oncology clinical
trials are known to terminate early or be extended due to inadequate accrual, negatively
affecting the resources of trial sponsors and participating institutions.[6, 10, 11] Delayed
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or early terminated trials hinder the marketing of new safe and effective cancer therapies
for patients.
Guided by the PRISMA statement, a sample of the literature was systematically
selected for the review.[12] Studies were included if they were: a) empirical studies that
analyzed trial-level factors that influenced accrual and/or completion of oncology trials
and b) studies that analyzed data from state, regional, national, or international clinical
trial databases. The systematic review’s findings indicated the following background
factors were associated with oncology clinical trial accrual and/or completion: sponsor,
number and location of participating institutions, competing trials, time of trial opening,
and fast-track status. Disease-related factors included the annual incidence and type(s) of
targeted cancer. Several types of treatment such as drugs, radiation and surgery were
examined in the studies. Trial design factors included trial development time, eligibility
criteria, randomization, sample size, trial phase, placebo use, and required protocol
procedures and their timing. Future studies with a theoretical foundation could be
conducted to assess the association between trial-level factors and accrual/trial
completion. Researchers also could concurrently investigate background, disease-related,
treatment-related, and trial design factors that affect accrual for specific cancers and
populations.
Manuscript #3: Predictors of Early Termination of Pediatric Oncology Clinical
Trials Due to Poor Accrual: An Exploratory Analysis
The third manuscript in this dissertation, Predictors of Early Termination of
Pediatric Oncology Clinical Trials Due to Poor Accrual: An Exploratory Analysis,
describes patterns in the presence of variables and completeness of data entry for
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variables in the ClinicalTrials.gov database over the past 20 years for pediatric oncology
clinical trials and investigates trial-related factors that may affect early termination of
pediatric oncology clinical trials due to low accrual. Due to low patient participation,
pediatric oncology clinical trials are often terminated early or extended. The Institute of
Medicine (IOM) has urged for improvement in the selection, conduct and completion of
oncology trials.[13]
The amount of available data in ClinicalTrials.gov differed among variables
across different time periods that were based on the effective dates of regulations
affecting ClinicalTrials.gov. Of the following trial-level factors, none were significantly
associated (p < 0.05) with early termination of pediatric oncology trials: enrollment,
primary purpose, intervention type, phase, interventional study model, allocation, arm
type, number of arms, masking, primary end points, number of primary outcomes,
sponsor, number of participating facilities, primary disease, and data monitoring
committee. However, the use of a data and safety monitoring committee and number of
primary outcomes warrant further investigation due to their odds ratios. None of the triallevel factors combined were predictive of early termination of pediatric oncology trials
due to low accrual. Future research can build upon this study by including pediatric
oncology clinical trials conducted throughout the world, rather than just those within the
United States. In addition, researchers can examine additional variables in the
ClinicalTrials.gov database that were not investigated in this study (e.g. eligibility
criteria).
Contributions
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The results of the individual manuscripts and the triangulation of their findings
contribute to the science of clinical trials. The scoping review found a gap in theoretically
based knowledge about trial-level barriers and facilitators to enrollment in pediatric
oncology clinical trials. The gap in knowledge supported the conduct of manuscript #3,
Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Poor
Accrual: An Exploratory Analysis. Also, due to gap in knowledge about trial-level
barriers and facilitators to enrollment in pediatric oncology clinical trials, currently
known trial-level barriers and facilitators to enrollment in adult oncology clinical trials
were investigated in the second manuscript, Trial-level Factors Affecting Accrual and
Completion of Oncology Clinical Trials: A Systematic Review. Several trial-level barriers
and facilitators to enrollment in adult oncology clinical trials were identified, such as
enrollment, intervention type, phase, allocation, arm type, sponsor, number of
participating facilities, primary disease. These trial-level barriers and facilitators were
subsequently utilized as independent variables in the analysis reported in manuscript #3
to determine predictors of early termination of pediatric oncology clinical trials due to
poor accrual. Other possible predictor variables were identified in ClinicalTrials.gov,
which included primary purpose, number of primary outcomes, interventional study
model, number of arms, and the use of a data and safety monitoring committee. As
indicated in Manuscript #3, none of the examined independent variables were predictive
of early termination of pediatric oncology trials due to low accrual. The basic information
available in ClinicalTrials.gov may not be detailed enough to evaluate some important
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factors, without having to code textual data on criteria factors and/or individually search
for the trials in the literature to glean additional details.
The triangulation of the three manuscripts’ findings contribute to the science of
clinical trials by identifying possible predictors of early termination of pediatric oncology
clinical trials due to poor accrual. National organizations, such as the Institute of
Medicine (IOM), have called for improvements in clinical trials. The IOM has appealed
for increased efficiency in clinical trials, higher rates of completion, and prioritization of
the most feasible and needed trials.[14] Evidence from the literature reviews performed
in this dissertation suggest that for pediatric oncology clinical trials to successfully
complete in an efficient manner, knowledge of trial-level factors that affect accrual and
completion of those trials is warranted.[5,15] In particular, knowledge of non-modifiable
trial-level factors such as trial phase may also enable healthcare providers to educate
patients, possibly increasing acceptance of and participation in trials.[6,15] Evidence
from this dissertation also indicates knowledge of trial-level factors that affect accrual
and completion of trials may also allow sponsors and institutions to accurately predict a
trial’s accrual and completion which, in turn, enables prioritization of the most feasible
trials.[7]
This dissertation also contributes to the science of clinical trials by demonstrating
additional research is needed to identify predictors of enrollment in pediatric oncology
clinical trials. This is evidenced by trial-level barriers and facilitators identified in
manuscripts #1 and #2 failing to align with the results of the exploratory analysis in
manuscript #3 which did not identify any predictors of early termination of pediatric
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oncology clinical trials due to poor accrual. Based on these findings, predictors of
enrollment in pediatric oncology clinical trials may differ from those in adult oncology
trials.
Limitations
This dissertation has limitations. The scoping and systematic reviews may not
have included all available literature due to inadvertently omitted search terms. Since
there was only one reviewer, studies included in the reviews could not be assessed for
inter-rater reliability based on inclusion and exclusion criteria. A limitation of the third
manuscript, an exploratory analysis of trial-related factors that may affect early
termination of pediatric oncology clinical trials due to low accrual, was lack of inclusion
of all clinical trials conducted worldwide. Some trials are not required to be registered on
ClinicalTrials.gov.[16] No other clinical trial registries were utilized due to the technical
difficulties in the identification and elimination of duplicate trials. Bias may also be
present since only one database, which could contain inaccurate data, was utilized.[17]
Other limitations of this dissertation are related to changes in regulations over the
last two decades which resulted in discrepancies in the type and completeness of data that
investigators submitted into the database during that time frame.[18] The amount of
available data differs among variables and across different time periods affected by new
regulations. Other than variables pertaining to results, recent trials have more
completeness of variables than those trials conducted in the more distant past, possibly
skewing this study’s results. Results could also differ based on the cut-off dates for time
periods as it takes time for laws and policies to be fully implemented.[19] For example,
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study design was not required to be entered on ClinicalTrials.gov until implementation in
2008 of the Food and Drug Administration Amendments Act of 2007 (FDAAA). It is
likely study design was entered for fewer trials in 2008 than 2010 due to the lag in
sponsors’ knowledge of and compliance to the Act. Therefore, there would be different
percentages of completeness for the study design variable data for period 2 and period 3
if the cutoff for those periods was 2010 rather than 2008. If 2010 had been utilized as the
cutoff date, the percentage of completeness for study design would likely have been
higher for period 2 and period 3. Results could also differ based on the date of the dataset
as sponsors/principal investigators can retrospectively update information on
ClinicalTrials.gov.[20] Finally, some of the groups within variables were small. This
increases the likelihood of type II errors, possibly resulting in missed identified
predictors.
Lessons Learned
There were many lessons learned in the dissertation process. First, large databases
such as ClinicalTrials.gov can be challenging to utilize as multiple strategies and much
time may be required to successfully import data files into SPSS. Second, it is important
to ensure the computer to be used for file import into SPSS and analyses has sufficient
memory and processing capabilities. Third, after files are imported, additional variables
need to be created and data correctly coded to facilitate analyses; this can be timeconsuming. Labeling of variables is of the utmost importance for organization when
many variables are present. Fourth, differences exist between missing data and data not
present due to it not being required so both need to be coded and analyzed appropriately.
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Fifth, many clinical trials cases are necessary when there are several variables and groups
for chi-square analyses. The researcher was unable to perform all chi-square analyses that
were originally planned due to this issue. Thus, groups were combined if appropriate and
Fisher’s exact test was performed.
Future Research
Future advancements in this area of scholarship specific to the program of triallevel research include an expansion of this dissertation’s investigation of trial-related
factors that may predict early termination of pediatric oncology clinical trials due to low
accrual. Future analyses of ClinicalTrials.gov data will include clinical trials throughout
the world, rather than merely those in the United States. Additional independent variables
that were not included in the compendium’s third manuscript due to time constraints will
be investigated. For example, the specific types of eligibility criteria which will require
manual review and coding as that variable is in free text format within the
ClinicalTrials.gov dataset. This knowledge may further assist with the strategic design of
pediatric oncology clinical trials to avoid inadequate accrual and early termination of the
trials. The results from a future manuscript describing these analyses will drive
subsequent studies evaluating strategies to offset the effects of trial-level factors that
adversely impact accrual and trial completion.
Conclusion
The major findings from this body of scholarship suggest there may be trial-level
factors that predict accrual and/or completion of pediatric oncology clinical trials.
Additional studies examining trial-level factors should investigate pediatric oncology
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trials that have been conducted worldwide and incorporate multiple trial databases such
as ClinicalTrials.gov and European Union Drug Regulating Authorities Clinical Trials
Database (EudraCT). The design of future oncology clinical trials should address
approaches to minimize trial-level factors such as burdensome eligibility criteria and a
single participating facility that are associated with or predictive of early trial termination
or institute additional measures to offset the impact of the factors.
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Appendix A

Institutional Review Board for Human Research (IRB)
Office of Research Integrity (ORI)
Medical University of South Carolina
Harborview Office Tower
19 Hagood Ave., Suite 601, MSC857
Charleston, SC 29425-8570
Federal Wide Assurance # 1888

To: Cherie Hauck, Ph.D. Student
From: Amy Haynes, CIP
IRB Administrator II
Date: July 1, 2019
Re: Not Human Research Determination
This memo is in response to the submitted Not Human Research (NHR) application,
Predictors of Early Termination of Pediatric Oncology Clinical Trials Due to Poor
Accrual (Pro00087993). Based on your application, this project meets the Not Human
Research criteria set forth by the Code of Federal Regulations (45CFR46) of:
a. the specimens and/or private information/data were not collected
specifically for the currently proposed research project through an
interaction/intervention with living individuals AND
b. the investigator(s) including collaborators on the proposed research
cannot readily ascertain the identity of the individual(s) to whom the
coded private information or specimens pertain
Therefore, this project has been deemed not to be human research and is not subject
to oversight by the Medical University of South Carolina IRB. If there are any changes
to the application you provided, please resubmit for a NHR determination.
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Appendix B Glossary of Common Site Terms for ClinicalTrials.gov
Term

Definition

Accepts healthy volunteers

A type of eligibility criteria that indicates whether people
who do not have the condition/disease being studied can
participate in that clinical study.

Active comparator arm

An arm type in which a group of participants receives
an intervention/treatment considered to be effective (or
active) by health care providers.

Adverse event

An unfavorable change in the health of a participant,
including abnormal laboratory findings, that happens
during a clinical study or within a certain amount of time
after the study has ended. This change may or may not
be caused by the intervention/treatment being studied.

Age or age group

A type of eligibility criteria that indicates the age a
person must be to participate in a clinical study. This
may be indicated by a specific age or the following age
groups:
The age groups are:
•
•
•

Child (birth-17)
Adult (18-64)
Older Adult (65+)

All-cause mortality

A measure of all deaths, due to any cause, that occur
during a clinical study.

Allocation

A method used to assign participants to an arm of a
clinical study. The types of allocation are randomized
allocation and nonrandomized.

Arm

A group or subgroup of participants in a clinical trial that
receives a specific intervention/treatment, or no
intervention, according to the trial's protocol.

Arm type

A general description of the clinical trial arm. It
identifies the role of the intervention that participants
receive. Types of arms include experimental arm, active
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comparator arm, placebo comparator arm, sham
comparator arm, and no intervention arm.
Baseline characteristics

Data collected at the beginning of a clinical study for all
participants and for each arm or comparison group.
These data include demographics, such as age,
sex/gender, race and ethnicity, and study-specific
measures (for example, systolic blood pressure, prior
antidepressant treatment).

Canceled submission

Indicates that the study sponsor or investigator recalled a
submission of study results before quality control (QC)
review took place. If the submission was canceled on or
after May 8, 2018, the date is shown. After submission of
study results, a study record cannot be modified until QC
review is completed, unless the submission is canceled.

Certain agreements

Information required by the Food and Drug
Administration Amendments Act of 2007. In general,
this is a description of any agreement between the
sponsor of a clinical study and the principal
investigator (PI) that does not allow the PI to discuss the
results of the study or publish the study results in a
scientific or academic journal after the study is
completed.

Certification

A sponsor or investigator may submit a certification to
delay submission of results information if they are
applying for FDA approval of a new drug or device, or
new use of an already approved drug or device. A
sponsor or investigator who submits a certification can
delay results submission up to 2 years after
the certification/extension first submitted date, unless
certain events occur sooner.

Clinical study

A research study involving human volunteers (also called
participants) that is intended to add to medical
knowledge. There are two types of clinical
studies: interventional studies (also called clinical trials)
and observational studies.

Clinical trial

Another name for an interventional study.
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ClinicalTrials.gov
identifier (NCT number)

The unique identification code given to each clinical
study upon registration at ClinicalTrials.gov. The format
is "NCT" followed by an 8-digit number (for example,
NCT00000419).

Collaborator

An organization other than the sponsor that provides
support for a clinical study. This support may include
activities related to funding, design, implementation, data
analysis, or reporting.

Condition/disease

The disease, disorder, syndrome, illness, or injury that is
being studied. On ClinicalTrials.gov, conditions may
also include other health-related issues, such as lifespan,
quality of life, and health risks.

Contact

The name and contact information for the person who
can answer enrollment questions for a clinical study.
Each location where the study is being conducted may
also have a specific contact, who may be better able to
answer those questions.

Country

The Country field is used to find clinical studies with
locations in a specific country.

Cross-over assignment

A type of intervention model describing a clinical trial in
which groups of participants receive two or more
interventions in a specific order. For example, two-bytwo cross-over assignment involves two groups of
participants. One group receives drug A during the initial
phase of the trial, followed by drug B during a later
phase. The other group receives drug B during the initial
phase, followed by drug A. So during the trial,
participants "cross over" to the other drug. All
participants receive drug A and drug B at some point
during the trial but in a different order, depending on the
group to which they are assigned.

Data Monitoring
Committee (DMC)

A group of independent scientists who monitor the safety
and scientific integrity of a clinical trial. The DMC can
recommend to the sponsor that the trial be stopped if it is
not effective, is harming participants, or is unlikely to
serve its scientific purpose. Members are chosen based
on the scientific skills and knowledge needed to monitor
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the particular trial. Also called a data safety and
monitoring board, or DSMB.
Early Phase 1 (formerly
listed as Phase 0)

A phase of research used to describe exploratory trials
conducted before traditional phase 1 trials to investigate
how or whether a drug affects the body. They involve
very limited human exposure to the drug and have no
therapeutic or diagnostic goals (for example, screening
studies, microdose studies).

Eligibility criteria

The key requirements that people who want to
participate in a clinical study must meet or the
characteristics they must have. Eligibility criteria consist
of both inclusion criteria (which are required for a person
to participate in the study) and exclusion criteria (which
prevent a person from participating). Types of eligibility
criteria include whether a study accepts healthy
volunteers, has age or age group requirements, or is
limited by sex.

Enrollment

The number of participants in a clinical study. The
"estimated" enrollment is the target number of
participants that the researchers need for the study.

Exclusion criteria

A type of eligibility criteria. These are reasons that a
person is not allowed to participate in a clinical study.

Expanded access

A way for patients with serious diseases or conditions
who cannot participate in a clinical trial to gain access to
a medical product that has not been approved by the U.S.
Food and Drug Administration (FDA). Also called
compassionate use. There are different expanded access
types.

Expanded access status

•

•

Available: Expanded access is currently available
for this investigational treatment, and patients
who are not participants in the clinical study may
be able to gain access to the drug, biologic, or
medical device being studied.
No longer available: Expanded access was
available for this intervention previously but is
not currently available and will not be available
in the future.
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•

•

Expanded access type

Temporarily not available: Expanded access is
not currently available for this intervention but is
expected to be available in the future.
Approved for marketing: The intervention has
been approved by the U.S. Food and Drug
Administration for use by the public.

Describes the category of expanded access under U.S.
Food and Drug Administration (FDA) regulations. There
are three types of expanded access:
•

•

•

Individual Patients: Allows a single patient, with
a serious disease or condition who cannot
participate in a clinical trial, access to a drug or
biological product that has not been approved by
the FDA. This category also includes access in an
emergency situation.
Intermediate-size Population: Allows more than
one patient (but generally fewer patients than
through a Treatment IND/Protocol) access to a
drug or biological product that has not been
approved by the FDA. This type of expanded
access is used when multiple patients with the
same disease or condition seek access to a
specific drug or biological product that has not
been approved by the FDA.
Treatment IND/Protocol: Allows a large,
widespread population access to a drug or
biological product that has not been approved by
the FDA. This type of expanded access can only
be provided if the product is already being
developed for marketing for the same use as the
expanded access use.

Experimental arm

An arm type in which a group of participants receives
the intervention/treatment that is the focus of the clinical
trial.

Extension request

In certain circumstances, a sponsor or investigator may
request an extension to delay the standard results
submission deadline (generally one year after
162

the primary completion date). The request for an
extension must demonstrate good cause (for example, the
need to preserve the scientific integrity of an
ongoing masked trial). All requests must be reviewed
and granted by the National Institutes of Health. This
process for review and granting of extension requests is
being developed.
Factorial assignment

A type of intervention model describing a clinical trial in
which groups of participants receive one of several
combinations of interventions. For example, two-by-two
factorial assignment involves four groups of participants.
Each group receives one of the following pairs of
interventions: (1) drug A and drug B, (2) drug A and a
placebo, (3) a placebo and drug B, or (4) a placebo and a
placebo. So during the trial, all possible combinations of
the two drugs (A and B) and the placebos are given to
different groups of participants.

First posted

The date on which the study record was first available on
ClinicalTrials.gov. There is typically a delay of a few
days between the date the study sponsor or investigator
submitted the study record and the first posted date.

First submitted

The date on which the study sponsor or investigator first
submitted a study record to ClinicalTrials.gov. There is
typically a delay of a few days between the first
submitted date and the record's availability on
ClinicalTrials.gov (the first posted date).

First submitted that met
QC criteria

The date on which the study sponsor or investigator first
submits a study record that is consistent with National
Library of Medicine (NLM) quality control (QC)
review criteria. The sponsor or investigator may need to
revise and submit a study record one or more times
before NLM's QC review criteria are met. It is the
responsibility of the sponsor or investigator to ensure
that the study record is consistent with the NLM QC
review criteria.

Food and Drug
Administration

U.S. Public Law 110-85, which was enacted on
September 27, 2007. Section 801 of FDAAA amends
Section 402 of the U.S. Public Health Service Act to
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Amendments Act of 2007,
Section 801 (FDAAA 801)

expand ClinicalTrials.gov and create a clinical
study results database.

Funder type

Describes the organization that provides funding or
support for a clinical study. This support may include
activities related to funding, design, implementation, data
analysis, or reporting. Organizations listed
as sponsors and collaborators for a study are considered
the funders of the study. ClinicalTrials.gov refers to four
types of funders:
•
•

•
•

U.S. National Institutes of Health
Other U.S. Federal agencies (for example, Food
and Drug Administration, Centers for Disease
Control and Prevention, or U.S. Department of
Veterans Affairs)
Industry (for example: pharmaceutical and device
companies)
All others (including individuals, universities,
and community-based organizations)

Gender-based eligibility

A type of eligibility criteria that indicates whether
eligibility to participate in a clinical study is based a
person's self-representation of gender identity or gender
(yes, no). Gender is distinct from sex.

Group/cohort

A group or subgroup of participants in an observational
study that is assessed for biomedical or health outcomes.

Human subjects protection
review board

A group of people who review, approve, and monitor the
clinical study's protocol. Their role is to protect the rights
and welfare of people participating in a study (referred to
as human research subjects), such as reviewing
the informed consent form. The group typically includes
people with varying backgrounds, including a
community member, to make sure that research activities
conducted by an organization are completely and
adequately reviewed. Also called an institutional review
board, or IRB, or an ethics committee.

Inclusion criteria

A type of eligibility criteria. These are the reasons that a
person is allowed to participate in a clinical study.
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Informed consent

A process used by researchers to communicate to
potential and enrolled participants the risks and potential
benefits of participating in a clinical study.

Informed consent form
(ICF)

The document used in the informed consent or process.

Intervention model

The general design of the strategy for assigning
interventions to participants in a clinical study. Types of
intervention models include: single group
assignment, parallel assignment, cross-over assignment,
and factorial assignment.

Intervention/treatment

A process or action that is the focus of a clinical study.
Interventions include drugs, medical devices, procedures,
vaccines, and other products that are either
investigational or already available. Interventions can
also include noninvasive approaches, such as education
or modifying diet and exercise.

Interventional study
(clinical trial)

A type of clinical study in which participants are
assigned to groups that receive one or
more intervention/treatment (or no intervention) so that
researchers can evaluate the effects of the interventions
on biomedical or health-related outcomes. The
assignments are determined by the study's protocol.
Participants may receive diagnostic, therapeutic, or other
types of interventions.

Investigator

A researcher involved in a clinical study. Related terms
include site principal investigator, site sub-investigator,
study chair, study director, and study principal
investigator.

Last update posted

The most recent date on which changes to a study
record were made available on ClinicalTrials.gov. There
may be a delay between when the changes were
submitted to ClinicalTrials.gov by the study's sponsor or
investigator (the last update submitted date) and the last
update posted date.

Last update submitted

The most recent date on which the study sponsor or
investigator submitted changes to a study record to
ClinicalTrials.gov. There is typically a delay of a few
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days between the last update submitted date and when
the date changes are posted on ClinicalTrials.gov
(the last update posted date).
Last update submitted that
met QC criteria

The most recent date on which the study sponsor or
investigator submitted changes to a study record that are
consistent with National Library of Medicine
(NLM) quality control (QC) review criteria. It is the
responsibility of the sponsor or investigator to ensure
that the study record is consistent with the NLM QC
review criteria.

Last verified

The most recent date on which the study sponsor or
investigator confirmed the information about a clinical
study on ClinicalTrials.gov as accurate and current. If a
study with a recruitment status of recruiting; not yet
recruiting; or active, not recruiting has not been
confirmed within the past 2 years, the study's recruitment
status is shown as unknown.

Listed location countries

Countries in which research facilities for a study are
located. A country is listed only once, even if there is
more than one facility in the country. The list includes all
countries as of the last update submitted date; any
country for which all facilities were removed from
the study record are listed under removed location
countries.

Location terms

In the search feature, the Location terms field is used to
narrow a search by location-related terms other than
Country, State, and City or distance. For example, you
may enter a specific facility name (such as National
Institutes of Health Clinical Center) or a part of a facility
name (such as Veteran for studies listing Veterans
Hospital or Veteran Affairs in the facility name). Note:
Not all study records include this level of detail about
locations.

Masking

A clinical trial design strategy in which one or more
parties involved in the trial, such as the investigator or
participants, do not know which participants have been
assigned which interventions. Types of masking include:
open label, single blind masking, and double-blind
masking.
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NCT number

A unique identification code given to each clinical study
record registered on ClinicalTrials.gov. The format is
"NCT" followed by an 8-digit number (for example,
NCT00000419). Also called the ClinicalTrials.gov
identifier.

No intervention arm

An arm type in which a group of participants does not
receive any intervention/treatment during the clinical
trial.

Observational study

A type of clinical study in which participants are
identified as belonging to study groups and are assessed
for biomedical or health outcomes. Participants may
receive diagnostic, therapeutic, or other types of
interventions, but the investigator does not assign
participants to a specific interventions/treatment.
A patient registry is a type of observational study.

Observational study model

The general design of the strategy for identifying and
following up with participants during an observational
study. Types of observational study models include
cohort, case-control, case-only, case-cross-over, ecologic
or community studies, family-based, and other.

Other adverse event

An adverse event that is not a serious adverse event,
meaning that it does not result in death, is not lifethreatening, does not require inpatient hospitalization or
extend a current hospital stay, does not result in an
ongoing or significant incapacity or interfere
substantially with normal life functions, and does not
cause a congenital anomaly or birth defect; it also does
not put the participant in danger and does not require
medical or surgical intervention to prevent one of the
results listed above.

Other study IDs

Identifiers or ID numbers other than the NCT
number that are assigned to a clinical study by the study's
sponsor, funders, or others. These numbers may include
unique identifiers from other trial registries and National
Institutes of Health grant numbers.
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Other terms

In the search feature, the Other terms field is used to
narrow a search. For example, you may enter the name
of a drug or the NCT number of a clinical study to limit
the search to study records that contain these words.

Outcome measure

For clinical trials, a planned measurement described in
the protocol that is used to determine the effect of
an intervention/treatment on participants.
For observational studies, a measurement or observation
that is used to describe patterns of diseases or traits, or
associations with exposures, risk factors, or treatment.
Types of outcome measures include primary outcome
measure and secondary outcome measure.

Parallel assignment

A type of intervention model describing a clinical trial in
which two or more groups of participants receive
different interventions. For example, a two-arm parallel
assignment involves two groups of participants. One
group receives drug A, and the other group receives drug
B. So during the trial, participants in one group receive
drug A "in parallel" to participants in the other group,
who receive drug B.

Participant flow

A summary of the progress of participants through each
stage of a clinical study, by study arm or group/cohort.
This includes the number of participants who started,
completed, and dropped out of the study.

Patient registry

A type of observational study that collects information
about patients' medical conditions and/or treatments to
better understand how a condition or treatment affects
patients in the real world.

Phase

The stage of a clinical trial studying a drug or biological
product, based on definitions developed by the U.S. Food
and Drug Administration (FDA). The phase is based on
the study's objective, the number of participants, and
other characteristics. There are five phases: Early Phase
1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3,
and Phase 4. Not Applicable is used to describe trials
without FDA-defined phases, including trials of devices
or behavioral interventions.
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Phase 1

Phase 2

Phase 3

Phase 4

Phase Not Applicable

A phase of research to describe clinical trials that focus
on the safety of a drug. They are usually conducted with
healthy volunteers, and the goal is to determine the
drug's most frequent and serious adverse events and,
often, how the drug is broken down and excreted by the
body. These trials usually involve a small number of
participants.
-typically 20-80 participants1
A phase of research to describe clinical trials that gather
preliminary data on whether a drug works in people who
have a certain condition/disease (that is, the drug's
effectiveness). For example, participants receiving the
drug may be compared to similar participants receiving a
different treatment, usually an inactive substance (called
a placebo) or a different drug. Safety continues to be
evaluated, and short-term adverse events are studied.
-typically 100 – 300 participants1
A phase of research to describe clinical trials that gather
more information about a drug's safety and effectiveness
by studying different populations and different dosages
and by using the drug in combination with other drugs.
These studies typically involve more participants.
-typically 1,000 – 3,000 participants1
A phase of research to describe clinical trials occurring
after FDA has approved a drug for marketing. They
include postmarket requirement and commitment studies
that are required of or agreed to by the study sponsor.
These trials gather additional information about a drug's
safety, efficacy, or optimal use.
Describes trials without FDA-defined phases, including
trials of devices or behavioral interventions.

Placebo

An inactive substance or treatment that looks the same
as, and is given in the same way as, an active drug
or intervention/treatment being studied.

Placebo comparator arm

An arm type in which a group of participants receives
a placebo during a clinical trial.

Primary completion date

The date on which the last participant in a clinical study
was examined or received an intervention to collect final
data for the primary outcome measure. Whether the
clinical study ended according to the protocol or was
terminated does not affect this date. For clinical studies
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with more than one primary outcome measure with
different completion dates, this term refers to the date on
which data collection is completed for all the primary
outcome measures. The "estimated" primary completion
date is the date that the researchers think will be the
primary completion date for the study.
Primary outcome measure

In a clinical study's protocol, the planned outcome
measure that is the most important for evaluating the
effect of an intervention/treatment. Most clinical studies
have one primary outcome measure, but some have more
than one.

Primary purpose

The main reason for the clinical trial. The types of
primary purpose are: treatment, prevention, diagnostic,
supportive care, screening, health services research, basic
science, and other.

Principal investigator (PI)

The person who is responsible for the scientific and
technical direction of the entire clinical study.

Protocol

The written description of a clinical study. It includes the
study's objectives, design, and methods. It may also
include relevant scientific background and statistical
information.

Quality control (QC)
review

National Library of Medicine (NLM) staff perform a
limited review of submitted study records for apparent
errors, deficiencies, or inconsistencies. NLM staff
identify potential major and advisory issues and provide
comments directly to the study sponsor or investigator.
Major issues identified in QC review must be addressed
or corrected (see First submitted that met QC
criteria and Results first submitted that met QC criteria).
Advisory issues are suggestions to help improve the
clarity of the record. NLM staff do not verify the
scientific validity or relevance of the submitted
information. The study sponsor or investigator is
responsible for ensuring that the studies follow all
applicable laws and regulations.

Randomized allocation

A type of allocation strategy in which participants are
assigned to the arms of a clinical trial by chance.
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Recruitment status

•
•
•

•

•
•

•

•
•

Not yet recruiting: The study has not started
recruiting participants.
Recruiting: The study is currently recruiting
participants.
Enrolling by invitation: The study is selecting its
participants from a population, or group of
people, decided on by the researchers in advance.
These studies are not open to everyone who
meets the eligibility criteria but only to people in
that particular population, who are specifically
invited to participate.
Active, not recruiting: The study is ongoing, and
participants are receiving an intervention or being
examined, but potential participants are not
currently being recruited or enrolled.
Suspended: The study has stopped early but may
start again.
Terminated: The study has stopped early and will
not start again. Participants are no longer being
examined or treated.
Completed: The study has ended normally, and
participants are no longer being examined or
treated (that is, the last participant's last visit has
occurred).
Withdrawn: The study stopped early, before
enrolling its first participant.
Unknown: A study on ClinicalTrials.gov whose
last known status was recruiting; not yet
recruiting; or active, not recruiting but that has
passed its completion date, and the status has not
been last verified within the past 2 years.

Registration

The process of submitting and updating summary
information about a clinical study and its protocol, from
its beginning to end, to a structured, public Webbased study registry that is accessible to the public, such
as ClinicalTrials.gov.

Removed location
countries

Countries that appeared under listed location
countries but were removed from the study record by the
sponsor or investigator.
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Reporting group

A grouping of participants in a clinical study that is used
for summarizing the data collected during the study. This
grouping may be the same as or different from a study
arm or group.

Responsible party

The person responsible for submitting information about
a clinical study to ClinicalTrials.gov and updating that
information. Usually the study sponsor or investigator.

Results database

A structured online system, such as the
ClinicalTrials.gov results database, that provides the
public with access to registration and summary results
information for completed or terminated clinical studies.
A study with results available on ClinicalTrials.gov is
described as having the results "posted."
Note: The ClinicalTrials.gov results database became
available in September 2008. Older studies are unlikely
to have results available in the database.

Results delayed

Indicates that the sponsor or investigator submitted
a certification or extension request.

Results first posted

The date on which summary results information was first
available on ClinicalTrials.gov. There is typically a delay
between the date the study sponsor or investigator first
submits summary results information (the results first
submitted date) and the results first posted date.

Results first submitted

The date on which the study sponsor or investigator first
submits a study record with summary results
information. There is typically a delay between the
results first submitted date and when summary results
information becomes available on ClinicalTrials.gov
(the results first posted date).

Results first submitted that
met QC criteria

The date on which the study sponsor or investigator first
submits a study record with summary results information
that is consistent with National Library of Medicine
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(NLM) quality control (QC) review criteria. The sponsor
or investigator may need to revise and submit results
information one or more times before NLM's QC review
criteria are met. It is the responsibility of the sponsor or
investigator to ensure that the study record is consistent
with the NLM QC review criteria.
Results returned after
quality control review

The date on which the National Library of Medicine
provided quality control (QC) review comments to the
study sponsor or investigator. The sponsor or
investigator must address major issues identified in the
review comments. If there is a date listed for results
returned after quality control review, but there is not a
subsequent date listed for results submitted to
ClinicalTrials.gov, this means that the submission is
pending changes by the sponsor or investigator.

Results submitted to
ClinicalTrials.gov

Indicates that the study sponsor or investigator has
submitted summary results information for a clinical
study to ClinicalTrials.gov but the quality control (QC)
review process has not concluded.
The results submitted date indicates when the study
sponsor or investigator first submitted summary results
information or submitted changes to summary results
information. Submissions with changes are typically in
response to QC review comments from the National
Library of Medicine (NLM). If there is a date listed for
results submitted to ClinicalTrials.gov, but there is not a
subsequent date listed for results returned after quality
control review, this means that the submission is pending
review by NLM.

Secondary outcome
measure

In a clinical study's protocol, a planned outcome measure
that is not as important as the primary outcome measure
for evaluating the effect of an intervention but is still of
interest. Most clinical studies have more than one
secondary outcome measure.

Serious adverse event

An adverse event that results in death, is life-threatening,
requires inpatient hospitalization or extends a current
hospital stay, results in an ongoing or significant
incapacity or interferes substantially with normal life
functions, or causes a congenital anomaly or birth defect.
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Medical events that do not result in death, are not lifethreatening, or do not require hospitalization may be
considered serious adverse events if they put the
participant in danger or require medical or surgical
intervention to prevent one of the results listed above.
Sex

A type of eligibility criteria that indicates the sex of
people who may participate in a clinical study (all,
female, male). Sex is a person's classification as female
or male based on biological distinctions. Sex is distinct
from gender-based eligibility.

Sham comparator arm

An arm type in which a group of participants receives a
procedure or device that appears to be the same as the
actual procedure or device being studied but does not
contain active processes or components.

Single group assignment

A type of intervention model describing a clinical trial in
which all participants receive the same
intervention/treatment.

Sponsor

The organization or person who initiates the study and
who has authority and control over the study.

State

The State field is used to find clinical studies with
locations in a specific state within the United States. If
you choose United States in the Country field, you can
search for studies with locations in a specific state.

Statistical analysis plan
(SAP)

The written description of the statistical considerations
and methods for analyzing the data collected in
the clinical study.

Status

Indicates the current recruitment status or the expanded
access status.

Study completion date

The date on which the last participant in a clinical study
was examined or received an intervention/treatment to
collect final data for the primary outcome
measures, secondary outcome measures, and adverse
events (that is, the last participant's last visit). The
"estimated" study completion date is the date that the
researchers think will be the study completion date.
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Study design

The investigative methods and strategies used in the
clinical study.

Study documents

Refers to the type of documents that the study sponsor or
principal investigator may add to their study record.
These include a study protocol, statistical analysis plan,
and informed consent form.

Study IDs

Identifiers that are assigned to a clinical study by the
study's sponsor, funders, or others. They include unique
identifiers from other trial study registries and National
Institutes of Health grant numbers. Note:
ClinicalTrials.gov assigns a unique identification code to
each clinical study registered on ClinicalTrials.gov. Also
called the NCT number, the format is "NCT" followed
by an 8-digit number (for example, NCT00000419).

Study record

An entry on ClinicalTrials.gov that contains a summary
of a clinical study's protocol information, including
the recruitment status; eligibility criteria; contact
information; and, in some cases, summary results. Each
study record is assigned a ClinicalTrials.gov identifier,
or NCT number.

Study registry

A structured online system, such as ClinicalTrials.gov,
that provides the public with access to summary
information about ongoing and completed clinical
studies.

Study results

A study record that includes the summary results posted
in the ClinicalTrials.gov results database. Summary
results information includes participant flow, baseline
characteristics, outcome measures, and adverse
events (including serious adverse events).

Study start date

The actual date on which the first participant was
enrolled in a clinical study. The "estimated" study start
date is the date that the researchers think will be the
study start date.

Study type

Describes the nature of a clinical study. Study types
include interventional studies (also called clinical
trials), observational studies (including patient
registries), and expanded access.
175

Submitted date

The date on which the study sponsor or investigator
submitted a study record that is consistent with National
Library of Medicine (NLM) quality control (QC) review
criteria.

Title

The official title of a protocol used to identify a clinical
study or a short title written in language intended for the
lay public.

Title acronym

The acronym or initials used to identify a clinical study
(not all studies have one). For example, the title acronym
for the Women's Health Initiative is "WHI."

U.S. Agency for
Healthcare Research and
Quality (AHRQ)

An agency within the U.S. Department of Health and
Human Services. AHRQ's mission is to produce
evidence to make health care safer, higher quality, more
accessible, equitable, and affordable, and to work within
the U.S. Department of Health and Human Services and
with other partners to make sure that the evidence is
understood and used.

U.S. Food and Drug
Administration (FDA)

An agency within the U.S. Department of Health and
Human Services. The FDA is responsible for protecting
the public health by making sure that human and
veterinary drugs, vaccines and other biological products,
medical devices, the Nation's food supply, cosmetics,
dietary supplements, and products that give off radiation
are safe, effective, and secure.

Unknown

A type of recruitment status. It identifies a study on
ClinicalTrials.gov whose last known status was
recruiting; not yet recruiting; or active, not recruiting but
that has passed its completion date, and the status has not
been verified within the past 2 years. Studies with an
unknown status are considered closed studies.
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